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 This thesis evaluates the effects of ancestry and admixture on the utility and 
generalizability of polygenic scores for risk prediction and stratification in diverse 
populations in the US and Latin America.  Historically, biomedical research has focused 
predominantly on European-origin individuals to the neglect of ancestrally and ethnically 
diverse populations.  My work is motivated by health disparities that disproportionately 
affect disadvantaged populations across the world, and in particular, those in the Americas.  
New World populations from the Americas are characterized by varying degrees of 
admixture among ancestral population groups from Africa, the Americas, and Europe.  I 
utilize thousands of genomes from diverse populations worldwide, along with hundreds of 
genome-wide association studies (GWAS) on thousands of human traits, to address three 
overarching questions: (1) which phenotypes vary among populations, and what explains 
that variance?; (2) is it possible to predict and stratify risk for common complex diseases 
across diverse populations?; and (3) can we apply already discovered genetic associations 
to risk prediction in new and ancestrally distinct populations?. 
In precision medicine, a patient’s genetics are used to inform treatment decisions.  
This approach relies on knowledge about the genetic architecture of disease, along with 
environmental and lifestyle effects, to accurately predict outcomes.  The treatments 
recommended by precision medicine can range from non-invasive preventative measures 
to highly invasive interventional practices – e.g., more frequent mammographic screening 
versus mastectomy in patients with predicted breast cancer risk.  Therefore, it is vitally 
important that medical practitioners have the best and most complete knowledge about a 
 xiv 
disease as possible.  Large-scale population genetics studies, GWAS, are what enable this 
knowledge gathering.  Moreover, precision public health seeks to apply precision medicine 
at the local and regional population level, which supports the implementation of public 
health initiatives that are most appropriate and most impactful for a given region. 
The populations of many countries, with notable exceptions, are composed of 
admixed individuals with ancestry derived from two or more ancestry groups – African, 
Southeast and East Asian, European, and Native American.  Two notable examples to the 
contrary, Iceland and Finland, are markedly homogenous – show the lowest between and 
within-population diversity of any populations studied in this dissertation.  This 
homogeneity has made these two populations popular for genomics research; their shared 
life histories and societal influences greatly simplify genomics research – freeing 
researchers of confounding socioeconomic, historical, and genetic factors that would 
otherwise complicate their work.  This theme of using simpler to study, ancestrally 
homogenous Eurocentric populations holds in the US and Latin America and has resulted 
in a large gap in genomics knowledge that only compounds existing health disparities. 
Health disparities are “preventable differences in the burden of disease, injury, 
violence, or opportunities to achieve optimal health that are experienced by socially 
disadvantaged populations” [1].  In terms of genetics research, these disparities are 
exacerbated by a lack of inclusive research that studies individuals and genomes of diverse 
ancestry.  This genomics research gap grows larger when it comes to translating research 
findings into the clinic as part of precision medicine initiatives.  Therefore, we must find a 
way to integrate and apply our existing knowledge to the treatment of disadvantaged and 
currently underrepresented populations.  My thesis research is focused on developing 
 xv 
platforms and methods that democratize access to population genetics research and support 
the application and analysis of existing information in new and diverse populations.  This 
was accomplished through the development of online platforms for population genetics 
research and the assessment and development of risk prediction methods in diverse 
populations. 
 GWAS have helped elucidate the population-specific genetic architecture of 
diseases by associating particular single nucleotide polymorphisms (SNPs) with changes 
in measurable phenotypes.  Polygenic scores (PGS) are an emerging translational genetics 
tool for predicting the magnitude of an individual’s phenotype, for both anthropometric 
(such as height or body mass index) and disease-related traits.  The standard approach to 
PGS construction is to use the results of a GWAS and related individual-level phenotypes 
data to iteratively arrive at the most informative set of SNP associations.   However, this 
approach is limited to the population from which the GWAS sampled from and frequently 
produces population-specific PGS.  My work attempts to generalize PGS into diverse 
populations and assess their effectiveness from a precision public health perspective.   
 My dissertation leverages GWAS, PGS, and epidemiology data to assess the utility 
of PGS for risk stratification of diseases in admixed Hispanic/Latino and Afro-descendant 
populations in the United States and Colombia.  I focus on common complex diseases, 
which are polygenic disorders with high prevalence and multifactorial etiology, such as 
type 2 diabetes (T2D) and coronary artery disease (CAD), which, together, affect upwards 
of 80% of some populations.  Relative differences in population PGS distributions are used 
to assess the effectiveness of PGS and controls developed herein.  Finally, I explore the 
 xvi 
relationship between ancestry and predicted outcomes across thousands of traits and 
evaluate the extent to which ancestry biases PGS.  
Research advance 1:  My first study explores the distribution of predicted 
phenotypic differences in 27 global populations, and I developed the first of its kind web-
based population genetics platform for computing and visualizing PGS.  The computational 
requirements for population genetics are frequently a substantial barrier to entry, 
particularly for researchers without bioinformatics expertise and from lower-income areas.  
Many of these lower-income areas are home to traditionally underserved populations, 
which are also uniquely at risk for particular complex common diseases [2, 3].  Web-based 
platforms have low barriers to entry, requiring no computational resources beyond an 
internet-connected device.  I developed two platforms for exploring the relationship 
between global genetic diversity and the genomic architecture underlying human 
phenotypic diversity. 
Research advance 2: My second study builds on the population precision health 
paradigm by integrating population genotype data with fine-scale epidemiology data for 
two adjacent and ancestrally diverse departments in Colombia.   This study assessed the 
utility of PGS, without individual-level phenotype data, for stratifying population risk for 
three categories of disease with high socioeconomic impact: (1) common complex: T2D, 
hypertension, chronic kidney disease, and ischemic stroke; (2) cancers: cancers of the 
central nervous system, leukemia, Hodgkin and non-Hodgkin’s lymphomas, ovarian, and 
pulmonary cancers; and (3) malaria caused by Plasmodium vivax and P. falciparum.  Using 
PGS derived from multi-ethnic associations, I show that predictions tend to be highly 
correlated with outcomes at the population level.  This study also highlights the impact of 
 xvii 
putative environmental effects on confounding PGS interpretation.  Genetic risk does not 
exist in a vacuum, and Genetic × Environmental effects must be accounted for in complex 
traits.  
Research advance 3:  My third and fourth studies focus on risk prediction for a single 
disease in two regional populations: type 2 diabetes in Hispanic/Latino populations in the 
US and Afro-descendant populations in Colombia.  T2D has high prevalence across the 
globe, and disproportionately affects non-European ancestry populations throughout the 
western world.  Diabetes is also one of the most and best-studied diseases in genetics, with 
highly diverse study populations compared to all other traits studied by GWAS.  This 
diversity in existing research provided a unique opportunity to develop ancestry-specific 
and ancestry-agnostic PGS for T2D in four populations; Afro-Colombians in Chocó, 
Colombia, Mestizos in Medellin, Colombia, Mexican-Americans in LA County, California 
and European-Americans in Utah.  The predicted risk for T2D was uniformly high for 
Afro-Colombians and Mexican-Americans, regardless of the GWAS and PGS ancestry 
composition.  Strikingly, while low socioeconomic status is strongly correlated with higher 
T2D risk and prevalence in the US, in Colombia, it has a protective effect.  Finally, a 
derived allele frequency-based control was proposed that enables the normalization of PGS 





CHAPTER 1. INTRODUCTION 
Genetic diversity underpins much of the observed human phenotypic diversity and plays an 
important role in human health and disease [4].  As ancient human populations migrated and 
became reproductively isolated, they accumulated population-specific variations, some of which 
were advantageous in their respective environments.  Eventually, these adaptive alleles increased 
in frequency and helped ancient communities survive by bolstering resistance to infectious disease 
[5, 6], aiding in the metabolism of complex biomolecules [7], and overcoming other environmental 
obstacles [8, 9].  In contemporary populations, these ancient adaptations may no longer be 
beneficial in the current environment and, through antagonistic pleiotropic effects, increase the 
risk of common complex diseases [10-12]. Common complex diseases are non-infectious 
polygenic disorders caused by the complex interaction between many genes and environmental 
factors, such as type 2 diabetes (T2D) and coronary artery disease (CAD) [13-15].   
Genome-wide associations studies (GWAS) have helped elucidate the population-specific 
genetic architecture of diseases by associating particular single nucleotide polymorphisms (SNPs) 
with changes in measurable phenotypes.  Thousands of GWAS, studying millions of people, have 
been performed over the last 15 years, but the majority – nearly 80% – of study participants have 
been of European ancestry [16].  As a result, there is a strong foundation of knowledge on the 
genetic architecture of disease in Europeans but not for ancestrally diverse populations in the 
Western world where most biomedical research takes place.  While global populations share 
significant portions of disease architecture [17-20], the actual magnitude and direction of effects 
are often different [18, 21-23].  The reliability of applying GWAS knowledge ascertained in 
Europeans to populations of diverse ancestry remains an open question [16, 18, 22, 23].   
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One proposed, and likely successful, method to close this gap is more GWAS in diverse 
populations.  Over the last ~10 years, researchers have increasingly pointed to the lack of genomic 
diversity and lobbied for more representation in studies.  Indeed, the raw number of Afro-
descendent, Hispanic/Latino, Native American, and Southeast Asian individuals represented in 
GWAS has increased dramatically; however, they still only represent a small portion of the total 
number of individuals studied (<20%) [24] despite making up the majority of peoples around the 
world.  This is further compounded by re-analysis efforts on large Eurocentric biobank cohorts, 
which lead to an inflation of low-diversity GWAS.  This effectively results in <10% of GWAS 
participants being from traditionally underrepresented populations. 
However, performing high power and ethnically diverse GWAS is prohibitively expensive, 
with costs ranging into the several millions of dollars per study.  More and larger GWAS in every 
population for every disease is not a sustainable or scalable approach.  Therefore, we must also 
find a way to apply existing knowledge to new populations.  The first steps in utilizing this existing 
knowledge are (1) estimating the transferability of European-derived SNP-trait associations into 
diverse populations, and (2) assessing and controlling for biases introduced while transferring this 
knowledge.  Throughout this dissertation, these two themes will be discussed at length, with 
applications in Hispanic/Latino and Afro-descendant populations.    
1.1 Polygenic traits and genome-wide association studies 
Early genetics research, in both humans and other model organisms, focused on readily 
observable and reliability inherited phenotypes.  These phenotypes are caused by genetic variants, 
or alterations in the genome, with the changes ranging from a single nucleotide change (SNPs) to 
the deletion of entire chromosomes.  These variants, or alleles, tended to be both very rare (𝐴𝐴𝐴𝐴 ≤
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 0.001) and highly penetrant.  Penetrance is the probability of phenotypic expression given the 
presence of a phenotype-conferring allele.  Highly penetrant alleles almost always confer 
phenotypic expression.  As an aside, it is essential not to conflate penetrance, the mere expression 
of a phenotype, with expressivity, the strength or intensity of phenotypic expression.  In section 
1.2 and 1.3, I will discuss in more detail the relationship between penetrance, expressivity, and 
what PGS attempt predict.  Diseases caused by such highly penetrant, rare alleles are often referred 
to as Mendelian diseases (Figure 1) since their mode of inheritance closely matches those noted 
by Gregor Mendel in his peas.  Because these disorders are caused by a single mutation impacting 
a single gene, they are sometimes also called monogenic disorders. 
On the other hand, common alleles (𝐴𝐴𝐴𝐴 ≥  0.1) associated with disease tend to be low 
penetrance (Figure 1).  A single low penetrance allele is unlikely to cause an observable phenotype, 
however in combination with few to many related low penetrance alleles, it can elicit a phenotype.  
This combination of alleles generally involves alleles that change the expression or function of 
multiple genes.  Such phenotypes are polygenic and, in some cases, such as height, are considered 
omnigenic – they involve the action of nearly all genes [25]. 
Discovering and characterizing the alleles that influence polygenic phenotypes is the 
purview of the case-control association study, also known as a genome-wide association study 
(GWAS).  In GWAS, many individuals who do (case) and do not (control) display a phenotype 
(e.g., diabetes) first have their genomic variation quantified.  The most popular and cost-effective 
method of quantification is microarray genotyping, which accurately determines sequence variants 
at many predetermined sites along the genome.  Investigators next scan along the genome and ask, 
“is the allele frequency of this variant significantly different between cases and controls?”.  In 
actual practice, performing a GWAS involves several controls, which are discussed below, and are 
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modeled in linear or logistic regression as covariates.  GWAS studies may uncover protective 
alleles, alleles that are in significantly higher frequency in controls, and risk alleles, alleles that are 
in significantly higher frequency in cases.  GWAS are not limited only to binary traits like disease 
status; they can also be applied to quantitative traits such as height or blood pressure.  In such 
studies, the genotype frequency of each allele is linearly regressed with quantitative measures and 
other covariates, such as ancestry and lifestyle factors. 
 
Figure 1. Allele frequency, penetrance, and disease   
The relationship between allele frequency and penetrance, as it relates to genetics research and 
our ability to detect such associations.  Adapted from [26]. 
5 
 
Crucially, GWAS must correct for both genetic and non-genetic effects, which may 
introduce error in the results.  Genetic effects include sample relatedness and population structure.  
Controlling for sample relatedness is often as simple as removing individuals who appear, based 
on their combination of genotypes, to be too closely related – in practice, this typically means 
eliminating individuals who appear to be second-degree relatives or closer.  It is important to 
remove related individuals as they may have shared family-specific deviations in allele frequency 
that are unrelated to the phenotype of interest but skew the allele frequency differences tested. 
Correcting for population structure involves computing the relatedness (or distance) between all 
study samples, by performing principal components analysis or multi-dimensional scaling, and 
using the resulting component vectors as covariates in the association test.  Of note, as shown in 
Figure 21, these components correspond to allele frequency differences between and within 
populations of different ancestry.  Non-genetic effects include environmental exposures, such as 
smoking tobacco and drinking alcohol, and quantitative measures such as blood iron levels or 
waist-to-hip ratio.  That smoking tobacco has a direct causal link to head and neck cancer is 
unsurprising in light of what we know about the carcinogenic compounds in cigarette smoke.  
However, we want to ascertain the genetic risk in the absence of the effects of tobacco smoke and 
include smoking status as a covariant in our association test model. 
Regardless of the type of trait studied, the outputs of a GWAS are the per-variant minor 
allele frequency (MAF), odds ratio (OR, the ratio of non-reference allele frequency between 
conditions) or beta (β), standard error, and p-value.  The widely-used value for genome-wide 
significance after multiple testing correction is 𝑝𝑝 <  5 × 10−8, which was determined by 
simulation studies in European populations [27].  The odds ratio/beta values are used to determine 
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the allele effect, with OR < 1 indicating the allele is found at higher frequency in cases and 
increases (risk of) the phenotype.   
1.2 Common complex diseases and public health 
A common complex disease (CCD) is, as the name would suggest, commonly prevalent in 
a population and has a complex etiology.  Estimates of commonness for CCD range from several 
percentage points, as is the case for many cancers, to upwards of 80% of the population in the case 
of diabetes and pre-diabetes metabolic disorder.  CCD are polygenic disorders caused by the 
combination of many, low-penetrance variants across multiple genes.  The hallmarks of CCD are 
the complex interaction between genetics and environment, so-called 𝐺𝐺 ×  𝐸𝐸 interactions, and 
non-Mendelian inheritance.  That risk for CCD is inheritable may seem obvious since the diseases 
arise from genetic variants but consider the case of cancers, which are driven by an accumulation 
of somatic mutations that cannot be passed to the next generation.  Therefore there might exist a 
combination of heritable alleles that contribute to the accumulation of somatic mutations that have 
direct and indirect functional consequences on oncogenesis.  GWAS enables researchers to 
discover both, directly and indirectly, risk modifying alleles and explore the environmental 
exposures that influence expressivity. 
  Precision medicine practitioners and public health agencies are particularly interested in 
CCDs since their expressivity is modifiable by environmental and lifestyle factors.  Take, for 
example, the leading causes of morbidity and mortality in the US: heart disease and diabetes.  The 
genetics and environmental mediators of both diseases are well studied across the US, in multi-
ethnic regional populations.  At the individual level, doctors can order panel-based genotyping 
tests to measure the genetic component of risk and recommend lifestyle changes to lower the 
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severity and risk of developing heart disease or diabetes.  At a population level, using population 
genetics data, public health agencies can recommend lifestyle changes for large groups of people 
to help lower their risk without incurring the (massive) expense of genotyping every individual.  
A significant roadblock to this population precision medicine approach is the availability of 
appropriate ancestry-matched population genetics data.  My dissertation attempts to expand the 
reach of these population precision medicine techniques by assessing the generalizability of 
existing population genetics knowledge across ancestries and assessing the utility of these 
predictions on populations in the US and Colombia. 
Precision public health is “providing the right intervention to the right population at the 
right time” [28].   The goals of precision public health are to decrease population-specific health 
disparities.  This is done through the targeted application of resources and technology, such as the 
recruitment and study of representative cohorts from communities, states, and across the country 
for genetic studies.  The end goal is to enable genomics-based treatment guidelines without 
requiring all individuals to undergo expensive sequencing-based tests.  In order to affect precision 
public health, we must understand population-specific risk profiles and be able to predict genetic 
risk. 
1.3 Genetic risk prediction and stratification 
An emerging tool in the precision medicine toolkit is the prediction of genetic 
predisposition and risk for disease using polygenic scores (PGS).  PGS leverage the genetic 
association and effect size estimates from GWAS to predict the heritable phenotypic expression.  
The computation and correction of PGS will be covered in detail throughout my dissertation. 
Population PGS distributions are essential in understanding population-specific risks and 
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disparities.  Population PGS distributions are useful in determining if any populations are uniquely 
at risk for, or protected from, a particular disease.  This stratification of population risk into low, 
moderate, and high make PGS well suited for preventative efforts.  Precision public health 
initiatives can focus on funding and awareness campaigns for high cost and high impact diseases 
that are predicted to be at high risk. 
Despite their apparent potential for discovering genetic changes that underlie phenotypic 
divergence among populations, recent studies have underscored several challenges entailed by 
cross-population comparisons of PGS [29].  Systematic differences in allele frequencies, 
proportions of ancestral versus derived alleles, and patterns of linkage disequilibrium can yield 
significant shifts in 𝑃𝑃𝐺𝐺𝑃𝑃 distributions that do not necessarily reflect observed phenotypic 
differences among populations [23, 30, 31].  Furthermore, the fact that the vast majority of GWAS 
have been conducted on cohorts of European ancestry [16, 32, 33] results in 𝑃𝑃𝐺𝐺𝑃𝑃 that are far more 
accurate for European populations compared to other, less-studied global population groups [24].  
In light of these challenges, my dissertation (1) characterize the genetic ancestry patterns for 
diverse populations from within two countries, (2) evaluates the impact of ancestry differences 
between these populations on the genetic variants associated with phenotype and function, and (3) 
consider observed differences in the frequencies of trait-associated variants in light of observed 
differences between the populations. 
1.4 Genetic admixture and ancestry  
Genetic admixture (herein “admixture”) is the combination of alleles from two or more 
genetically differentiated populations.  In its simplest form, admixture occurs when two 
individuals from previously geographically or reproductively isolated populations mate and have 
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offspring.   These offspring have combinations of alleles, found in contiguous chromosomal blocks 
called haplotypes, that come from each parent.  In the modern era, admixture can be much more 
complicated, especially when two admixed individuals mate.  The new combination of alleles 
produced by admixture contains alleles adaptive for multiple environments, and whether or not 
they confer a selective advantage in the current environment is unknown. 
In the above example, the allele frequencies within each haplotype are population-specific 
since they, by definition, must come from one parent or the other and are passed down through 
generations.  As a result, we can computationally reconstruct ancestral haplotypes in a population 
with a high degree of certainty using allele frequency alone.  Haplotype reconstruction becomes 
more difficult the older the admixture event(s) is because the haplotype structure breaks down as 
a result of genetic drift, adaption, and additional mating.  We define genetic ancestry as the 
proportions of the genome that are attributable to one or more putative ancestral populations.  Put 
simply, for each haplotype in an individual’s genome, we find the ancestral population that has the 
best matching combination of alleles at the same genomic location, creating a block of ancestry.  
After this procedure, we sum up the length of each ancestry block to find the percent ancestry for 
each putative ancestral component in an individual’s genome.  The exact method of assigning 
ancestry varies and can produce either global or local ancestry estimates.  Global estimates, 
produced by the program ADMIXTURE, do not reconstruct an individual’s haplotypes, and thus 
does not directly attribute ancestry to given genomic loci but instead provided a single estimate 
across the entire genome for a given ancestry.  In contrast, local ancestry, assigned by RFMix, 
involves the reconstruction and attribution of ancestry to specific genomic loci and can, therefore, 
be used to analyze patterns in admixture across the genome. 
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Estimates of global and local ancestry from ADMIXTURE and RFMix are highly 
concordant, and for most of the analysis in my dissertation, I will use global estimates.  
ADMIXTURE provides a K-way vector of K putative ancestral fraction that sum to ≈1, with K 
being a user-defined parameter defining the number of a priori expected ancestral populations.  
ADMIXTURE infers the ancestral groups based on allele frequencies within the input individuals 
by partitioning haplotypes into K groups.  ADMIXTURE was run with K=3 ancestral populations 
for all the populations studied here, with the three populations corresponding to putative ancestral 




CHAPTER 2. EXPLORING THE WORLDWIDE DIVERSITY IN 
POLYGENIC TRAITS 
2.1 Abstract 
 Human populations from around the world show striking phenotypic variation across a 
wide variety of traits.  GWAS are used to uncover genetic variants that influence the expression 
of heritable human traits; accordingly, population-specific distributions of GWAS-implicated 
variants may shed light on the genetic basis of human phenotypic diversity.  With this in mind, I 
developed the GlobAl Distribution of GEnetic Traits web server (GADGET 
http://gadget.biosci.gatech.edu).  The GADGET web server provides users with a dynamic visual 
platform for exploring the relationship between worldwide genetic diversity and the genetic 
architecture underlying numerous human phenotypes.  GADGET integrates trait-implicated single 
nucleotide polymorphisms (SNPs) from GWAS, with population genetic data from the 1000 
Genomes Project, to calculate genome-wide polygenic trait scores (PTS) for 818 phenotypes in 
2,504 individual genomes.  Population-specific distributions of PTS are shown for 26 human 
populations across 5 continental population groups, with traits ordered based on the extent of 
variation observed among populations.  Users of GADGET can also upload custom trait SNP sets 
to visualize global PTS distributions for their traits of interest. 
2.2 Background 
All human traits that have been measured thus far show evidence for some amount of 
heritability [4].  The expression of heritable traits is influenced, to varying degrees, by the presence 
of specific genetic variants.  Since the frequencies of most genetic variants are known to vary 
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among human populations, heritable traits may be expected to differ across populations as well.  
Indeed, human populations around the world show tremendous variation for a wide variety of 
heritable traits.   
GWAS can shed light on the genetic architecture underlying heritable human traits.  Over 
the last ten or so years, numerous GWAS studies have been used to discover thousands of genetic 
variants that influence the expression of hundreds of human traits, including anthropomorphic, 
behavioral, and health-related phenotypes [34].  Exploration of the distribution of GWAS 
implicated variants across global populations has the potential to yield insight into the genetic basis 
of human phenotypic variation.  
Heritable human traits are complex and polygenic; they are influenced by the action of 
genetic variants at multiple loci throughout the genome, along with environmental effects.  
Recently, genome-wide PGS have emerged as a powerful tool for predicting individuals’ 
phenotypes based on the numbers of effect (risk) alleles encoded in their genomes [35-37].  PTS 
can be computed by summing the numbers of effect alleles encoded in an individual genome, and 
scores can be weighted by considering allele effect sizes.  In the case of health-related phenotypes, 
PTS are often referred to as genetic risk scores, reflecting the predicted health risk to individuals 
entailed by the presence of disease-implicated variants in their genomes.  We reasoned that the 
calculation of PTS for different human population groups could be used to shed light on 
population-specific variation for heritable human traits.  To this end, we developed the GlobAl 
Distribution of GEnetic Traits (GADGET) web server, providing users with an intuitive tool for 
exploring the relationship between worldwide genetic diversity and the genomic architecture 
underlying a wide variety of human phenotypes (Figure 2).  The GADGET web server allows 
users to explore the population-specific distributions of pre-computed PTS for >800 human traits 
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across 26 global populations.  Users also have the option to upload custom SNP sets in order to 
assess the global distribution of PTS for their traits of interest. 
It should be noted that GADGET is intended as a tool for researchers to explore population-
specific distributions of genetic variants that have been associated with a wide variety of human 
traits.  Users of the site should treat the results with caution, as the interpretation of PTS across 
populations can be complicated by many factors [31].  In this sense, the PTS distributions returned 
by GADGET can perhaps best be considered as working hypotheses, rather than definitive 




Figure 2. Schematic overview of the GADGET web server workflow.   
Curated (Explore mode) or user-provided (Compute mode) trait SNP sets are used to calculate 
genome-wide PTS.  Population-specific PTS distributions are shown for 26 global populations 
organized into 5 continental (super) population groups.  Among population PTS variation is 
quantified with ANOVA (F-stats and P-values provided).     
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2.3 Material and Methods 
2.3.1 GADGET Platform 
The GlobAl Distribution of GEnetic Traits (GADGET) webserver frontend and 
visualizations are built using the R programming language (https://www.r-project.org) with the 
Shiny web development package (http://shiny.rstudio.com).  The user-editable spreadsheet is 
provided by rhandsontable (https://github.com/jrowen/rhandsontable), and shinyjs 
(https://github.com/daattali/shinyjs) provides the R-to-javascript interface for custom tab 
interactions and input validation.  GADGET results are visualized with ggplot2 (http://ggplot2.org) 
(box plots and strip charts) and leaflet.js (http://leafletjs.com) (maps).  The computation backend 
consists of an SQL database and companion Perl and Python scripts for data validation and PTS 
score calculation.  In an effort to simplify the deployment of the Explore module, pre-computed 
results are exported to flat-files.  GADGET supports the sharing of results via the “Share Table” 
function. 
2.3.2 Polygenic trait SNP data 
The GADGET web server allows users to (1) explore the global distributions of pre-
computed genome-wide polygenic trait scores (PTS) for >800 phenotypes, or (2) to compute 
worldwide PTS for user-defined traits of interest.  The pre-computed PTS are based on trait-
specific sets of SNPs taken from the NHGRI-EBI GWAS Catalog. In contrast, the user-defined 
PTS are derived using user-supplied sets of SNPs corresponding to traits of interest.  Both pre-
computed and user-defined PTS are calculated using genome sequence variant data for 2,504 




Polygenic trait and SNP (effect allele) information used to compute PTS were taken from 
the NHGRI-EBI GWAS Catalog version 1.0.1 [34], and trait descriptors were organized into 
functionally coherent trait categories using the EBI Experimental Factor Ontology [38] November 
2017 data release.  We rely on the NHGRI-EBI GWAS Catalog study eligibility criteria and SNP 
reporting methods (https://www.ebi.ac.uk/gwas/docs/methods) to curate SNPs associated with 
specific traits; accordingly, SNPs are incorporated into our trait-specific SNP sets if they show a 
genome-wide association P-value < 1.0e-5.  The trait-associated SNPs curated from the NHGRI-
EBI GWAS Catalog are all based on dbSNP build 150 and the human genome assembly version 
GRCh38.p10.  For each trait-associated SNP, we record the effect allele reported by the GWAS 
catalog for PTS score calculation.  SNP effect alleles are all indexed to the positive strand.    
Two classes of trait-specific SNP sets were curated for subsequent PTS calculation: (1) 
individual trait SNP sets parsed directly from the NHGRI-EBI GWAS Catalog annotations, and 
(2) higher-order trait SNP sets organized according to the EBI Experimental Factor Ontology.  For 
the individual trait SNP sets, text strings from the NHGRI-EBI GWAS Catalog were first 
normalized in order to import the data into an SQL database.  Primary SNP sets were created by 
querying the database for each unique entry in the “DISEASE/TRAIT” column.  Resulting subsets 
were then filtered to remove interaction terms, duplicate variants, and multi-allelic variants that do 
not have defined effect alleles.  Effect and non-effect alleles were swapped as needed to be 
consistent within a set (e.g., all effect alleles in the “Type 2 Diabetes” set should increase the risk 
of diabetes).  Finally, trait SNP sets with fewer than three variants were removed after the other 
filters were applied.   
For the higher-order trait SNP sets, the EBI Experimental Factor Ontology was parsed to 
obtain terminal nodes and subterminal (internal) nodes with high numbers of connected terminal 
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nodes.  First, the terminal node trait descriptors were used to create trait SNP sets from the filtered 
NHGRI-EBI GWAS Catalog annotations described in the previous paragraph.  The majority of 
the resulting trait SNP sets were identical to the existing individual trait SNP sets taken directly 
from the NHGRI-EBI GWAS Catalog.  The resulting trait SNP sets that differed from the existing 
sets were retained as additional sets for subsequent PTS calculation.  Second, trait descriptors from 
the highly connected subterminal nodes were used to create higher-order, functionally coherent 
trait SNP sets from the filtered NHGRI-EBI GWAS Catalog annotations.  The rationale for this 
approach was to maximize the ability to calculate PTS for the traits reported in the NHGRI-EBI 
GWAS Catalog.  For example, there are a number of GWAS studies for which the NHGRI-EBI 
GWAS Catalog only reports a single SNP for a given trait, and thus do not yield sufficient 
information for PTS calculation.  Combining identical or related traits into more densely populated 
higher-order SNP sets allows for greater trait coverage of the GWAS Catalog for PTS calculations.   
All of the trait descriptors parsed from the Experimental Factor Ontology were 
hierarchically organized into a custom ontology containing 818 discrete traits, a browsable 
visualization of which is available online at https://gadget.biosci.gatech.edu/ontology.html.  This 
custom ontology was created to yield a simplified and more intuitive organizational scheme for 
human phenotypes, which we used to classify our trait SNP sets into 11 functionally related 
categories for visualizing PTS results: aging, brain health and disorders, cancer, diabetes, general 
health, heart and health disorders, immune disease and disorders, miscellaneous, obesity, 
pulmonology, and reproductive health. 
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2.3.3 Individual and population-specific SNP variant data 
The GADGET web server uses publicly available genotype data from the 1000 Genomes 
Project (1KGP) Phase 3 data release [39] to compute genome-wide PTS for 2,504 individuals from 
26 worldwide populations, which are organized into five continental (or super) population groups 
according to the 1KGP scheme: African (AFR), Admixed American (AMR), East Asian (EAS), 
European (EUR), and South Asian (SAS).  SNP variant genotype data for these individuals were 
downloaded as VCF files from the 1KGP website at http://www.internationalgenome.org/data.  
The VCF files were processed to remove SNP variants with >5% missingness, and the remaining 
variants were annotated with SnpEff [40].  A customized version of the Gemini v0.20.0 application 
[41] was used to import the resulting filtered and annotated VCF files into an SQLite3 database.  
The same database was populated with trait and GWAS citation information for all of the trait SNP 
sets created as previously described.  The resulting combined database is queryable by 
chromosomal position, rsID, gene symbol, trait name, and PMID.  
2.3.4 Genome-wide polygenic trait scores 
Genome-wide PTS are calculated for individual genome sequences from the processed 
1KGP SNP variant data using the curated trait SNP sets described previously (Explore mode) or 
with user-supplied SNP sets that correspond to traits of interest (Compute mode).  In the Explore 
mode, unweighted PTS (uPTS) are calculated as the normalized sums of the number of effect 
alleles found in the genome for all trait-associated SNPs: 






�  (1) 
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where 𝐸𝐸𝐴𝐴𝑖𝑖 ∈ {0, 1, 2} are homozygous absent, heterozygous, and homozygote present effect 
alleles for each trait-associated SNP i and 𝐴𝐴𝑖𝑖 ∈ {0, 1, 2} are the total number of alleles with 
basecalls at each SNP i.  PTS are only computed for cases where there are at least 3 SNP positions 
with basecalls, i.e., when ∑ 𝐴𝐴𝑖𝑖  𝑛𝑛𝑖𝑖=1 ≥ 6, thereby eliminating the possibility of any division by zero 
error.  In the Compute mode, PTS can be computed for user-supplied SNP sets as either 
unweighted or weighted sums of the number of effect alleles.  Weighted PTS (wPTS) employ 
effect size estimates, either odds ratios or β-values, to weight the numbers of observed effect alleles 
for each trait-associated SNP: 






�  (2) 
where esi is the SNP-specific effect size estimate. 
2.4 Results 
2.4.1 Explore mode 
In the Explore mode of the GADGET web server, users can visualize the global 
distributions of genome-wide PTS for 821 polygenic traits organized into 11 phenotypic 
categories.  For each trait, unweighted PTS (equation (1)) are calculated for the 2,504 individual 
genomes from the 1KGP, and population-specific PTS distributions are shown for 26 global 
populations organized into 5 continental (super) population groups.  The resulting population-
specific PTS are visualized as scaled circles on a global map as well as population-specific box 
plots.  The area (𝐴𝐴) of the circle for each population (𝑖𝑖) is computed as: 𝐴𝐴𝑖𝑖 = 𝜋𝜋𝑟𝑟2, where 𝑟𝑟 =
10 × (2𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖 max𝑃𝑃𝑃𝑃𝑃𝑃⁄ ).  The among population variance of trait-specific PTS is measured using 
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ANOVA, for the five continental population groups, with F-statistics, P-values and false discovery 
rate q-values reported in the trait table.  A detailed summary of population-specific PTS values, 
along with the results of the ANOVA analyses, are provided in the ‘Summary statistics’ field.    
Figure 3 shows an example of the Explore mode output for the trait diisocyanate-induced 
asthma, which shows the most extreme population-specific PTS distributions for any of the pre-
computed traits.  Diisocyanates are chemical building blocks used to make a wide array of 
polyurethane products and represent a ubiquitous environmental contaminant.  They are a leading 
cause of workplace respiratory problems and representative of a large class of environmental 
triggers for respiratory distress [42, 43].  Accordingly, diisocyanate-induced asthma has been 
investigated by GWAS in an effort to elucidate the genetic architecture of environmentally 
triggered asthma [44].  Results generated by the GADGET web server show that individuals from 
African populations have a far higher genetic risk for environmentally triggered asthma than any 
other population group, as measured by their diisocyanate-induced asthma PTS.  The East Asian 
and Admixed American population groups, which show similar diisocyanate-induced asthma PTS 
distributions, have the next highest genetic risk profiles for this trait. In contrast, European 
populations show uniformly low diisocyanate-induced asthma PTS.   
These PTS distributions reflect known health disparities for asthma, underscoring the 
potential utility of comparing PTS across global population groups for investigating the genetic 
basis of population-specific health outcomes.  The results are consistent with previous work 
showing a relationship between African genetic ancestry and asthma risk in African Americans 
[45].  Furthermore, in the United States, African-Americans have the highest prevalence of 
environmentally triggered asthma, followed by Hispanics and East Asians, with European 
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Figure 3. Example output for the GADGET Explore mode.   
Users can explore global PTS distributions for 821 traits organized into 11 phenotypic 
categories.  The summary table shows traits in descending order of their ANOVA F-statistics, 
measuring the extent of among population PTS variation, alongside their statistical significance 
values (P and q).  Example results are shown for the highlighted trait diisocyanate-induced 
asthma.  Scaled circles are used to represent population-specific PTS values on a global map.  
Box-plot PTS distributions are shown for all 26 global populations and the 5 continental (super) 
population groups.  Users have the option to view all the SNPs and effect alleles used to compute 
PTS for the displayed trait.  
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2.4.2 Compute mode  
In the Compute mode of the GADGET web server, users can supply their own SNP sets in order 
to analyze global PTS distributions for their traits of interest.  The required fields for user-supplied 
trait SNP tables are: rsIDs, the identity of the effect allele, trait name, and effect size estimates.  
PTS for the 1KGP individuals and populations can be computed as unweighted or weighted, and 
users can supply SNP sets for one or more traits of interest in a single file.  The SNP set input file 
format requirements are specified on the website along with an example SNP table that can be 
downloaded and/or run on the server. 
Figure 4 shows the Compute mode output for acute kidney disease based on the example SNP 
table that is found on the website.  These SNPs were curated from a trans-ethnic meta-analysis of 
five acute kidney disease GWAS, wherein SNP effects were inferred separately for African, 
European, and Native American ancestry groups [47].  The example input SNP table for this trait 
considers SNP effects separately for African-American (AfrAm), American Indian (AmInd), and 
European American (EurAm) GWAS-implicated SNPs, following the convention of the original 
paper, as can be seen in phenotype column labels.  Once the PTS are computed for the three distinct 
SNP sets, users can toggle among the results for each set using the dropdown menu (‘Choose a 
phenotype to explore’).  In this way, the extent to which PTS are influenced by the population 
ancestry of the study subjects in the GWAS can be assessed.  For this particular trait, the global 
PTS distributions are highly similar across each of the three ancestry-specific SNP sets.  African 
populations consistently show the highest PTS distributions for acute kidney disease, with the 
European and Admixed American groups being intermediate and the two Asian population groups 




Figure 4. Example output for the GADGET compute mode.   
Users can supply their own trait SNP sets for PTS calculation and global PTS distribution 
visualization.  An example trait SNP table, for acute kidney disease, is shown here.  This trait is 
broken down into three phenotypes based on the ancestry-origin of the GWAS SNPs used for 
PTS calculation.  PTS are calculated for all phenotypes, and users can explore each phenotype 
individually.  As with the pre-computed PTS shown in the explore mode, PTS calculated from 
user-supplied SNP sets are visualized on a global map and as population-specific box plots.  




2.5.1 Methods for calculating PTS 
There are a number of different factors that need to be considered when choosing the 
specific set of SNPs to be used in PTS calculation for any given trait (BioRxiv: 
https://www.biorxiv.org/content/early/2017/02/05/106062).  The most fundamental decision 
relates to the number of SNPs to include in a trait set.  At the extreme ends of the spectrum, there 
is the top-SNP approach, whereby only SNPs that reach genome-wide significance are used for 
either unweighted or weighted score calculation, versus the all-SNP approach, whereby effect sizes 
are used to weight the phenotypic contributions of all the SNPs that were genotyped in a given 
study.  Between these two extremes, PTS calculation methods can use different GWAS P-value 
thresholds to determine whether SNPs should be included in a trait set.  The approach that the 
GADGET web server uses to calculate PTS can be considered as a soft version of the top-SNP 
approach since it employs a fairly stringent P-value threshold of 10-5, which is nevertheless far 
more inclusive than the standard GWAS genome-wide significance threshold of 10-8.  Our 
approach is also distinguished by the fact that it sometimes combines SNPs from multiple GWAS 
into single trait sets.  We have found that this approach provides additional resolution for PTS 
calculation, based in part on the use of larger numbers of SNPs for PTS calculation.  Since the 
effect sizes between multiple studies may not be directly comparable, the pre-computed PTS 
reported in the server’s explore mode are calculated via the unweighted approach.  The option for 
users to supply their own SNP sets provides more flexibility for the computation of PTS, both with 
respect to the number of SNPs that can be used as well as the weighting scheme.
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2.5.2 Genetic ancestry effects on PTS calculation 
The vast majority of GWAS have been conducted in populations with European ancestry 
[16, 33], and the extent to which GWAS-implicated variants replicate across populations remains 
a matter of contention [32].  On the one hand, a number of trans-ethnic studies have shown that 
the majority of GWAS implicated variants replicate across populations [48-50].  This is even true 
for traits such as type 2 diabetes [51, 52], which shows highly population-specific PTS 
distributions [53, 54].  Furthermore, while the same tag SNPs may not reach genome-wide 
significance in distinct populations, the haplotypes that they mark are often found to replicate 
among populations.  Nevertheless, even SNPs that replicate between populations could differ with 
respect to population-specific effect size and explanatory power.  Furthermore, a recent study 
showed that the effects of demographic history on allele frequencies could reduce the accuracy of 
PTS calculated among divergent populations; for example, PTS for the highly heritable trait height 
was found to be unreliable across populations [31].  Even GWAS variants that do replicate across 
populations can show substantial heterogeneity with respect to effect sizes in different populations 
(BioRxiv: https://www.biorxiv.org/content/early/2017/09/15/188094). 
In any case, the results reported by our web server should be interpreted with caution in 
light of the fact that population-specific PTS will inevitably be generated from SNPs implicated 
by GWAS on subjects with distinct ancestries.  Thus, the PTS distributions that we show may best 
be considered as hypotheses that can be used to stimulate and guide further investigations.  It is 
also worth noting that, as we illustrated in the example for acute kidney disease, the Compute 
utility provided on our webserver, whereby users provide their own SNP sets for traits of interest, 
provides one way to explore whether and how the ancestry of GWAS study subjects influences 
population-specific distributions of PTS.  In addition, the comparison of unweighted and weighted 
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scores for user-supplied SNP sets can be used to evaluate the effect of ancestry-specific effect size 
estimates on PTS population differences. 
2.6 Conclusion 
2.6.1 Interpreting PTS differences across populations 
As mentioned previously, the meaning of PTS differences across human populations very 
much remains an area of active investigation, and there are numerous possible interpretations for 
such results.  It is important to keep these alternative explanations in mind when interpreting the 
worldwide PTS distributions generated by the GADGET server.  Some of the possible 
explanations for PTS differences among global populations are: (1) the genetic predisposition to 
the trait differs among populations, (2) the top SNPs used for the analysis differ among 
populations, but the overall genetic predisposition for the trait would balance out if additional 
SNPs were included in the PTS calculation, (3) the apparent population differences in the genetic 
predisposition for any given trait could disappear due to heterogeneous effect sizes among 
populations, (4) observed population differences in PTS could be due to stochastic effects related 
to demographic factors (e.g., genetic drift).  These are just some of the possible explanations; the 
list is by no means exhaustive.  In addition, problems with the original GWAS studies or issues 
with the accuracy of the GWAS database used to generate trait-associated SNP sets could also 
cause problems with global PTS distributions.  In light of these caveats, PTS results generated by 
GADGET should be treated with caution.  
Finally, users are cautioned not to use GADGET to draw conclusions regarding the genetic 
basis of racial differences.  GADGET allows for the interrogation of PTS differences across human 
population groups characterized as part of the 1KGP, which are defined by geographic origin and 
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distinguished by genetic ancestry.  We make no attempt to delineate racial groups from these 
populations and the extent to which racial classifications accurately reflect genetic ancestry 
remains a matter of contention [55-57].  
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CHAPTER 3. THE PHENOTYPIC CONSEQUENCES OF GENETIC 
DIVERGENCE BETWEEN ADMIXED LATIN AMERICAN 
POPULATIONS: ANTIOQUIA AND CHOCÓ, COLOMBIA  
3.1 Abstract 
Genome-wide association studies have uncovered thousands of genetic variants that are 
associated with a wide variety of human traits.  Knowledge of how trait-associated variants are 
distributed within and between populations can provide insight into the genetic basis of group-
specific phenotypic differences, particularly for health-related traits.  We analyzed the genetic 
divergence levels for (i) individual trait-associated variants and (ii) collections of variants that 
function together to encode polygenic traits, between two neighboring populations in Colombia 
that have distinct demographic profiles: Antioquia (Mestizo) and Chocó (Afro-Colombian).  
Genetic ancestry analysis showed 62% European, 32% Native American, and 6% African ancestry 
for Antioquia compared to 76% African, 10% European, and 14% Native American ancestry for 
Chocó, consistent with demography and previous results.  Ancestry differences can confound 
cross-population comparison of polygenic risk scores (𝑃𝑃𝑃𝑃𝑃𝑃); however, we did not find any 
systematic bias in 𝑃𝑃𝑃𝑃𝑃𝑃 distributions for the two populations studied here, and population-specific 
differences in 𝑃𝑃𝑃𝑃𝑃𝑃 were, for the most part, small and symmetrically distributed around zero.  Both 
genetic differentiation at individual trait-associated SNPs and population-specific 𝑃𝑃𝑃𝑃𝑃𝑃 differences 
between Antioquia and Chocó largely reflected anthropometric phenotypic differences that can be 
readily observed between the populations along with reported disease prevalence differences.  
Cases where population-specific differences in genetic risk did not align with observed trait 
(disease) prevalence point to the importance of environmental contributions to the phenotypic 
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variance for both infectious and complex common diseases.  The results reported here are 
distributed via a web-based platform for searching trait-associated variants and 𝑃𝑃𝑃𝑃𝑃𝑃 divergence 
levels at http://map.chocogen.com.  
3.2 Background 
The genetic basis of human phenotypic diversity is both an issue of fundamental 
evolutionary interest and critical to a deeper understanding of health disparities.  Early genetic 
linkage analyses, and more recent GWAS, have uncovered thousands of genetic variants that are 
associated with a wide variety of human traits [34, 58].  Investigations of how trait-associated 
genetic variants are distributed within and between populations have the potential to shed light on 
the genetic architecture of human phenotypic diversity, particularly as related to disease prevalence 
disparities [59, 60].   
The power of this approach has long been apparent for single locus traits.  Population-
specific distributions of rare and highly penetrant variants that cause Mendelian diseases are 
responsible for a wide variety of population health disparities, such as sickle-cell anemia (OMIM: 
603903), cystic fibrosis (OMIM: 219700) and Tay-Sachs disease (OMIM: 272800).  Of course, 
the vast majority of human traits are encoded by multiple loci, each of which contributes only a 
small fraction of the total trait variance [61]. Individuals’ genomic predispositions to such multi-
locus traits can be captured by 𝑃𝑃𝑃𝑃𝑃𝑃 – also known as polygenic risk scores, genome-wide risk 
scores, or genetic risk scores – which are calculated as (weighted) sums of the total number of 
trait-associated or trait-increasing alleles present in the genome [35, 62].  Changes in 𝑃𝑃𝑃𝑃𝑃𝑃 
distributions across populations have been taken as evidence of polygenic selection on a number 
of anthropometric [63-65], neurological [66], and disease-related traits [67]. 
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Despite their apparent potential for discovering genetic changes that underlie phenotypic 
divergence among populations, recent studies have underscored a number of challenges entailed 
by cross-population comparisons of 𝑃𝑃𝑃𝑃𝑃𝑃.  Systematic differences in allele frequencies, proportions 
of ancestral versus derived alleles, and patterns of linkage disequilibrium can yield large shifts in 
𝑃𝑃𝑃𝑃𝑃𝑃 distributions that do not necessarily reflect observed phenotypic differences among 
populations [23, 30, 31].  Furthermore, the fact that the vast majority of GWAS have been 
conducted on cohorts of European ancestry [16, 32, 33] yields 𝑃𝑃𝑃𝑃𝑃𝑃 that are far more accurate for 
European populations compared to other, less-studied global population groups [24].  In light of 
these challenges, the goals of this study were to: (1) characterize the genetic ancestry patterns for 
diverse populations from within a single Latin American country, (2) evaluate the impact of 
ancestry differences between these populations on the genetic variants associated with 
anthropometric and disease traits, and (3) consider observed differences in the frequencies of trait-
associated variants in light of known phenotypic differences between the populations. 
Recently admixed populations hold great promise for studies aimed at characterizing the 
genetic basis of phenotypic divergence [68], but studies of cross-population 𝑃𝑃𝑃𝑃𝑃𝑃 have yet to focus 
explicitly on admixed populations.  Furthermore, studies of this kind have not focused on diverse 
populations that often co-exist in close physical proximity in the modern world.  Our research 
group is focused on the study of admixed American populations, with the broad aim of relating 
differences in ancestry to genetic determinants of health-related phenotypes [69-74].  Latin 
American populations are particularly interesting for studies of this kind, given their high levels 
of genetic admixture among ancestral African, European, and Native American population groups 
[75-78].  Populations within and between Latin American countries are characterized by different 
levels of continental and regional ancestry.  We have been studying two neighboring populations 
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from Colombia – Antioquia and Chocó – that are distinguished by a combination of close 
proximity and divergent demographic profiles.  We previously found that sample donors from 
Antioquia show primarily European genetic ancestry, whereas donors from Chocó show majority 
African ancestry [79, 80], and we showed that this divergent genetic ancestry, and the allele 
frequency differences that it entails, lead to an increase in the predicted risk of type 2 diabetes 
(T2D) in Chocó compared to Antioquia [54].  T2D is an intensively studied disease, and this 
pattern of greater predicted T2D risk in Chocó holds irrespective of the ancestry of the GWAS 
cohorts used for risk allele discovery [81].  For this study, we performed a broader survey of the 
genetic divergence levels for trait-associated variants and differences in 𝑃𝑃𝑃𝑃𝑃𝑃 for these two 
admixed Colombian populations, and we considered the results of these comparisons in light of 
known (observable) demographic and phenotypic characteristics for these two populations. 
3.3 Materials and Methods 
3.3.1 Genomic data  
The sources of genomic data used for this study are shown in Table 1.  Whole genome 
genotype data for the population of Chocó, Colombia, were taken from the ChocoGen research 
project https://www.chocogen.com [79, 80].  The ChocoGen project was conducted with the 
approval of the Ethics Committee of the Universidad Tecnológica del Chocó (ACTA No 01-v1) 
following the Helsinki ethical principles for medical research involving human subjects.  All 
sample donors signed informed consent documents.  Whole genome sequence data for the 
population of Antioquia, Colombia were taken from the phase 3 data release of the 1000 Genomes 
Project [82].  The 1000 Genomes Project human genome sequence data are de-identified and made 
publicly available for research use without restriction.   
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The whole genome sequence and genotype data for continental reference populations from 
Africa, the Americas, and Europe were taken from the 1000 Genomes Project and a collection of 
previously characterized Native American populations [83].  The Native American genotype data 
are de-identified and made publicly available for research according to the terms of a data use 
agreement from the Universidad de Antioquia.  A list of all bioinformatics programs and databases 
used for the analyses is shown in Table 2.       
3.3.2 Genetic ancestry analysis 
Whole genome genotype and sequence variant data were merged using PLINK version 1.9 
[84], with SNPs common to all three data sources retained for subsequent analysis and SNP strand 
orientations corrected as needed.  The merged SNP set was phased using ShapeIT version 2.r837 
with the 1000 Genomes Project haplotype reference panel [85, 86], and PLINK was used to prune 
linked SNPs from the phased genotype dataset with an r2 threshold of 0.1.  The merged and pruned 
SNP set was used to infer three-way continental ancestry (fAfrican, fEuropean, fNativeAmerican) for 
Antioquia and Chocó using the program ADMIXTURE version 1.3.0  [87] run in unsupervised 
mode, with K=3  continental ancestral groups corresponding to the African, European, and Native 
American reference populations shown in Table 1.  SNP allele frequency differences and Fixation 
Index (FST) values between Antioquia and Chocó were computed from the merged SNP set using 
PLINK.  FST values were calculated using the Weir and Cockerham estimator [88].  Ternary plots 
were constructed using the inferred global ancestry fractions for each individual and the position 














𝐸𝐸 + 𝐴𝐴 + 𝑁𝑁
 (3) 
 where 𝐸𝐸, 𝐴𝐴, and 𝑁𝑁 are the inferred European, African, and Native American ancestry components. 
3.3.3 SNP trait-associations and polygenic scores 
SNP trait-associations were taken from the NHGRI-EBI GWAS Catalog 
(https://www.ebi.ac.uk/gwas/) [89], with the SNP rsid number, effect allele, effect size, and study 
population recorded for all associations.  Effect alleles are operationally defined as the allele for 
any given SNP that is associated with cases, for case-control GWAS, or with an increase in the 
trait under consideration for quantitative trait GWAS.  The SNP associations used here are limited 
to biallelic variants, do not include SNP interactions, and are all significant at P<1x10-5 (# of SNPs 
= 107,784).  SNP associations were grouped into polygenic traits using the NHGRI-EBI GWAS 
Catalog trait terms (# of traits = 2,382), which are derived from the EBI Experimental Factor 
Ontology (https://www.ebi.ac.uk/efo/) [90].  After filtering, 65,283 (60.5%) SNPs remained.  Of 
the 27,886 (39.5%) associations excluded: 25,305 (23.5%) had an unknown or unreported effect 
allele (effect allele = “?”); 14,615 (13.5%) had multiple reported effect alleles for the same trait 
and reported effect alleles were not strand-flips (i.e., A and C); and 2,581 (2.4%) had no associated 
rsID (i.e., the variant is given by chromosomal location, chr1:2345). 
Whole genome genotype data from Chocó were imputed up to 1000 Genomes phase 3 
variant calls using the program IMPUTE2 version 2.3.2 [91, 92] and the 1000 Genomes Project 
haplotype reference panel.  Imputed sites were retained for subsequent analysis if they had a 95% 
imputation rate across samples and an INFO score > 0.4.  The imputed data from Chocó were 
merged with the whole genome sequence variant data from Antioquia using PLINK. 
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Polygenic risk scores (𝑃𝑃𝑃𝑃𝑃𝑃) were computed for each GWAS trait 𝑖𝑖 as the sum of the effect 
alleles across all trait-associated SNPs as previously described (Equation (1):  The “top-SNP” 
approach, i.e., the use of only highly significantly associated SNPs for 𝑃𝑃𝑃𝑃𝑃𝑃 calculation, was 
chosen to mitigate confounding effects of population structure on 𝑃𝑃𝑃𝑃𝑃𝑃 comparisons.  Unweighted 
𝑃𝑃𝑃𝑃𝑃𝑃 were used to allow for combining SNP trait-associations across multiple studies, each with 
distinct effect size estimates.  We opted not to use linkage disequilibrium (LD) pruning for 𝑃𝑃𝑃𝑃𝑃𝑃 
calculation to facilitate direct comparison of PRS between populations with divergent LD 
structure.    
For each of the three continental ancestry components (fAfrican, fEuropean, fNativeAmerican), 
individuals' continental ancestry fractions were regressed against their PRS using unweighted 
ordinary least squares regression (OLS): 
𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖 =  𝛼𝛼 + β𝑥𝑥𝑖𝑖 + 𝜀𝜀𝑖𝑖 (4) 
where 𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖is the predicted polygenic risk score for individual 𝑖𝑖; α and β are constants describing 
the intercept and slope, respectively; 𝑥𝑥𝑖𝑖 is the ancestry fraction for individual 𝑖𝑖; and 𝜀𝜀𝑖𝑖 is an error 
term describing the deviation from the fitted line.  The resulting OLS produces: β0, the model β 
or slope; the standard error of the model; the 𝑟𝑟2 value describing the model's fit; the model t-
statistic; and a two-tailed P-value. 
Trait-associated SNPs were mapped to the nearest genes for pathway enrichment analysis 
using the ENSEMBL rsID to HGNC mapping API (getBM) provided as part of the biomaRt R 
package (attributes = refsnp_id, ensemble_gene_stable_id, hgnc_symbol, entrezgene_id; filter = 
snp_filter & ensembl_gene_id; values = GWAS Catalog SNP rsIDs).  SNPs that did not return an 
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HGNC mapping were discarded.  Genes were assigned population-specific effect allele frequency 
difference values (∆𝑓𝑓 = 𝑓𝑓(𝐸𝐸𝐴𝐴𝐴𝐴𝑛𝑛𝐴𝐴) − 𝑓𝑓(𝐸𝐸𝐴𝐴𝐶𝐶ℎ𝑜𝑜)) based on the SNP with the maximum effect allele 
frequency difference: max |∆𝑓𝑓𝑔𝑔,𝑖𝑖|, where 𝑔𝑔 is a trait-associated gene, and 𝑖𝑖 is 𝑖𝑖th SNP in the gene 
𝑔𝑔.  The ∆𝑓𝑓 values for all mapped trait-associated genes were used to create population-specific 
gene lists for pathway over-representation analysis using the hypergeometric test implemented in 
the “enricher” function from the clusterProflier version 3.14.0 R package [93].  Briefly, for each 
gene, the sign on ∆𝑓𝑓 was used to assign a gene to the Antioquia (positive) or Chocó (negative) 
gene lists.  For each population-specific gene list and for each gene set, a hypergeometric test was 






, where 𝑚𝑚 is the number of population-specific genes, 𝑘𝑘 is the number 
of population-specific genes in the gene set, 𝑛𝑛 is the number of genes in gene set, and 𝑁𝑁 is number 
of genes in the background.  Gene sets from the KEGG, MSigDB 
(http://software.broadinstitute.org/gsea/msigdb/), and PID (http://pid.nci.nih.gov) were used in the 
enrichment analysis. 
The relative predicted disease risk and observed disease prevalence for Antioquia and 
Chocó were computed as the log2 odds ratio for the effect of allele frequencies and the reported 
age-adjusted disease prevalence values for Chocó/Antioquia.  For each disease-associated SNP, 
its log odds ratio is computed as: log2
𝑝𝑝𝐶𝐶ℎ𝑜𝑜 𝑞𝑞𝐶𝐶ℎ𝑜𝑜⁄
𝑝𝑝𝐴𝐴𝑛𝑛𝐴𝐴 𝑞𝑞𝐴𝐴𝑛𝑛𝐴𝐴⁄
, where 𝑝𝑝𝑝𝑝𝑜𝑜𝑝𝑝 is the population-specific frequency 
of the effect allele and 𝑞𝑞𝑝𝑝𝑜𝑜𝑝𝑝 is the population-specific frequency of the non-effect allele.  The log 
odds ratio values for all associated SNPs were summed for each disease.  The log odds ratio for 
disease prevalence is computed as: log2
𝐷𝐷𝑖𝑖𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐶𝐶ℎ𝑜𝑜 𝑁𝑁𝑜𝑜 𝑑𝑑𝑖𝑖𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐶𝐶ℎ𝑜𝑜⁄
𝐷𝐷𝑖𝑖𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐴𝐴𝑛𝑛𝐴𝐴 𝑁𝑁𝑜𝑜 𝑑𝑑𝑖𝑖𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐴𝐴𝑛𝑛𝐴𝐴⁄
.  Disease prevalence (𝐷𝐷𝑖𝑖𝑒𝑒𝑒𝑒𝐷𝐷𝑒𝑒𝑒𝑒𝑝𝑝𝑜𝑜𝑝𝑝 
and 𝑁𝑁𝑁𝑁 𝑑𝑑𝑖𝑖𝑒𝑒𝑒𝑒𝐷𝐷𝑒𝑒𝑒𝑒𝑝𝑝𝑜𝑜𝑝𝑝) was defined as the population- and age-adjusted prevalence per 100,000 and 
(100,000 –  𝑝𝑝𝑟𝑟𝑒𝑒𝑝𝑝𝐷𝐷𝑝𝑝𝑒𝑒𝑛𝑛𝑝𝑝𝑒𝑒) reported for each department in 2017 and were taken from Colombian 
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governmental and non-governmental resources (see Demographic, lifestyle and disease 
prevalence data section below). 
3.3.4 Demographic, lifestyle and disease prevalence data 
A variety of sources was used to curate demographic, lifestyle, and disease prevalence data 
for Antioquia and Chocó.  The 2005 general census published by the Colombian Departamento 
Administrativo Nacional de Estadística (DANE) was used for demographic and socio-economic 
status data [94].  Disease prevalence data were taken from three epidemiological databases: (1) 
Cuenta de Alto Costo (https://cuentadealtocosto.org/), (2) Observatorio de Diabetes de Colombia 
(http://www.odc.org.co/), and (3) the Sistema Integral de Información de la Protección    Social 
(https://www.minsalud.gov.co/salud/Paginas/SistemaIntegraldeInformaciónSISPRO.aspx).  Diet 
and lifestyle data were taken from the Colombian national nutritional survey [95]. 
3.4 Results and discussion 
3.4.1 Demography and genetic ancestry in Antioquia and Chocó 
Antioquia and Chocó are Colombian administrative departments (i.e., states) that are 
located in the northwestern part of the country and share a common border (Figure 5A).  Chocó 
runs along the Pacific coast and borders Panamá to the north; it is the only department in Colombia 
with Pacific and Atlantic coasts.  Antioquia is situated due east of Chocó, in the interior of the 
country, and also has a short Atlantic coastline.  Despite their close proximity, the two departments 
have very distinct geography and climate, as well as distinct historical and demographic profiles.  
Antioquia occupies the mountainous Andean region of the country and is traversed by the Western 
and Central Andes mountain ranges.  According to the 2005 census, approximately 89% of the 
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Antioquia population identifies as white or mestizo compared to 11% black or Afro-Colombian 
and less than 1% Indigenous.  Chocó lies along the lowland Pacific coastal region and is almost 
entirely covered by dense tropical rainforest.  The climate is hot and humid, and the region receives 
some of the highest rainfall totals in the world.  The population of Chocó identifies as 8% Afro-
Colombian, 13% Indigenous, and 5% white or mestizo. 
Genome-wide variant data from Antioquia and Chocó were compared to data from African, 
European, and Native American continental reference populations to infer the patterns of genetic 
ancestry and admixture in the two Colombian populations.  The genetic ancestry of Antioquia and 
Chocó reflect their distinct historical founding populations, physical and cultural barriers to 
migration, and current demographic profiles (Figure 5B and C).  Antioquia shows predominantly 
European genetic ancestry (average ± standard error; 62% ± 1.55) followed by Native American 
(32% ± 1.24) and then African (6% ± 0.83) components; whereas, Chocó has primarily African 
genetic ancestry (76% ± 1.65) with approximately equal parts Native American (14% ± 0.83) and 





Figure 5. Genetic ancestry in Antioquia and Chocó. 
(A) The locations of the Colombian administrative departments of Chocó (purple) and Antioquia 
(green) are shown along with pie charts indicating the average continental ancestry fractions: 
African (blue), European (orange), and Native American (red).  (B) Ternary plots showing the 
relative contributions of African, European, and Native American ancestry to individuals from 
Antioquia (green) and Chocó (purple).  (C) ADMIXTURE plot showing the continental ancestry 
fractions for African (blue), European (orange), and Native American (red) reference 




3.4.2 Single variant divergence and phenotypic associations 
The potential impact of ancestry differences between Antioquia and Chocó on the genetic 
architecture of phenotype and function was assessed for individual SNP trait-associations (Figure 
6).  A total of 47,398 SNP trait-associations were curated and evaluated with respect to the extent 
and direction of differentiation between Antioquia and Chocó.  Population differentiation was 
measured by effect allele FST values and frequency differences between the two populations 
(Figure 6A and B, Table 5).  The top 20 most extreme values correspond to both known phenotype 
and disease prevalence differences between the two populations as well as novel differences 
(Figure 11).  Pigmentation associated variants for both skin and hair show expected differences 
with lighter skin and hair effect alleles found in higher frequency in Antioquia compared to Chocó.  
Antioquia also shows higher frequencies of Crohn’s and inflammatory bowel disease SNP effect 
alleles than Chocó. In contrast, Chocó shows higher frequencies of variants associated with 
prostate and breast cancer along with Alzheimer’s and asthma, consistent with known health 
disparities around the world.  Chocó also showed a substantially higher frequency of variants 
linked to resistance to the malaria parasite Plasmodium vivax.  Unexpected results include the 
higher frequency of nicotine use associated SNP effect alleles in Chocó, as tobacco use is known 
to be lower in Chocó compared to Antioquia, the greater waist-hip ratio in Antioquia, and the 
increased longevity in Chocó.   
Word clouds provide a visual sense of the overall between-population divergence for all 
trait-associated SNPs, with the most enriched traits highlighted for each population (Figure 6C).  
The word clouds were generated using all trait-associated SNPs that showed FST > 0.2, 61 SNPs 
for Antioquia and 98 for Chocó, and therefore provide additional resolution on the divergence of 
single variant associations between populations.  For example, schizophrenia appears in the word 
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clouds for both populations (Figure 6C), with more weight in Chocó. However, it was not present 
in the top 20 divergent associations shown in Figure 6 panels A and B.  Obesity-related traits 
appears as overrepresented in Chocó in the word cloud (Figure 6C), even though the most diverged 
body mass index SNP shows higher frequency in Antioquia (Figure 6A & B).  This is due to a 
preponderance of obesity-associated SNPs among the complete set of variants with FST > 0.2 and 
is consistent with what is seen via polygenic trait divergence analysis (see next section and Figure 
7).  Overall, the population divergence observed for single variant associations is consistent with 




Figure 6. Single nucleotide variant phenotype associations. 
(A) Polarized fixation index (FST) values for divergent trait-associated SNP effect alleles: higher 
effect allele frequency in Antioquia (left, green) and higher effect allele frequency Chocó (right, 
purple).  The corresponding SNP associations are shown in panel B.  (B) Heatmap of population-
specific effect allele frequencies (see key) and their SNP associations.  (C) Word clouds showing 




Figure 7. Polygenic risk divergence. 
(A) Distribution of the differences in population-average polygenic trait scores (𝑃𝑃𝑃𝑃𝑃𝑃) are shown 
for significantly divergent traits: higher in Antioquia (above, green) and higher in Chocó (below, 
purple).  (B)  Population-specific 𝑃𝑃𝑃𝑃𝑃𝑃 distributions for examples of anthropometric and disease 
traits are shown for Antioquia (green) and Chocó (purple) along with the significance levels for 
the distribution differences. Traits with increased prevalence/risk in Antioquia are shown on the 




3.4.3 Polygenic trait divergence 
Most human phenotypes are encoded by multiple loci across the genome, each of which 
contributes to a small fraction of the overall trait variance, i.e., they are polygenic.  The relationship 
between genetic ancestry and polygenic trait architecture in Antioquia and Chocó was assessed by 
comparing distributions of 𝑃𝑃𝑃𝑃𝑃𝑃 between the two populations (Figure 7,  
Table 7).  A total of 1,983 𝑃𝑃𝑃𝑃𝑃𝑃 were compared between the two populations, and the overall 
distribution of ∆𝑃𝑃𝑃𝑃𝑃𝑃 (𝐴𝐴𝑛𝑛𝐴𝐴 − 𝐶𝐶ℎ𝑁𝑁𝑝𝑝) is symmetrically distributed around -0.01 (Figure 12), 
indicating that the differences in genetic ancestry between the populations are slightly biased 
towards increased predicted risk in Chocó in cross-population 𝑃𝑃𝑃𝑃𝑃𝑃 inference (p < 0.001).  This is 
consistent with theoretical results showing that the divergence of neutral polygenic traits between 
populations is expected to be small, no different from the expectation for single gene traits, and 
symmetrically distributed around zero [96, 97].   ∆𝑃𝑃𝑃𝑃𝑃𝑃 (𝐴𝐴𝑛𝑛𝐴𝐴 − 𝐶𝐶ℎ𝑁𝑁𝑝𝑝) values for traits that show 
significantly different mean 𝑃𝑃𝑃𝑃𝑃𝑃 (Holm-Bonferroni corrected P<0.05) are shown in Figure 7A 
(column D in  
Table 7), and population-specific 𝑃𝑃𝑃𝑃𝑃𝑃 distributions for individual traits of interest are shown in 
Figure 7B.  The specific traits of interest were chosen based on their highly divergent 𝑃𝑃𝑃𝑃𝑃𝑃 values 
and their relevance to Colombia owing to the reported public health burden in the country and as 
reflected by their descriptions in epidemiological and/or census databases.  
The individual 𝑃𝑃𝑃𝑃𝑃𝑃 distributions shown in Figure 7B are organized into anthropometric 
and disease traits, most of which correspond to the top SNPs from Figure 6.  For anthropometric 
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traits, Antioquia has a higher predicted height and body mass index (BMI), whereas Chocó has 
higher predicted values for several pigmentation related traits: hair, eye, and skin color.  For 
disease traits, Antioquia has a greater predicted risk for inflammatory bowel disease, ischemic 
stroke, and allergic sensitization, whereas Chocó has a higher predicted risk for mortality in heart 
failure, immunity to malaria, and environmentally (diisocyanate) induced asthma.  We also 
explored the impact of GWAS discovery and replication population ancestry on PRS differences 
for four selected traits from Figure 6 and Figure 7 for which multiple GWAS utilizing different 
ancestry populations were available: asthma, ischemic stroke, myopia, and type 2 diabetes (Figure 
13, Table 8).  In all cases, significant differences in predicted population risk profiles were robust 
to discovery population ancestry, suggesting a shared genetic architecture of risk.  In addition, 
predicted population-specific disease risk profiles are consistent with what has been observed in 
Colombia (Table 6) as well as with known ancestry-disease associations worldwide: e.g., asthma 
[98, 99], heart failure [100, 101], irritable bowel disease [102, 103], malaria [104-106], and stroke 
[107]. 
We also explored population-specific differences in endophenotypes, with respect to 
specific pathways and biochemical functions that underlie the observed trait differences, using 
pathway enrichment analysis (Figure 8).  Antioquia shows enrichment for integrin pathways 
implicated in a number of cancers and inflammatory bowel disease.  Chocó shows enrichment for 
a number of cancer-related pathways, including prostate cancer, which is known to be more 
prevalent in men of African ancestry [108, 109], as well as T2D and related glycerolipid 
metabolism pathways.   
Given the differences in genetic ancestry seen for Antioquia and Chocó (Figure 5), we 
evaluated the relationship between individuals’ continental genetic ancestry fractions and their 
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𝑃𝑃𝑃𝑃𝑃𝑃 for each trait considered here.  It should be noted that, despite the clear differences in the 
overall ancestry differences seen for the two Colombian populations, almost all individuals 
analyzed here show substantial admixture with varying fractions of African, European, and Native 
American ancestry.  This fact allowed us to correlate genetic ancestry and 𝑃𝑃𝑃𝑃𝑃𝑃 along a continuum 
of continental ancestry fractions (Figure 9).  There are significant differences in the magnitude of 
the 𝑃𝑃𝑃𝑃𝑃𝑃 correlations among the three ancestry components (F=4.79, P=8.3×10-3); African ancestry 
shows the highest overall correlation with the 𝑃𝑃𝑃𝑃𝑃𝑃 values of all traits analyzed here, as shown by 
the median of the distribution, followed by the European and then the Native American ancestry 
components (Figure 9A).  All three populations show a number of apparent cases of high 
correlations between ancestry and 𝑃𝑃𝑃𝑃𝑃𝑃.  All traits that show r2>0.4 for any of the three ancestry 
components are shown in Figure 9B, and individual examples of ancestry × 𝑃𝑃𝑃𝑃𝑃𝑃 regressions are 
shown in Figure 9C.  Breast cancer 𝑃𝑃𝑃𝑃𝑃𝑃 is positively associated with European ancestry and 
negatively associated with African ancestry (Figure 9C), in contrast to what was seen for an 
individual breast cancer associated variant found at higher frequency in Chocó (Figure 6B).  This 
difference is best explained by the analysis of individual SNPs shown in Figure 6 and the PRS 
based on multiple SNPs, which are likely to be more reliable, shown in Figure 7 and Figure 9.  All 
ancestry × 𝑃𝑃𝑃𝑃𝑃𝑃 r2 values are shown in Table 9.    
The high correlations observed between ancestry and 𝑃𝑃𝑃𝑃𝑃𝑃 could be attributed to artifacts 
related to uneven cohort sampling in GWAS, as previously discussed, or they could represent 
actual ancestry-related phenotypic differences between the two populations.  The small overall 
systematic bias in 𝑃𝑃𝑃𝑃𝑃𝑃 for the two populations (Figure 12), considered together with the fact that 
most of these ancestry-associations conform to observable anthropometric features and/or 
previously suggest that these associations reflect real phenotypic differences.  However, definitive 
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proof for this would require individual-level phenotype data, as opposed to the population-level 
data used here, as well as the use of trait-associated variants that replicate across ancestry-specific 
GWAS.  It should also be noted that these regressions could be confounded by a number of other 
variables including sex, age, and socioeconomic status that are not available for this study, and 
which would need to be simultaneously modeled to ensure that the correlations between ancestry 





Figure 8. Population-specific differences in trait endophenotypes: pathways and 
biochemical functions. 
Gene set enrichment was used to uncover pathways and functional gene sets that are enriched 
for divergent associated SNPs in each population.  For each pathway or function, circles are 
scaled to the relative number of implicated genes for each population and colored according to 







Figure 9. Genetic ancestry and polygenic trait divergence. 
(A) Distributions of the correlations (r2) between individuals’ genetic ancestry fractions– African (blue), European (orange), Native 
American (red) – and their polygenic trait scores (𝑃𝑃𝑃𝑃𝑃𝑃) for all traits analyzed here.  Vertical lines show the median for each 
distribution.  (B) Ancestry x 𝑃𝑃𝑃𝑃𝑃𝑃 correlations (r2) polarized by the direction of the correlation (positive or negative) are shown for all 
traits where r2>0.4 for at least one ancestry component – African (A), European (E), and Native American (N).  (C)  Examples of 
polygenic traits with high correlations between ancestry and 𝑃𝑃𝑃𝑃𝑃𝑃 are shown.  Ancestry components are color-coded as in panel A, 
and for each scatter plot, ancestry fractions (y-axis) are regressed against 𝑃𝑃𝑃𝑃𝑃𝑃 (x-axis).  Linear trend lines with 95% confidence 




3.4.4 Predicted versus observed disease risk profiles 
Population-specific differences for trait-associated variants, both for single SNP 
associations and polygenic traits, showed an overall concordance between genetic risk predictions 
and observed anthropometric and epidemiological profiles for Antioquia and Chocó (Figure 6 and 
Figure 7).  We quantified the relationship between predicted disease risk and observed prevalence 
for twelve high impact diseases that have been prioritized by the Colombian Ministry of Health 
via the ‘Cuenta de Alto Costo’ (http://www.cuentadealtocosto.org/).  This analysis was done for 
complex common diseases, cancers, and infectious diseases (Figure 10).  T2D shows the largest 
difference between predicted disease risk versus observed disease prevalence for Antioquia and 
Chocó.  We previously showed that this difference could be attributed to the higher genetic risk 
associated with African genetic ancestry and T2D protective environmental factors associated with 
socioeconomic status in Chocó [54].  In Colombia, environmental factors associated with 
differences in development across the country appear to have a high impact on the risk of complex 
common diseases like T2D.  A similar, albeit not nearly as extreme, difference can be seen for 
chronic kidney disease; Chocó has a higher predicted genetic risk but lower prevalence compared 
to Antioquia.  Higher risk for chronic kidney disease has been observed for Afro-descendant 
populations in other countries [110, 111], consistent with the higher genetic risk for Chocó seen 
here; thus it may be the case that similar environmental protective factors, with respect to diet and 
lifestyle, serve as a protective factor for chronic kidney disease in Chocó.  Finally, there are large 
differences in predicted risk (susceptibility) versus observed prevalence for malaria caused by both 
Plasmodium vivax and P. falciparum.  The population of Chocó has a lower predicted risk for 
malaria infections, consistent with previous studies on Afro-descendant populations [104-106]. 
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However, both P. vivax and P. falciparum are far more prevalent in Chocó compared to Antioquia 
[112-114], thereby explaining the higher malaria prevalence in Chocó. 
 
Figure 10. Predicted versus observed disease risk. 
Left: For each disease, the predicted genetic risk difference for Antioquia compared to Chocó 
(red circles) is compared to the observed prevalence of the disease (blue circles).  Right: The 
differences between predicted disease risk minus observed prevalence.  Diseases are grouped 
into bands as complex, common diseases (yellow), cancer (blue), and infectious disease (red).  
The x-axis values are log odds ratios for population-specific disease risk allele frequencies and 
observed disease prevalence values, as described in the Materials and Methods.  
 
3.5 Conclusions 
Results on the population divergence of trait-associated variants reported here should be 
interpreted with caution in light of the previously discussed challenges to cross-population genetic 
risk inference [23, 24, 30, 31].  This is particularly true for populations that have strikingly different 
ancestry profiles, as is the case for Antioquia and Chocó.  However, for this study, the general 
concordance seen between genetically inferred (predicted) phenotypic differences and the 
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observed differences for anthropometric traits, or known prevalence differences in the case of 
disease traits, supports the approach taken here (Table 6).  It should be stressed that both trait-
associated variant allele frequencies and 𝑃𝑃𝑃𝑃𝑃𝑃 distributions overlap substantially between 
Antioquia and Chocó; in other words, predicted phenotypic differences vary along a continuum, 
with distinct group-specific averages in a minority of cases, as opposed to showing discrete values 
between populations.  This is consistent with the expectation that the majority of genetic variation 
is found within rather than between human populations [115, 116]. 
Finally, it is important to note that detailed individual-level phenotypic information will be 
needed to more rigorously evaluate the implications of genetic divergence at trait-associated 
variants in diverse populations of the kind studied here.  Fortunately, data of this kind are 
increasingly being generated by biobank collections around the world, via the combination of 
genetic profiles and detailed phenotypic information gleaned from participant surveys and 
electronic health records.  Many of these biobanks – e.g., All of Us, BioMe, and the UK Biobank 
– include the kind of ancestrally diverse participant cohorts that can facilitate detailed 
investigations on the genetic basis of group-specific trait differences and health disparities. 
The results reported here are distributed via a web-based platform that allows users to 




3.6 Supplemental information 
3.6.1 𝑃𝑃𝑃𝑃𝑃𝑃 calculation and comparison among divergent populations 
Our approach to 𝑃𝑃𝑃𝑃𝑃𝑃 calculation and comparison between populations is characterized by 
three important choices: (1) the use of only significantly associated SNPs (P<10-5) for 𝑃𝑃𝑃𝑃𝑃𝑃 
calculation, (2) the calculation of 𝑃𝑃𝑃𝑃𝑃𝑃 that are unweighted by SNP effect sizes, and (3) the 
calculation of 𝑃𝑃𝑃𝑃𝑃𝑃 without the use of linkage disequilibrium (LD) pruning or clumping.  𝑃𝑃𝑃𝑃𝑃𝑃 were 
calculated in this way to facilitate comparisons of 𝑃𝑃𝑃𝑃𝑃𝑃 distributions between divergent populations 
with distinct ancestry profiles.  This conservative approach to 𝑃𝑃𝑃𝑃𝑃𝑃 calculation and comparison is 
supported by (1) the lack of apparent systematic bias in 𝑃𝑃𝑃𝑃𝑃𝑃 differences between populations 
(Figure 12), (2) the consistency of predicted risk differences between populations with previously 
reported trait and disease prevalence differences (Table 6), and (3) the consistency of 𝑃𝑃𝑃𝑃𝑃𝑃 
differences found when different ancestry SNP-association cohorts were used (Figure 13).  Here, 
we provide additional justification for our approach to 𝑃𝑃𝑃𝑃𝑃𝑃 calculation.  
3.6.1.1 Top-SNP approach 
  There are many different ways to compute 𝑃𝑃𝑃𝑃𝑃𝑃, and the extremes are the “top-SNP” 
approach, where only highly significantly associated SNPs are used for PRS calculation and the 
“all-SNP” approach, whereas many SNPs as possible are used to calculate 𝑃𝑃𝑃𝑃𝑃𝑃.  The top-SNP 
approach is more conservative as it relies only on robust associations. In contrast, the all-SNP 
approach derives additional resolution by capturing more of the genome-wide trait heritability.  
Most importantly, for our study, the all-SNP approach will also capture most or all of the 
population structure between divergent populations, whereas the top-SNP approach is not expected 
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to do so.  In other words, when the all-SNP approach is used to compare 𝑃𝑃𝑃𝑃𝑃𝑃 for divergent 
populations, such as the kind studied here, the resulting 𝑃𝑃𝑃𝑃𝑃𝑃 are essentially guaranteed to show 
large differences between populations.  This has been convincingly shown in a recent study, where 
increasing numbers of SNPs used for 𝑃𝑃𝑃𝑃𝑃𝑃 yielded increasingly greater between-population 
differences, particularly for divergent populations [117]. 
Furthermore, recent work by Khera et al. suggests that the all-SNP approach only provides 
a marginal increase in prediction accuracy compared to the top SNP approach [118].  For example, 
a top-SNP PRS for coronary artery disease using 74 variants showed 79% accuracy compared to 
81% accuracy when 6.6 million SNPs were used for PRS calculation.   Similar marginal increases 
in accuracy between the top-SNP and all-SNP approaches were observed for the four other traits 
analyzed in the same study.  These findings support both the utility of the top-SNP approach for 
cross-population PRS comparisons and its resolution for capturing the majority of variance in trait 
risk. 
3.6.1.2 Unweighted PRS 
𝑃𝑃𝑃𝑃𝑃𝑃 can be calculated as unweighted scores by simply summing the numbers of trait-
associated effect alleles genome-wide, or they can be calculated as weighted scores, whereby each 
effect allele is weighted by its effect size (odds ratio or beta value).  As with our previous studies 
[54, 59], we chose to use unweighted 𝑃𝑃𝑃𝑃𝑃𝑃 here to facilitate the inclusion of SNP trait-associations 
from multiple studies.  Effect sizes from different studies cannot be readily combined owing to 
differences in study cohorts, including cohort size, allele frequencies, and population structure.  
Furthermore, since effect sizes represent SNP heritability estimates, which are dependent on the 
particular cohort that is being studied, it does not make sense to attempt to normalize effect sizes 
across studies.  Meta-analyses can perform this kind of normalization, as they have access to 
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individual-level phenotype data, but we do not have access to data of that kind data here.  Finally, 
the use of multiple studies allowed us to ascertain as many trait-associated SNPs as possible, which 
is particularly important given our choice of the conservative top-SNP approach that is limited to 
significantly associated SNPs. 
3.6.1.3 No linkage disequilibrium (LD) pruning 
𝑃𝑃𝑃𝑃𝑃𝑃 are often calculated using linkage disequilibrium pruning or clumping, whereby only 
a single SNP from any given LD block is used for 𝑃𝑃𝑃𝑃𝑃𝑃 calculation.  We opted not to use LD 
pruning or clumping here because (1) we use a top-SNP approach for 𝑃𝑃𝑃𝑃𝑃𝑃 calculation, and (2) the 
two populations under study have a highly divergent LD structure.  The top-SNP approach means 
that we are using a relatively small number of SNPs per population, and the divergent LD structure 
means that different subsets of this small number of SNPs would likely be removed from each 
population if LD pruning were used.  For example, LD pruning here may remove SNPs that are 
population-private (that is, a SNP that appears in Chocó but not Antioquia) or whose LD patterns 
are discordant between the two populations (i.e., the SNP is in moderate LD in Antioquia but low 
LD in Chocó).  This would severely mitigate our ability to compare 𝑃𝑃𝑃𝑃𝑃𝑃 between populations.  An 
alternative approach, as discussed previously, would be to use a very large number of variants 
together with LD pruning for 𝑃𝑃𝑃𝑃𝑃𝑃 computation, i.e., essentially covering most of all of the LD 
blocks in the genome for the 𝑃𝑃𝑃𝑃𝑃𝑃, as has been done in a number of studies.  However, when tens- 
or hundreds-of-thousands, or even millions, of SNPs are used for 𝑃𝑃𝑃𝑃𝑃𝑃 calculation between 
divergent populations, then the 𝑃𝑃𝑃𝑃𝑃𝑃 is essentially modeling the population structure between the 
populations.  In this case, all traits will be highly divergent if you are comparing divergent 
populations.  Our approach to PRS calculation without LD pruning provides for both additional 
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resolution, in terms of the numbers of SNPs available for analysis, and more direct comparisons 
between divergent populations.  Several studies, including our work, have shown that 𝑃𝑃𝑃𝑃𝑃𝑃 
calculated with and without LD pruning, do not show big differences [119, 120].   
Table 1. Human populations analyzed in this study. 
1KGP = 1000 Genomes Project Phase III 
Dataset Year Population Name Short n 
Colombian Populations 
Medina et al 2016 Chocoano in Quibdó, Colombia CHG 94 
1KGP 2015 Colombian in Medellin, Colombia CLM 94 
 Continental reference populations 
1KGP 2015 Yoruba in Ibadan, Nigeria YRI 108 
1KGP 2015 Iberian populations in Spain IBS 107 
1KGP 2015 Peruvian in Lima, Peru PEL 85 
Reich et al 2012 Embera in Colombia Embera 5 
Reich et al 2012 Quechua in Peru Quechua 40 







Table 2. Bioinformatics methods used in this study. 
Software Use Access 
PLINK version 1.9  SNP quality control, merging, 
and pruning 
https://www.cog-genomics.org/plink2/ 
ShapeIT version 2.r837 SNP phasing https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.html 
ADMIXTURE version 1.3.0 Continental genetic ancestry 
inference 
http://software.genetics.ucla.edu/admixture/ 
IMPUTE2 version 2.3.2 Genome variant imputation https://mathgen.stats.ox.ac.uk/impute/impute_v2.html 
 
Database Use Access 
NHGRI-EBI GWAS Catalog SNP trait associations and 
polygenic trait scores 





Figure 11. Distribution of polarized FST values between Antioquia and Chocó. 
FST values were polarized to facilitate comparison between Antioquia (positive) and Chocó 
(negative).  Highly differentiated alleles selected for Figure 2 are annotated (blue points).  SNP 






Figure 12. Distribution of PRS differences between Antioquia and Chocó 
A histogram of the observed 𝑃𝑃𝑃𝑃𝑃𝑃 differences is shown along with the corresponding smoothed 







Figure 13. Effect of GWAS discovery population ancestry on PRS 
Four selected traits from Figure 2 and Figure 3 were further analyzed with respect to GWAS 
discovery population ancestry, with two traits chosen for both Antioquia (ischemic stroke, myopia) 
and Chocó (asthma, type 2 diabetes).  Trends in populations PRS distributions are similar 




Figure 14. Correlations and SNP overlap among PRS 
(A) All-by-all pairwise correlations between 𝑃𝑃𝑃𝑃𝑃𝑃 from Figure 3B, hierarchically clustered by their 
Pearson correlations. (B) Distribution of Pearson correlation values, excluding self-correlation 
(n=132, mean=0.003).  (C) Distribution of the fraction of SNPs shared between PRS (common 
SNPs in intersection/union of SNPs between scores).  (D) Relationship between the fraction of 




CHAPTER 4. INFLUENCE OF GENETIC ANCESTRY AND 
SOCIOECONOMIC STATUS ON DIABETES IN THE DIVERSE 
COLOMBIAN POPULATIONS OF CHOCÓ AND ANTIOQUIA  
4.1 Abstract 
Differences in genetic ancestry and socioeconomic status (SES) among Latin American 
populations have been linked to health disparities for a number of complex diseases, such as 
diabetes.  We used a population genomic approach to investigate the role that genetic ancestry and 
socioeconomic status (SES) play in the epidemiology of type 2 diabetes (T2D) for two Colombian 
populations: Chocó (Afro-Latino) and Antioquia (Mestizo).  Chocó has significantly higher 
predicted genetic risk for T2D compared to Antioquia, and the elevated predicted risk for T2D in 
Chocó is correlated with higher African ancestry.  Despite its elevated predicted genetic risk, the 
population of Chocó has a three-times lower observed T2D prevalence than Antioquia, indicating 
that environmental factors better explain differences in T2D outcomes for Colombia.  Chocó has 
substantially lower SES than Antioquia, suggesting that low SES in Chocó serves as a protective 
factor against T2D.  The combination of lower prevalence of T2D and lower SES in Chocó may 
seem surprising given the protective nature of elevated SES in many populations in developed 
countries.  However, low SES has also been documented to be a protective factor in rural 
populations in less developed countries, and this also appears to be the case when comparing 





With ongoing economic development and the lifestyle changes that accompany increased 
standards of living, the primary disease burden in Latin America is shifting from infectious to non-
communicable, complex diseases[121].  In fact, complex common diseases such as heart disease, 
cancer, and diabetes already account for the majority of the morbidity and mortality in the 
region[122].  Complex multifactorial diseases of this kind are associated with the effects of 
multiple genetic loci combined with a variety of environmental factors, such as diet, lifestyle, and 
exposure to toxins.  The burden of complex disease is not evenly distributed within or between 
countries in Latin America; genetic and environmental differences among Latino populations often 
lead to pronounced health disparities[123].  Furthermore, population health disparities in Latin 
America tend to have a disproportionate impact on vulnerable Native American and Afro-Latino 
communities[124]. 
Diabetes mellitus is a complex multifactorial disease characterized by both a very high 
disease burden and strikingly disparate impacts among distinct populations in the Americas.  For 
example, type 2 diabetes (T2D) has a substantially higher prevalence in both Native Americans 
and African-Americans compared to European-Americans in the United States (US)[125-130].  
The higher prevalence of T2D in these populations has been associated with both genetic and 
environmental factors.  Genetic risk for T2D is correlated with both increased Native American 
and African ancestry[131-134], and low socioeconomic status (SES) has also been widely 
associated with increased T2D prevalence in Native American and African-American 
populations[135-137]. 
Latin American populations are characterized by substantial genetic admixture – with 
predominant ancestry contributions from Europe, the Americas, and Africa – owing to historical 
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patterns of migration, conquest, and slavery[138].  Colombia has among the highest levels of three-
way genetic admixture seen for any Latin American country[74, 76] and is home to a large 
population of Afro-descendants[73, 80, 139].  Estimates for the size of the Afro-Colombian 
population range from 9-20 million, making it the second-largest population of its kind in Latin 
America after Brazil.  The collaborative ChocoGen research project was conceived to study the 
genetic heritage of the Afro-Colombian population from the administrative department (i.e., state) 
of Chocó, located along Colombia’s Pacific coast (http://www.chocogen.com)[80, 139].  The 
ChocoGen project has the joint aims of (1) characterizing the genetic ancestry of the population of 
Chocó, and (2) exploring the relationship between genetic ancestry and determinants of health and 
disease in the region. 
The objective of the study was to evaluate the contributions of genetic ancestry and 
environmental factors to population health disparities in Chocó, and we addressed this issue here 
via a population genomic study of the genetic risk and the observed prevalence of T2D.  Our efforts 
towards this end involve a comparison between the populations of Chocó and the neighboring state 
of Antioquia, which borders Chocó to the east (Figure 19).  Despite their proximity, Chocó and 
Antioquia have very distinct demographic and economic profiles.  According to the 2005 
Colombian census, the population of Chocó was 82% Afro-Colombian, 13% Native American and 
5% European/Mestizo, whereas Antioquia was 93% European/Mestizo, 7% Afro-Colombian and 
~0.1% Native American[140].  The population of Chocó is considered to be particularly 
vulnerable, with high levels of poverty and low measures of economic development across several 
indices compared to Antioquia.  We chose to focus our comparative study of genetic and health 
differences between Chocó and Antioquia on T2D for several reasons: (1) its high disease burden, 
(2) its known contribution to population health disparities, and (3) the relative wealth of knowledge 
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regarding its underlying genetic architecture.  We set out to assess whether and how genetic and 
environmental differences between these two very distinct regions may manifest themselves with 
respect to population-specific levels of T2D genetic risk and/or differences in observed prevalence 
for the disease. 
4.3 Materials and Methods 
4.3.1 Genome sequence and genotype data sources 
Whole genome sequence data and whole genome genotype data were analyzed in order to 
infer the genetic ancestry and admixture profiles for the Colombian populations of Chocó and 
Antioquia (Table 4).  Whole genome genotypes for 94 individuals from Chocó were characterized 
as part of the ChocoGen research project (http://www.chocogen.com/) as previously 
described[80].  Sample donors from the ChocoGen project signed informed consent documents 
indicating their understanding of the potential risks of the project, along with how their data would 
be handled and how their identity would be protected. Collection, genotyping, and comparative 
analyses of human DNA samples were conducted with the approval of the ethics committee of the 
Universidad Tecnológica del Chocó[80].   
All of the other data used for the analysis described here corresponds to publicly available 
and de-identified genome sequences or genotypes.  Publicly available whole genome sequences 
for 94 individuals from Medellín, Antioquia were characterized as part of the 1000 Genomes 
Project (1KGP)[82].  Whole genome sequences from several additional admixed American 
populations were taken from the 1KGP for analysis: Utah residents with European ancestry (n=99), 




Genome sequence and genotype data were also sampled from putative ancestral 
populations corresponding to the three major continental regions that are known to contribute to 
genetic admixture in Colombia[73, 74, 76, 138]: Africa, Europe, and the Americas.  African 
ancestry was inferred using whole genome sequences for a Yoruba population from Ibadan, 
Nigeria (n=108), and European ancestry was inferred using whole genome sequences for an 
Iberian population from Spain (n=107), both of which were characterized as part of the 1KGP.  
Whole genome genotypes for three Native American populations – Embera from Colombia (n=5), 
Quecha from Peru (n=40), and Zapotec from Mexico (n=43) – were taken from a dataset collected 
as part of a previous study on Native American genetic ancestry[83]. 
4.3.2 Genetic ancestry and admixture analysis 
Whole genome sequence data and whole genome genotype data were merged using the 
program PLINK[141], and the resulting merged single nucleotide polymorphism (SNP) dataset 
was pruned in order to remove SNPs that are in linkage disequilibrium (r ≥ 0.05).  This resulted in 
a final dataset of 220,724 SNPs across 736 individual genome samples.  Pairwise genomic 
distances between individuals were calculated as allele sharing distances between all pairs of 
merged/pruned SNP sets, also using PLINK.  The pairwise allele sharing distance matrix was 
reduced to two-dimensions with principal component analysis (PCA) using the prcomp function 
from the R package for statistical computing[142] (Figure 15A).  Ancestry fractions – African, 
European, and Native American – were calculated for each genome from Chocó and Antioquia 
using the program ADMIXTURE[87], with global reference populations (Table 4) and K=3 
clusters corresponding to each of the major continental ancestry groups (Figure 20 and Figure 





Figure 15. Genetic ancestry of the individuals from Chocó and Antioquia analyzed here. 
(A) Principal components analysis (PCA) plot representing the pairwise distances among 
individual genomes from the admixed Colombian populations of Chocó and Antioquia along with 
putative ancestral source populations from Africa (Nigeria), Europe (Spain) and the Americas 
(Embera, Quechua, and Zapotec).  (B) Box-plot distributions of the ancestry fractions for 
individuals from Chocó and Antioquia.  The population-average values of African (blue), 
European (orange), and Native American (red) ancestry are shown above the distributions. Type 
2 diabetes genetic risk calculation
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The underlying genetic architecture of type 2 diabetes (T2D) was assayed from a series of 
29 case-control genome-wide association studies (GWAS).  T2D SNP association data from these 
studies were taken from the NHGRI-EBI GWAS catalog[143].  Individual SNP entries from the 
GWAS catalog were considered to be significantly associated with T2D if (1) the SNP association 
was uncovered via a case-control study based on at least 100,000 genotyped SNPs, (2) the SNP 
had the strongest association seen for its genomic locus, and (3) the SNP showed a genome-wide 
T2D association P-value<1.0e-5.  This yielded a set of 165 T2D-associated SNPs, and for each 
SNP, the identity of the risk allele (i.e., specific nucleotide variant) linked to T2D was taken from 
the study where it was reported. 
 
Imputation was performed on whole genome genotype data from the ChocoGen project in 
order to facilitate direct comparison of genome-wide T2D risk scores computed for datasets from 
Chocó (genotypes) and Antioquia (genome sequences).  Before imputation, the whole genome 
genotypes of individuals from Chocó were phased using the program SHAPEIT[144, 145] using 
the 1KGP phase 3 haplotype reference panel.  The phased whole genome genotypes from Chocó, 
consisting of 522,458 SNPs per individual, were then imputed using the program IMPUTE2[146-
148] with the 1KGP phase 3 haplotype reference panel[145].  This process resulted in the 
imputation of 35,056,488 additional SNPs across all samples.  The accuracy of the imputation 
process was evaluated by comparing the genetic ancestry relationships between individuals from 
Chocó, computed before and after imputation, and a panel of global reference populations.  The 
observed genetic ancestry relationships for the individuals from Chocó are virtually identical 




For each T2D-associated SNP, a log odds ratio (𝑂𝑂𝑃𝑃) was used to compute the relative 





where 𝑃𝑃𝐴𝐴𝑖𝑖 and 𝑁𝑁𝑃𝑃𝐴𝐴𝑖𝑖 are the risk allele frequency and non-risk allele frequency, respectively, in 
population 𝑖𝑖 (𝐶𝐶𝐶𝐶𝑂𝑂=Chocó and 𝐴𝐴𝑁𝑁𝑢𝑢=Antioquia).  A meta-analysis was conducted to evaluate the 
joint effect of all 165 T2D-associated SNPs on the relative genetic risk of T2D in Chocó versus 
Antioquia using the metafor package in R[149].  95% confidence intervals for the individual SNP 
and meta-analysis 𝑂𝑂𝑃𝑃 values were computed using both fixed- and random-effects models.  The 
fixed- and random-effects models were both computed with moderators via linear (mixed-effects) 
models. 
 
T2D polygenic risk scores (𝑃𝑃𝑃𝑃𝑃𝑃) for individual genomes were computed as the 
unweighted, normalized sum of the number of risk alleles for all 165 T2D-associated SNPs (Figure 
17, Equation (1).  SNP association effect sizes were not used to weight the T2D 𝑃𝑃𝑃𝑃𝑃𝑃 values owing 
to the fact that the T2D associated SNPs analyzed here were taken from different studies, and the 






Figure 16. Relative genetic risk for type 2 diabetes (T2D) and genetic ancestry in Chocó 
versus Antioquia.   
(A) The relative genetic risk of T2D in the two Colombian populations is shown as log odds ratios 
(OR) – Chocó/Antioquia – of the risk versus non-risk allele frequencies for 165 T2D-associated 
SNPs.  The formula for calculating OR values is shown in the Methods subsection ‘Type 2 diabetes 
genetic risk calculation’ (formula 1).  OR values > 0 indicate greater risk in Chocó (purple), 
whereas OR values < 0 show greater risk in Antioquia (green).  95% confidence intervals (CI) for 
individual SNP OR values are shown.  The diamonds below the plot show OR values (±95% CI) 
corresponding to fixed- and random-effects meta-analysis of all 165 T2D-associated SNPs as well 
as the mean OR value from the bootstrap analysis; P-values indicating the statistical significance 
level of the three meta OR values are shown.  (B) The observed OR value for the relative genetic 
risk of T2D (Chocó/Antioquia) is compared to a bootstrap distribution of OR values based on 
random sampling with replacement from the set of T2D-associated SNPs.  The values of z and P 
for a z-test comparing the distribution of bootstrap T2D SNP OR values to 0 are shown.  (C) The 
observed OR value for the relative genetic risk of T2D (Chocó/Antioquia) is compared to a null 
distribution of expected OR values for randomly simulated SNP sets of the same size as the T2D-
associated SNP set.  The values of z and P for a z-test comparing the observed and expected T2D 
SNP OR values are shown.  (D) The distribution of genetic risk score (PRS) differences (Chocó-
Antioquia) for 324 diseases is shown along with the mean and standard deviation values for the 





Figure 17. Genetic ancestry and predicted risk for T2D.   
(A) Box-plot distributions of individuals’ T2D polygenic risk scores are shown for four 
populations: Spain (orange), Antioquia (green), Chocó (purple), and Nigeria (blue).  The values 
of F and P for an ANOVA test comparing the mean values of the distributions are shown.  (B) 
Regression of T2D polygenic risk scores (y-axis) against the percent African ancestry for genome 
sequences from Colombia and the US (x-axis).  Box plots are shown for decile bins, and the linear 
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trend line is shown in blue with 95% CI in gray.  The values of r and P for the Pearson correlation 
coefficient of the regression are shown.  (C) Box-plot distributions of individuals’ T2D polygenic 
risk scores are shown for five European populations (orange) and seven African populations 
(blue).  The values of F and P for an ANOVA test comparing the mean values of the distributions 
are shown.        
4.3.3 Genetic risk calculation controls 
A series of controls was performed to check for systematic biases in the frequencies allelic 
variants used to compare genetic risk scores between populations.  (1) Bootstrap: random sampling 
with replacement from the 165 T2D-associated SNPs was used to create 10,000 replicate SNP sets, 
each of which was used for genetic risk 𝑂𝑂𝑃𝑃 calculation and meta-analysis as described above.  The 
resulting distribution of bootstrap meta-analysis 𝑂𝑂𝑃𝑃 values was compared to the observed value 
for the T2D SNP set to evaluate how outliers may affect T2D genetic risk calculation and 
comparison between populations (Figure 16B).  (2) Random disease-associated SNP sets: random 
sampling of T2D size-matched (n=165) disease-associated SNP sets from the NHGRI-EBI GWAS 
catalog was used to create 500,000 replicate SNP sets, each of which was used for genetic risk 𝑂𝑂𝑃𝑃 
calculation and meta-analysis as described above.  The resulting distribution of random disease-
associated SNP set meta-analysis 𝑂𝑂𝑃𝑃 values was compared to the observed value to evaluate 
whether systematic biases in disease-associated allele frequencies between populations may affect 
the comparison of genetic risk (Figure 16C).  (3) Disease genetic risk comparisons: SNP disease-
associations from the NHGRI-EBI GWAS catalog were mined to compare polygenic risk scores 
(PRS), as described above for T2D, for 324 diseases between Chocó and Antioquia in order to 
assess whether there is any systematic bias in disease genetic risk score computation between the 
two populations (Figure 16D). 
4.3.4  Diabetes prevalence and socioeconomic status (SES) data sources 
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Data on age-adjusted diabetes prevalence per 100,000 inhabitants for the Colombian 
administrative departments (i.e., states) was taken from three database sources: (1) Cuenta de Alto 
Costo (https://cuentadealtocosto.org/), (2) Observatorio de Diabetes de Colombia 
(http://www.odc.org.co/), and (3) the Sistema Integral de Información de la Protección Social 
databases 
(https://www.minsalud.gov.co/salud/Paginas/SistemaIntegraldeInformaci%C3%B3nSISPRO.asp
x) (Figure 18).  Data on SES indicators was collected from the Departamento Administrativo 






Figure 18. Prevalence of diabetes in Colombia.   
(A) Age-adjusted diabetes mellitus prevalence per 100,000 inhabitants.  (B) Comparison of 
Colombian diabetes state-by-state prevalence estimates taken from the three different database 
sources.  Regression plots for all three possible pairwise comparisons between the different 
databases are shown, with the values for Chocó and Antioquia indicated.  For each regression, 




4.4.1 Comparative genetic ancestry 
Here and elsewhere[74, 80], we characterized the genetic heritage of Chocó and Antioquia 
with respect to their populations’ ancestry proportions derived from Africa, Europe, and the 
Americas.  To do so, whole genome genotypes characterized for donors from Chocó, along with 
publicly available whole genome sequences from Antioquia, were compared to genomes from 
putative ancestral source populations collected from a variety of sources (Table 4).  Details of the 
approaches we used for all comparative genomic analyses can be found in the Methods section.  
Pairwise genomic distances projected onto two dimensions group individuals from Chocó with an 
African population from Nigeria, whereas individuals from Antioquia group most closely with a 
European population from Spain (Figure 15A).  Nevertheless, both populations show visual 
evidence of substantial admixture among the three major continental population groups on this 
same plot.  The inferred continental genetic ancestry fractions for Chocó and Antioquia are also 
largely consistent with the states’ demographic profiles, which were gleaned from self-reported 
ethnicity, with Chocó having predominantly African ancestry and Antioquia having mainly 
European ancestry.  Admixture analysis revealed that the population of Chocó has 76% African, 
13% European, and 11% Native American ancestry, whereas Antioquia has 75% European, 18% 
Native American and 7% African ancestry (Figure 15B and Figure 20).  
4.4.2 Comparative T2D genetic risk 
We asked whether the differences in genetic ancestry between Chocó and Antioquia are 
related to population-specific genetic risk for diabetes by comparing the distributions of known 
T2D risk alleles for the two populations using the previously described genomic datasets.  T2D 
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risk alleles for a total of 165 single nucleotide polymorphisms (SNPs) were mined from a 
collection of 29 T2D genome-wide association studies (GWAS) (Table 3).  Population-specific 
frequencies of the risk and non-risk alleles for each T2D-associated SNP were measured and used 
to calculate a log odds ratio (OR) that expresses the relative genetic risk of T2D for the two 
populations: Chocó/Antioquia.  Log odds ratios were used to provide a statistical framework to 
measure the T2D risk contributions of individual SNPs and to allow for a meta-analysis that 
considers the additive genetic risk contribution of all SNPs together.  Details of this approach are 
provided in the Methods section.  The majority of T2D associated SNPs show higher risk allele 
frequencies in Chocó compared to Antioquia, pointing to a relatively higher genetic risk of T2D 
in the population of Chocó (Figure 16A).  Ninety-one (91) individual SNPs show significant 
differences in risk versus non-risk allele frequencies in Chocó compared to Antioquia; 62 (68%) 
of those SNPs reflect significantly greater T2D genetic risk in Chocó compared to only 29 (32%) 
with a higher risk in Antioquia.  When all of the T2D-associated SNPs are considered together 
using meta-analysis, Chocó shows a significantly greater population-wide genetic risk for T2D 
than Antioquia.  Chocó/Antioquia T2D meta-analysis OR values, along with their 95% confidence 
intervals, were computed using both fixed and random effect models as well as via bootstrap 
analysis.  All three approaches show significantly higher T2D genetic risk in Chocó compared to 
Antioquia (Figure 16A).   
 
We performed a series of controls in an effort to ensure that the difference observed for 
T2D genetic risk between Chocó and Antioquia cannot be attributed to any systematic bias in the 
SNP allele frequencies of the two populations (Methods).  First, we used a bootstrap analysis of 
the T2D SNP set to evaluate the signal-to-noise ratio in the data.  In particular, we wanted to assess 
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whether the observed difference in T2D genetic risk between Chocó and Antioquia may be due to 
a few outlier SNPs (Figure 22).  Sampling with replacement from the set of T2D-associated SNPs 
was used to generate 10,000 replicate T2D SNP sets, each of which was used to calculate a meta-
analysis OR value.  The distribution of bootstrap replicate OR values is centered around observed 
OR value, and the mean bootstrap OR value is significantly greater than 0 (Figure 16B; z=-3.99, 
P=6.6 x 10-5).  The results of the bootstrap analysis are consistent with greater T2D genetic risk in 
Chocó. They indicate that the signal in the data, based on the individual SNP OR values, is robust 
to sampling noise.   
We next addressed whether the observed difference in T2D genetic risk can be attributed 
to a systematic bias in the allele frequencies for disease-associated SNPs between the two 
populations.  This is particularly relevant given the fact that the vast majority of GWAS are 
conducted on populations of European ancestry, more similar to what is seen for Antioquia.  In 
fact, it has recently been shown that attempts to compare genetic risk between populations with 
divergent ancestry profiles can be confounded by demographic factors that yield differences in the 
overall frequencies of risk alleles; effects of this kind can, in turn, lead to systematic biases in 
population-specific genetic risk estimates[31].  We attempted to control against this possibility 
using the two approaches described below. 
 
We developed a simulation-based approach in order to control for the possible effects of 
demographic history on estimates of population-specific T2D genetic risk for Chocó and 
Antioquia.  If the apparent elevated genetic risk for T2D in Chocó reflects a bias in the relative 
frequencies of disease-associated SNPs, perhaps owing to increased African ancestry of the 
population, then we would expect to see an overall shift to higher estimated disease risk for Chocó 
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compared to Antioquia.  To evaluate this possibility, 500,000 SNP sets of the same size as the set 
of T2D-associated SNPs were randomly simulated from a collection of disease-associated SNPs 
taken from the NHGRI-EBI GWAS catalog[143].  For each of these random SNP sets, a meta-
analysis of the SNP relative genetic risk log odds ratios (Chocó/Antioquia) was performed, 
yielding a random meta-analysis log odds ratio value (OR).  The null distribution of the resulting 
random meta-analysis OR values was then compared to the observed T2D relative genetic risk OR 
value for Chocó/Antioquia.  Contrary to the expectations of the demographic bias model, 
Antioquia shows a higher overall relative genetic risk when ensembles of randomly sampled 
disease-associated SNP sets are analyzed (Figure 16C).  In addition, the observed T2D relative 
genetic risk OR value for Chocó/Antioquia is significantly greater than the expected OR value 
based on the null distribution, further validating the observed elevated genetic risk for T2D in 
Chocó (z=4.0, P=6.3 x 10-5). 
In addition to the simulation-based approach described above, we also used disease-
associated SNPs from the NHGRI-EBI GWAS catalog to compute the relative genetic risk 
between Chocó and Antioquia for 324 additional diseases.  In this case, a systematic bias in the 
population-specific allele frequencies of disease-associated SNPs would be expected to reveal an 
overall elevation of disease genetic risk in one of the two populations.  However, the distribution 
of the differences in predicted genetic risk for these diseases is centered very close to 0 and more 
or less symmetrical (Figure 16D); the mean genetic risk difference (Chocó - Antioquia) for these 
diseases is not significantly different from 0 (z=-0.1, P=0.92).  Taken together, these three controls 
suggest that the observed difference in T2D genetic risk for Chocó versus Antioquia cannot be 
attributed to any systematic bias in disease-associated allele frequencies between the two 




4.4.3 Genetic ancestry and T2D risk 
Considering their respective ancestry profiles, the higher T2D genetic risk that we observe 
for the population of Chocó compared to Antioquia is consistent with previous results showing a 
correlation between African genetic ancestry and T2D prevalence in the US[132].  We asked 
whether the elevated genetic risk of T2D in Chocó may also be related to greater African ancestry, 
and conversely, lower European ancestry, in Chocó compared to Antioquia.  To do this, we 
computed polygenic T2D risk scores for individuals from Chocó and Antioquia along with 
individuals from their most closely related putative ancestral populations in Europe (Spain) and 
Africa (Nigeria).  We applied a widely used approach that computes polygenic risk scores for 
individual genomes, or whole genome genotypes, based on the sum of risk alleles present across 
all associated SNPs[37, 150-152] (Methods).  The Antioquia population has the lowest T2D 
genetic risk measured this way, followed by the Spanish population; however, the T2D genetic 
risk score distributions between these two populations are not significantly different (t=0.3, P=0.8; 
Figure 17A).  Chocó has significantly greater T2D genetic risk than Antioquia (t=5.7, P=4.1 x 10-
8), and the Nigerian population has the highest overall risk (Figure 17A).  Thus, the T2D genetic 
risk score distributions for these populations follow the increasing proportions of African ancestry 
and decreasing European ancestry, seen among them.  We also performed a similar analysis of 
T2D genetic risk analyses for a pair of African-American and European-American populations 
from the US, and find the same patterns of elevated T2D genetic risk associated with African 
ancestry that we see for Colombia, consistent with previous results[132] (Figure 23).  Finally, we 
show that the African ancestry percentages for individuals from Colombia and the US are 
positively correlated with their polygenic risk scores for T2D (r=0.81, P=2.7 x 10-44; Figure 18B).    
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We further evaluated the relationship between genetic ancestry and T2D genetic risk 
worldwide by comparing five European populations to seven African populations (Figure 17C).  
All of the African populations have higher T2D genetic risk than the European populations, and 
the difference between the African versus European ancestry group T2D genetic risk averages is 
highly significant (t=33.9, P=1.4 x 10-164).  These results lend additional support to the association 
of African genetic ancestry with elevated T2D genetic risk. 
4.4.4 Observed T2D prevalence 
Given the elevated genetic risk for T2D in the Afro-Colombian population of Chocó, along 
with its association with African ancestry, we expected to see a substantially higher prevalence of 
diabetes in Chocó compared to Antioquia.  Indeed, numerous studies report that African-
Americans in the US have a far higher prevalence of T2D than European-Americans[128-130].  
However, we were surprised to find that the reported prevalence of diabetes is, in fact, more than 
three times higher in Antioquia than in Chocó (Figure 18A).  Averaging data from three separate 
epidemiological database sources, maintained by governmental and non-governmental 
organizations, shows Antioquia with an age-adjusted diabetes prevalence of 1.9%, which is the 4th 
highest out of 32 states in the country, compared to 0.6% for Chocó, which is ranked 27th.  The 
large difference in diabetes prevalence observed for Chocó versus Antioquia is highly consistent 
across the three different Colombian epidemiological databases that we sourced (Figure 18B). 
The far lower prevalence of diabetes in Chocó versus Antioquia, compared to what may be 
expected based on the genetic profiles of their populations, strongly suggests that environmental 
factors predominantly shape diabetes outcomes in the region.  This would be consistent with 
several large cohort studies showing that environmental factors contribute substantially more to 
T2D than genetic factors[153-155], and the populations of Chocó and Antioquia do indeed occupy 
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very distinct environments.  In particular, as previously stated, the population of Chocó has far 
lower overall SES compared to Antioquia (Table 2).  For example, the per capita gross domestic 
product in Chocó is almost three times lower than that of Antioquia.  Chocó also has lower levels 
of literacy, life expectancy, employment, and modern housing, along with higher dietary deficits 
of protein and calcium than Antioquia.  Considered together, these factors give Chocó a human 
development index (HDI) of 0.73, ranked 31st out of 32 Colombian states, compared to an HDI of 
0.85 for Antioquia, which ranks 4th in the country.  Thus, it appears that even though low SES has 
been associated with the risk for T2D in numerous studies[156], in Chocó low SES somehow 
serves as a protective factor against T2D.  This unexpected finding suggests that poverty may play 
a very different role in the etiology of complex disease, particularly for diabetes and perhaps other 
metabolic syndrome disorders, in Colombia compared to more developed countries in the Global 
North. 
4.5 Discussion 
Our study of the contributions of genetic ancestry and environmental factors to T2D 
prevalence in two divergent Colombian populations suggests that poverty can serve as a T2D 
protective factor in Colombia.  The possibility that poverty in Chocó is an environmental protective 
factor against T2D, as opposed to a strong risk factor as seen for African-Americans in the US, 
may be attributed to the differing nature of poverty in developed countries compared to some parts 
of the developing world.  Poverty in the US is associated with poor diet and other lifestyle factors 
that elevate T2D prevalence[136, 137, 157, 158].  However, poverty in Chocó, which is generally 
more extreme than what is found in the US, is actually associated with a diet that is protective 
against T2D, particularly when compared to Antioquia.  The dietary staples of Chocó are fish, 
plantains, yucca, and rice; fish are readily available from the Atrato River and its tributaries, and 
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plantains and yucca are cultivated along the banks of this vast river system[159, 160].  Thus, the 
typical diet of Chocó is high in polyunsaturated lipids, such as omega-3 and omega-6 fatty acids, 
and fiber, both of which are known to mitigate T2D risk.  In Antioquia, the main sources of protein 
are beef and pork, which are rich in both cholesterol and triglycerides formed by saturated fatty 
acids, known risk factors for T2D.  In addition to the ready availability of fish in the region, SES 
in Chocó also impacts dietary choices in a way that is protective against T2D.  In Quibdó, the 
capital of Chocó, one kilogram of meat costs 9000 Colombian pesos or approximately $3 US 
dollars; 10kg of fish from the Atrato River can be bought for the same amount, providing a week’s 
worth of protein.  
We also found Chocó and Antioquia to be distinct with respect to the prevalence of alcohol 
consumption and tobacco use, both of which have been implicated as environmental factors that 
influence T2D outcomes.  A 2013 government survey on the consumption of psychoactive 
substances in Colombia found that Chocó had the highest prevalence of alcohol consumption for 
the country, with 44.6% of respondents reporting alcohol consumption over the past 30 days 
compared to 36.6% for Antioquia[161].  Since moderate alcohol consumption has been linked to 
reduced risk for the onset of T2D[162-164], this could represent an additional protective factor 
associated with the lifestyle in Chocó.  Conversely, Antioquia was found to have higher tobacco 
use in the same survey, with 14.1% use over the last month compared to 6.6% for Chocó.  Smoking 
is a known risk factor for T2D[165-167], pointing to yet another possible advantage of the lifestyle 
in Chocó with respect to T2D prevalence. 
Another way to consider the discordant results that we observed for population-specific 
genetic risk versus the observed prevalence of diabetes in Colombia is through the lens of 
economic development as opposed to poverty per se.  While the notion that poverty in Chocó 
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serves as a protective factor against diabetes was certainly unexpected to us, if we consider Chocó 
to be under-developed relative to Antioquia, then the environmental protective effect may not be 
as surprising.  Indeed, as previously stated, the HDI for Chocó points to substantial under-
development compared to the rest of the country, and the pyramid-shaped age distribution of 
Chocó is more consistent with what is seen in less developed countries; the narrower age 
distribution of Antioquia, on the other hand, resembles those of more developed countries (Figure 
24).  T2D has been considered to be a disease of the developed world, as it is generally more 
prevalent in industrialized than less-developed countries[168].  In fact, studies have shown 
precipitous increases in T2D prevalence in populations that have undergone rapid transitions to 
more developed economies[169].  The comparison of Chocó versus Antioquia may underscore the 
public health relevance of stark differences in economic development within a single country, 
albeit in a way that counterintuitively favors the less developed region.  
 
It is also worth noting that Chocó is more rural and less urbanized than Antioquia.  Chocó is 
relatively underpopulated, with a population density of 11 individuals per km2 compared to 99 per 
km2 for Antioquia.  The rural setting of Chocó, along with the overall challenging conditions of 
its environment, is associated with a more physically active lifestyle compared to more modernized 
parts of the country[159, 160], highlighting yet another potentially protective factor against T2D.  
Interestingly, a recent study in India showed that low SES is simultaneously a risk factor for T2D 
in cities and a protective factor for T2D in more rural areas [170].  Thus, it may be the case that 
urban poverty in developing countries is more reminiscent of overall poverty in the developed 
world, in terms of risk for T2D, whereas the features of rural poverty in the developing world are 
distinctive and protective for T2D. 
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We explored the relationship between economic development and T2D for the entire 
country by comparing HDI levels to T2D prevalence estimates for all states.  We observe a strong 
positive correlation between HDI and T2D prevalence across Colombia, with more developed 
regions of the country showing higher T2D prevalence estimates (Figure 25A).  This finding is 
consistent with the notion that lower levels of development within the country can serve as a 
protective factor against T2D.  However, it could also be taken to suggest the possibility that the 
lower prevalence of T2D in Chocó reflects a bias in disease reporting, owing to lower SES and 
accordingly reduced access to healthcare services.  We evaluated this possibility by comparing 
prevalence estimates for 43 diseases between Chocó and Antioquia.  A reporting bias for Chocó, 
based on reduced access to healthcare, would be expected to reveal itself as an overall reduction 
in prevalence estimates for numerous diseases.  In fact, Chocó shows a greater prevalence for 24 
diseases, compared to 19 for Antioquia, and the difference between the two is not statistically 
significant (Figure 25B).  These results indicate that a reporting bias based on differential access 
to healthcare does not likely explain the lower prevalence of T2D observed for Chocó. 
Genomic approaches to health care, while still in their infancy in the region, hold great 
promise for Latin America, especially as the public health burden continues to shift toward 
common complex diseases with at least partial genetic etiology.  The distinction that we observe 
between population-specific genetic risk and observed prevalence of T2D provides lessons for the 
implementation of genomic approaches to personalized and precision medicine in Latin American 
countries such as Colombia.  Caution should be taken when extrapolating results from studies in 
the Global North, where the vast majority of this kind of research is still conducted[16, 32, 33], to 
developing countries in Latin America.  For instance, a commonly accepted environmental risk 
factor for many common diseases, such as SES, may have very different implications in Latin 
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America compared to the US.  In addition, the public health value of dietary and lifestyle choices, 
which may have been historically dictated by poverty, should be recognized and incorporated into 
public health campaigns as countries in Latin America continue to experience rapid economic 
development and urbanization.  A corollary of this suggestion would be to strategically avoid 
pitfalls of urbanization in the developed world, such as the increasingly sedentary lifestyle, the 
reliance on processed and fast foods as well as the emergence of so-called ‘food deserts’ in poor 
neighborhoods where it is exceedingly difficult, if not impossible, to access fresh and whole foods.   
Finally, caution also needs to be exercised when extrapolating the results of studies on the 
genetic architecture of complex diseases between populations with distinct ancestry profiles[31].  
Genetic associations discovered in one population may not replicate in a different population, and 
ancestry and admixture can have additional confounding effects on the expression of genetic 
variants.  Nevertheless, as we have endeavored to show here, exploration of disease-associated 
variants in understudied populations can provide valuable insight into the joint contributions of 
genetics and environment to common complex diseases, which are an increasing public health 




4.6 Supplementary Information 
 
 
Figure 19.  Relief map of Colombia showing the locations of the administrative 
departments (i.e., states) of Chocó and Antioquia. 
Map adapted from https://commons.wikimedia.org/wiki/File:Mapa_de_Colombia_(relieve).svg, 
edited to highlight the states of interest.     The image file is licensed under the Creative Commons 






Figure 20.  Admixture bar chart showing the percentage of African (blue), European (orange), and Native American (red) 
ancestry for the individuals from Antioquia Chocó analyzed here.   
ADMIXTURE was run with K=3 clusters, corresponding to the three continental ancestry groups, using the global putative ancestral 






Figure 21.  Validation of the SNP imputation process for the Chocó genotypes via 
comparison of genetic ancestry patterns before (original genotypes) and after 
(imputed genotypes) imputation.   
Pairwise genomic distances between individuals from Chocó and a panel of global 
reference populations (see color key) characterized via whole genome sequencing as part 




Table 3. Type 2 diabetes (T2D) associated SNPs analyzed in this study.   
165 T2D-associated SNPs, corresponding to 29 studies, were taken from the NHRGI-EBI 
GWAS database.  1T2D-associated SNP identifier numbers, from the NCBI Single 
Nucleotide Polymorphism database (dbSNP https://www.ncbi.nlm.nih.gov/projects/SNP/).  
2Chromosomal locations for the T2D-associated SNPs, corresponding to the GRh37/h19 
version of the human genome reference sequence. 3Identity of the risk alleles (nucleotide 
variants) that are associated with a higher risk of T2D for each SNP.  Risk allele identities 
are shown here for the positive DNA strand.  4HGNC gene symbols for the genes 
considered to be influenced by the T2D-associated SNPs, according to each study.  5NCBI 
PubMed identifier numbers for the publications where each T2D-associated SNP was 
reported. 
rsID1 Chr
2 Pos2 Risk Allele
3 Gene(s)4 PubMed ID5 
rs5945326 X 153634467 A DUSP9 20581827 
rs17106184 1 50444313 G FAF1 24509480 
rs11165354 1 91728765 A TGFBR3 23209189 
rs7542900 1 94604485 C SLC44A3, F3 22238593 
rs10923931 1 119975336 T NOTCH2, ADAM30 18372903 
rs2075423 1 213981376 G PROX1 24509480 
rs2820446 1 219575476 C LYPLAL1 24509480 
rs6426514 1 228744368 A RHOU 23300278 
rs12027542 1 233204408 A PCNXL2 21490949 
rs679992 1 241024982 T intergenic 25102180 
rs10190052 2 646674 C TMEM18 24509480 
rs11677370 2 3793830 T intergenic 21490949 
rs12613372 2 30845153 G GALNT14, CAPN13 25102180 
rs7578597 2 43505684 T THADA 18372903 
rs243088 2 60341610 T BCL11A 24509480 
rs243021 2 60357684 A BCL11A 20581827 
rs73954691 2 127663671 G LIMS2 25483131 
rs6723108 2 134722410 T TMEM163 23209189 
rs7560163 2 150781422 C RBM43, RND3 22238593 
rs3923113 2 164645339 A GRB14 21874001 
rs2943640 2 226228869 C IRS1 24509480 
rs17036101 3 12236345 G SYN2, PPARG 18372903 
rs13081389 3 12248301 A PPARG 20581827 
rs1801282 3 12351626 C PPARG 17463246 
rs6780569 3 23156993 G UBE2E2 23945395 
rs7612463 3 23294959 C UBE2E2 24509480 
rs831571 3 64062621 c PSMD6 22158537 
rs4607103 3 64726228 C ADAMTS9 18372903 
rs2063640 3 102484201 A ZPLD1 21490949 
rs11708067 3 123346931 A ADCY5 22693455 
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Table 3 continued 
rsID1 Chr2 Pos2 Risk Allele
3 Gene(s)4 PubMed ID5 
rs11717195 3 123363551 T ADCY5 24509480 
rs3773506 3 142712158 C PLS1 21490949 
rs7630877 3 179943530 A PEX5L 21490949 
rs4402960 3 185793899 T IGF2BP2 17463246 
rs1470579 3 185811292 C IGF2BP2 20581827 
rs6769511 3 185812502 C IGF2BP2 18711366 
rs1374910 3 185813873 T IGF2BP2 21573907 
rs16861329 3 186948673 C ST64GAL1 24509480 
rs6808574 3 188022735 C LPP 24509480 
rs6815464 4 1316113 C MAEA 22158537 
rs4458523 4 6288259 G WFS1 24509480 
rs1801214 4 6301295 T WFS1 20581827 
rs7659604 4 121744359 T NR 17554300 
rs6813195 4 152599323 C TMEM154 24509480 
rs702634 5 53975590 A ARL15 24509480 
rs10461617 5 56808481 A MAP3K1 23209189 
rs4457053 5 77129124 G ZBED3 20581827 
rs319598 5 134904545 C PCBD2 24509480 
rs17053082 5 155967220 T intergenic 23300278 
rs9295474 6 20652486 G CDKAL1 21490949 
rs4712523 6 20657333 G CDKAL1 19401414 
rs4712524 6 20657634 G CDKAL1 18711366 
rs10946398 6 20660803 C CDKAL1 17463249 
rs7754840 6 20661019 C CDKAL1 17463246 
rs7756992 6 20679478 G CDKAL1 17460697 
rs10440833 6 20687890 A CDKAL1 20581827 
rs6931514 6 20703721 G CDKAL1 18372903 
rs9465871 6 20717024 C CDKAL1 17554300 
rs2244020 6 31379674 G HLA-B 25102180 
rs3916765 6 32717773 A HLA-DQA2 22693455 
rs9470794 6 38139068 C ZFAND3 22158537 
rs1535500 6 39316274 T KCNK16 22158537 
rs9472138 6 43844025 T VEGFA 18372903 
rs1048886 6 70579486 G C6orf57 21490949 
rs4273712 6 126643364 G C6orf173 24509480 
rs6937795 6 136970143 A IL20RA 24509480 
rs642858 6 139952510 A intergenic 21490949 
rs7795991 7 13861106 G ETV1 24509480 
rs17168486 7 14858657 T DGKB 24509480 
rs864745 7 28140937 T JAZF1 18372903 
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Table 3 continued 
rsID1 Chr2 Pos2 Risk Allele
3 Gene(s)4 PubMed ID5 
rs849134 7 28156603 A JAZF1 20581827 
rs849135 7 28156794 G JAZF1 24509480 
rs10231619 7 43280995 T HECW1 25102180 
rs7636 7 100892456 A ACHE 21490949 
rs6467136 7 127524904 G PAX4, GCC1 22158537 
rs10229583 7 127606849 G ARF5, PAX4, SND1 23532257 
rs791595 7 128222749 A MIR129, LEP 23945395 
rs972283 7 130782095 G KLF14 20581827 
rs516946 8 41661730 C ANK1 24509480 
rs7003257 8 67701155 T CPA6 25102180 
rs17359493 8 94844683 G INTS8 25102180 
rs7845219 8 94925274 T TP53INP1 24509480 
rs896854 8 94948283 T TP53INP1 20581827 
rs13266634 8 117172544 C SLC30A8 17293876 
rs3802177 8 117172786 G SLC30A8 20581827 
rs1561927 8 128555832 C TMEM75 24509480 
rs4527850 8 133184606 T WISP1 23300278 
rs5219 9 22029548 T KCNJ11 17463246 
rs2383208 9 22132077 A CDKN2A, CDKN2B 19401414 
rs11257655 10 12265895 T CDC123 22961080 
rs10906115 10 12272998 A CDC123, CAMK1D 20862305 
rs12779790 10 12286011 G CDC123, CAMK1D 18372903 
rs2812533 10 69692529 C C10orf35 24509480 
rs12571751 10 79182874 A ZMIZ1 24509480 
rs10788575 10 88008827 A PTEN 24509480 
rs6583826 10 92588073 G KIF11 21490949 
rs1111875 10 92703125 C HHEX 17463246 
rs5015480 10 92705802 C HHEX 17463249 
rs34872471 10 112994312 C TCF7L2 25483131 
rs7901695 10 112994329 C TCF7L2 17463249 
rs4506565 10 112996282 T TCF7L2 17554300 
rs10886471 10 119389891 C GRK5 22961080 
rs10510110 10 122432914 C PLEKHA1 24509480 
rs10741243 10 131149699 G TCERG1L 21490949 
rs3842770 11 2157440 A INS-IGF2 25102180 
rs11043007 11 2183058 G ASCL2, TH 25102180 
rs231362 11 2670241 G KCNQ1 20581827 
rs231356 11 2684113 T KCNQ1 25102180 
rs2237892 11 2818521 C KCNQ1 18711367 
rs163182 11 2822986 C KCNQ1 21799836 
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Table 3 continued 
rsID1 Chr2 Pos2 Risk Allele
3 Gene(s)4 PubMed ID5 
rs163184 11 2825839 G KCNQ1 24509480 
rs2283228 11 2828300 A KCNQ1 25102180 
rs2237895 11 2835964 C KCNQ1 20174558 
rs2237897 11 2837316 C KCNQ1 18711366 
rs2722769 11 11206827 C GALNTL4, LOC729013 22238593 
rs5215 11 17387083 C KCNJ11 17463249 
rs9300039 11 41893816 C intergenic 17463248 
rs1552224 11 72722053 A CENTD2 20581827 
rs1387153 11 92940662 T MTNR1B 20581827 
rs10830963 11 92975544 G MTNR1B 24509480 
rs7107217 11 129603795 C TMEM45B, BARX2 22238593 
rs10842994 12 27812217 C KLHDC5 24509480 
rs12304921 12 50963759 G NR 17554300 
rs1153188 12 54705212 A DCD 18372903 
rs1531343 12 65781114 C HMGA2 20581827 
rs2261181 12 65818538 T HMGA2 24509480 
rs343092 12 65857160 T HMGA2 25102180 
rs1495377 12 71183321 G NR 17554300 
rs4760790 12 71241014 A LGR5, TSPAN8 20581827 
rs7961581 12 71269322 C LGR5, TSPAN8 18372903 
rs7305618 12 120965129 C HNF1A 21573907 
rs12427353 12 120989098 G HNF1A 24509480 
rs7957197 12 121022883 T HNF1A 20581827 
rs1727313 12 123156306 C MPHOSPH9 24509480 
rs10507349 13 26207391 G RNF6 24509480 
rs1359790 13 80143021 G SPRY2 20862305 
rs730570 14 100676553 G C14orf70 21573907 
rs7403531 15 38530704 T RASGRP1 22961080 
rs335810 15 60076007 A ANXA2 25102180 
rs7163757 15 62099409 C C2CD4A 24509480 
rs7172432 15 62104190 A C2CD4A 20818381 
rs1436955 15 62112183 C C2CD4B 20862305 
rs7178572 15 77454848 G HMG20A 22693455 
rs7119 15 77485290 T HMG20A 21490949 
rs11634397 15 80139880 G ZFAND6 20581827 
rs2028299 15 89831025 C AP3S2 21874001 
rs8042680 15 90978107 A PRC1 20581827 
rs12899811 15 91000846 G PRC1 24509480 
rs8050136 16 53782363 A FTO 17463248 
rs9936385 16 53785257 C FTO 24509480 
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Table 3 continued 
rsID1 Chr2 Pos2 Risk Allele
3 Gene(s)4 PubMed ID5 
rs9939609 16 53786615 A FTO 17554300 
rs11642841 16 53811575 A FTO 20581827 
rs17797882 16 79373021 T WWOX 22158537 
rs623323 17 796780 T NXN 23300278 
rs312457 17 7037074 G SLC16A13 23945395 
rs4430796 17 37738049 G HNF1B, TCF2 20581827 
rs10460009 18 2948031 C LPIN2 21490949 
rs8090011 18 7068463 G LAMA1 22693455 
rs275856 18 24259188 T OSBPL1A 25483131 
rs12970134 18 60217517 A MC4R 24509480 
rs3786897 19 33402102 A PEPD 22158537 
rs6017317 20 44318326 G FITM2, R3HDML, 
 
22158537 
rs4812829 20 44360627 A HNF4A 21874001 
rs328506 20 57454548 C CTCFL, RBM38, 
  
23300278 









Figure 22.  Distributions of T2D SNP OR values along with control analysis 
distributions.   
The distribution of 𝑂𝑂𝑃𝑃 values for the 165 individual T2D-associated SNPs is shown in 
gray, and the observed T2D meta-analysis 𝑂𝑂𝑃𝑃 value is indicated with a dashed line.  The 
bootstrap T2D SNP set 𝑂𝑂𝑃𝑃 value distribution is shown in red, and the random disease-
associated SNP set 𝑂𝑂𝑃𝑃 value distribution is shown in blue.  Mean values for all three 








Figure 23.  Type 2 diabetes polygenic risk score distributions for European-
American (orange) and African-American (green) populations from the US.   
The significance of the difference between the two distributions, based on the Student’s t-








Figure 24.  Age pyramids for Chocó and Antioquia.   







Figure 25.  Economic development and disease prevalence reporting in Chocó and 
Antioquia.   
(A) Regression of the human development index (HDI, y-axis) against diabetes prevalence 
estimates (x-axis) for Colombian administrative departments (i.e., states).  The linear trend 
line is shown in blue with 95% CI in gray.  The values of r and P for the Pearson correlation 
coefficient of the regression are shown.  (B) Disease prevalence estimate differences 
(Chocó – Antioquia) for 43 reported diseases.  The values of W and P for a binomial sign 
test of consistent differences between pairs of disease prevalence estimates are shown.  
Note that the x-axis breaks at the two highest values for malaria, which has a far higher 





CHAPTER 5. ANCESTRY EFFECTS ON DIABETES GENETIC 
RISK INFERENCE IN HISPANIC/LATINO POPULATIONS 
5.1 Abstract 
5.1.1 Background 
Hispanic/Latino (HL) populations bear a disproportionately high burden of type 2 
diabetes (T2D).  The ability to predict T2D genetic risk using polygenic risk scores (PRS) 
offers great promise for improved screening and prevention.  However, there are a number 
of complications related to the accurate inference of genetic risk across HL populations 
with distinct ancestry profiles.   
5.1.2 Results 
We investigated how ancestry affects the inference of T2D genetic risk using PRS 
in diverse HL populations from Colombia and the United States (US).  In Colombia, we 
compared T2D genetic risk for the Mestizo population of Antioquia to the Afro-Colombian 
population of Chocó. In the US, we compared European-American versus Mexican-
American populations.  T2D genetic risk in these HL populations is positively correlated 
with African and Native American ancestry and negatively correlated with European 
ancestry.  The inferred relative risk of T2D is robust to differences in the ancestry of the 
cohorts used for variant discovery.  Nevertheless, explicit consideration of genetic ancestry 




In particular, T2D associations that replicate across populations provide for more 
reliable risk inference, and modeling population-specific frequencies of ancestral and 
derived risk alleles can help control for biases in PRS estimation.    
5.2 Background 
Diabetes mellitus is a global pandemic [171-173].  The prevalence of adult-onset 
(type 2) diabetes has nearly doubled over the last thirty years, and the number of cases has 
increased by more than 300 million.  This increase has been driven largely by 
modernization and the accompanying changes in diet and lifestyle.  According to the 
International Diabetes Federation (IDF) Atlas [174], 425 million adults worldwide are 
currently living with diabetes, with half of them remaining undiagnosed.  In the United 
States (US) alone, more than 100 million adults have either prediabetes or diabetes.  US 
Hispanic/Latino (HL) populations bear a disproportionate burden of type 2 diabetes (T2D), 
with a prevalence almost twice as high as that of non-Hispanic whites [175, 176].  Globally, 
countries from the Latin America and Caribbean region show the highest diabetes 
prevalence compared to six other regions. 
T2D is a multifactorial disease with a complex set of interacting environmental and 
genetic causes contributing to its etiology.  Historically, risk management for T2D has been 
focused squarely on environmental factors, with an emphasis on changes in diet and 
lifestyle.  Physicians have been taught to evaluate a suite of clinically measurable risk 
factors, e.g., weight and blood pressure along with blood sugar and cholesterol levels, in 
assessing patients’ likelihood of developing T2D.  In addition to these clinical features, 
family history and race/ethnicity are also widely recognized as T2D risk factors, 
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underscoring genetic contributions to disease expression.  Indeed, genetic factors have been 
estimated to account for 20-80% of the variance in T2D development [177-179].  It follows 
that an understanding of individual patients’ genetic risk should become part of the 
standard of care for T2D screening and prevention.   
Individuals’ risk for common heritable diseases, such as T2D, can be quantified as 
polygenic risk scores (PRS) [180].  The ability to calculate PRS rests on genome-wide 
association studies (GWAS), which characterize specific genetic variants (alleles) that 
increase disease risk [181].  GWAS typically uncover numerous variants across the 
genome, each of which contributes a small fraction of the overall disease risk.  PRS can be 
computed by summing the number of risk-increasing alleles in individuals’ genomes, and 
scores can be weighted by the effect sizes of the risk alleles [182].  This approach to 
inferring genetic risk works very well when it is applied to patient cohorts from the same 
populations where the GWAS was conducted.  However, the extent to which genetic risk 
can be accurately calculated across populations with divergent ancestries is a matter of 
contention [120, 183].  On the one hand, many GWAS are highly replicable, with the same 
variants often discovered in multiple populations [22, 184].  On the other hand, recent 
studies have shown that differences in genetic ancestry can lead to misestimation of PRS 
across populations [23, 29, 185].   
The challenge of accurate PRS estimation across ancestry groups is particularly 
pressing for HL populations.  First, there is a severe bias towards European ancestry 
cohorts in GWAS.  As of 2006, only 0.06% of GWAS samples were from HL cohorts, and 
the fraction had only risen slightly to 0.54% by 2016 [16, 32].  Second, HL is a politically 
inspired, pan-ethnic label that does not correspond to any natural (i.e., genetic) 
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classification of human populations [186].  Individuals with origins in Latin America 
typically have three-way ancestry contributions from African, European, and Native 
American source populations, and they can differ dramatically with respect to the relative 
proportions of each [75-78, 187].  Even neighboring populations from within the same 
Latin American country can show widely divergent ancestry profiles [188].  Accordingly, 
the extent to which existing GWAS variants can be used to infer genetic risk among diverse 
HL populations accurately is currently unknown.   
In this study, we explored the relationship between ancestry and T2D genetic risk 
inference in HL populations from Colombia and the US.  We found that T2D genetic risk 
is positively correlated with African and Native American ancestry and negatively 
correlated with European ancestry, consistent with epidemiological results.  We also show 
that T2D genetic risk inference holds up well across different GWAS ancestry cohorts and 
propose an approach whereby ancestry information can be used to support cross-population 
risk inference. 
5.3 Materials and Methods 
5.3.1 Diabetes epidemiological data 
Data on the worldwide prevalence of diabetes mellitus were taken from The World 
Bank [189].  Worldwide diabetes prevalence values are expressed as the percentage of the 
population between the ages of 20 and 79 diagnosed with diabetes.  Prevalence values are 
reported for 264 countries, which were broken down into seven World Health Organization 
(WHO) regions and four WHO income groups.  Data on the prevalence of diabetes for the 
United States (US) were taken from the American Diabetes Association [190].  US diabetes 
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prevalence values are expressed as the age-adjusted percentage of the population diagnosed 
with diabetes.  Prevalence values are broken down by the US census self-identified 
race/ethnicity groups and further sub-divided into country/region of origin for individuals 
who self-identify as Hispanic/Latino (HL).  Diabetes prevalence values for the European-
American (EA) and Mexican-American (MA) populations were taken from the Utah 
Department of Public Health [191] and the County of Los Angeles Public Health agency 
[192].  Note that these US diabetes prevalence values correspond to the specific 
populations sampled as part of the 1000 Genomes Project and used for genetic risk 
inference (see Methods section on Type 2 diabetes (T2D) genetic risk inference).            
5.3.2 Genome-wide association study (GWAS) data 
GWAS data were taken from the NHGRI-EBI GWAS Catalog [181].  All reported 
GWAS (as of 3/31/2018) were characterized with respect to the trait under consideration 
and the ancestry of the study cohort.  GWAS cohorts were characterized as African, East 
Asian, European, Hispanic/Latino, or Native American following the GWAS Catalog 
framework for the representation of ancestry data in genomic studies [193].  The total 
number of single-nucleotide polymorphism (SNP) associations that reach the GWAS 
Catalog significance threshold (P<1x10-5) were recorded for each GWAS trait.  For each 
T2D SNP association, we recorded the study(ies) where it was reported, the cohort 
ancestry, the SNP identifier, its chromosomal location, and the identity of the trait-
increasing effect allele.  T2D GWAS summary statistics for a trans-ethnic meta-analysis, 
which integrated cohorts with four distinct ancestries, were taken from the DIAGRAM 
consortium http://diagram-consortium.org/ [194, 195].  For these data, the GWAS SNP 
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effect alleles, ancestry-specific directions of effect, effect sizes, and P-values were 
recorded. 
5.3.3 Type 2 diabetes (T2D) genetic risk inference 
Whole genome sequences from the 1000 Genomes Project [196] and imputed 
whole genome genotypes from the ChocoGen Research Project 
https://www.chocogen.com [197] were used for T2D polygenic risk score (PRS) 
calculation (Table 3).  For the 1000 Genomes Project data, SNP data were taken from the 
phase 3 data release for one Colombian population – Colombians from Medellín, Colombia 
– and two US populations: Utah Residents (CEPH) with Northern and Western European 
Ancestry and Mexican Ancestry from Los Angeles USA.  The 1000 Genomes Project 
human genome sequence data are de-identified and made publicly available for research 
use without restriction.  For the ChocoGen Research Project, whole genome genotypes for 
sample donors were characterized using the Illumina HumanOmniExpress-24 SNP array 
as previously described, yielding ~500,000 SNPs per individual [188, 197].  The genotypes 
were imputed using the program IMPUTE2 [198] with the 1000 Genomes Project phase 3 
haplotype reference panel [199] as previously described [200], yielding ~35 million 
additional SNPs across all samples.  The ChocoGen project was conducted with the 
approval of the Ethics Committee of the Universidad Tecnológica del Chocó (ACTA No 




Table 4. Populations analyzed in this study. 
a1KGP = 1000 Genomes Project.  bn = number of sample donors per population 
   
Data 
Sourcea Population Description Population Name n
b 
ChocoGen Chocoano in Quibdó, Colombia Chocó 94 
1KGP Colombian in Medellin, Colombia Antioquia 94 
1KGP Yoruba in Ibadan, Nigeria African 108 
1KGP Iberian populations in Spain European 107 
1KGP Utah residents with NW European ancestry European-American (EA) 99 
1KGP Mexican Ancestry from Los Angeles USA Mexican-American (MA) 64 
1KGP Peruvian in Lima, Peru Native American 85 
 
For each genome, an unweighted T2D PRS was computed by calculating the 
normalized sum of the number of T2D SNP effect alleles found in the genome [182].  It 
should be noted that T2D PRS were not weighted by SNP effect sizes owing to the fact 
that the T2D SNP associations used here were curated from multiple studies whose effect 
sizes cannot be accurately combined [184].  T2D PRS were calculated as in Equation (1  
T2D PRS were compared to individuals’ continental genetic ancestry fractions – African, 
European, and Native American – which were taken from our previous studies [188, 200]. 
 T2D PRS were computed for the Colombian and US populations using an unpruned 
set of 165 T2D-associated SNPs along with a reduced linkage disequilibrium (LD) pruned 
set of 42 SNPs.  LD pruning was performed on the four Colombian, and US populations 
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analyzed here using the program PLINK [201] with 2000 SNP window size and a threshold 
of r2 > 0.1, where r2 corresponds to the level of linkage disequilibrium between pairs of 
SNPs in the window.  An additional round of LD clumping was performed on the 
DIAGRAM GWAS summary statistic data using the LDpred program, with the same 
suggested window size of 2000 SNPs [202].  LDpred uses the LDscore method to choose 
the highest effect size SNP for each LD window and subsequently reweights the effect 
sizes for all retained SNPs.   
5.3.4 Genetic ancestry and T2D risk 
The program ADMIXTURE was used to compute the three-way continental 
ancestry percentages – African, European, and Native American – for all individuals from 
the Colombian and US populations analyzed here [203].  The modern Colombian and US 
populations were compared to the proxy ancestral reference populations shown in Table 4, 
with ADMIXTURE run for K=3 ancestral components, corresponding to each of the three 
continental population groups that admixed to form modern American populations.  This 
process yields a vector of three ancestry fractions for any individual admixed genome 
sampled from the modern populations: fAfrican, fEuropean, fNativeAmerican (Additional file 2: 
Figure S1).  Then, for each of the three continental ancestry components, individuals’ 
continental ancestry fractions were regressed against their T2D PRS using unweighted 
ordinary least squares regression (OLS) with the lm function in R (Equation (5).  The 
resulting OLS produces: β0, the model β or slope; the standard error of the model; the 𝑟𝑟2 
value describing the model’s fit; the model t-statistic; and a two-tailed P-value.  For 
visualization purposes, a best fit line with confidence intervals was computed using local 




5.4.1 Diabetes prevalence and population disparities 
Diabetes is characterized by an extremely high disease burden along with 
pronounced disparities in prevalence among countries, regions, and income groups 
worldwide (Figure 26A and B).  It should be noted that, while these prevalence data are 
not broken down into diabetes types, the vast majority of diabetes cases correspond to 
adult-onset, non-insulin-dependent, type 2 diabetes (T2D).  The US is no exception to this 
trend; there is a high overall diabetes prevalence in the country and marked disparities 
among racial and ethnic groups (Figure 26C).  Native Americans, African Americans, and 
Hispanic/Latino (HL) populations bear a disproportionately high share of the diabetes 
disease burden in the US compared to Asian Americans and European Americans.  
Interestingly, there are also notable disparities within ethnic groups.  HL populations with 
distinct origins in Latin America can have very different diabetes prevalence (Figure 26D).  
Individuals from South America show diabetes prevalence close to what is seen for Asian 
Americans, whereas Mexican Americans show a two-times greater prevalence, close to 
what is seen for Native Americans.  Among HL regional groups, diabetes prevalence can 
also differ between males and females in a group-specific manner. 
The observed diabetes prevalence disparities among HL groups with distinct 
origins begs an explanation.  Diabetes is a complex common disease with multifactorial 
causes, including genetic and environmental effects, along with interactions between them.  
Nevertheless, T2D, in particular, is strongly genetically influenced with estimates of 
heritability ranging from 20 to 80% [177-179].  Furthermore, genetic ancestry is known to 
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impact the burden T2D; both African and Native American ancestry have been associated 
with increased T2D prevalence [128, 130, 204-206].  Thus, one may naively expect to 
observe more uniformity in T2D prevalence within a single ethnic group.  However, the 
pan-ethnic HL label does not, in fact, correspond to a ‘natural’ group with shared genetic 
ancestry.  Rather, HL groups encompass an extraordinarily diverse set of populations, 
which are characterized by distinct combinations of ancestry from Africa, Europe, and the 
Americas [75-78, 187].  Additionally, the Native American component of HL ancestry 
varies substantially according to the regional origins of the populations [188, 207, 208].  
With this in mind, we have been investigating the contributions of ancestry to genetic risk 





Figure 26. Diabetes global prevalence and population disparities.   
(A) Diabetes prevalence distributions are shown for (A) the seven world health 
organization (WHO) geographic regions and (B) the four WHO income groups.  (C) 
Diabetes prevalence for the United States (US) census race/ethnicity groups.  (D) 
Hispanic/Latino (HL) diabetes prevalence in the US broken down by country (region) of 




5.4.2 GWAS ancestry bias and T2D risk inference 
The power to infer genetic risk for complex common diseases, such as T2D, has 
exploded in recent years owing to the accumulation of GWAS for a wide variety of health-
related traits [180, 181].  GWAS yield lists of trait SNP associations, including the identity 
of trait-increasing effect alleles, each of which slightly increases the risk of disease.  
Accordingly, an individual’s genetic risk for a given trait can be estimated as a polygenic 
risk score (PRS), which is calculated as the normalized sum of risk (effect) alleles encoded 
in their genome.  However, the overwhelming bias towards European cohorts in GWAS 
[16, 32] presents a major challenge to this paradigm.  Specifically, the extent to which PRS 
can be accurately inferred across population groups with distinct ancestry profiles is a 
matter of great concern [120, 183].  On the one hand, many robust SNP associations are 
known to replicate across populations [22, 184].  On the other hand, GWAS SNP 
ascertainment biases and demographic processes have been shown to yield systematic 
errors in PRS calculation across populations [23, 29, 185].   
Here, we aimed to explore the effects of ancestry on the calculation of PRS for T2D 
across diverse populations.  In support of this effort, we found that T2D is distinct 
compared to GWAS for most other traits in several respects, largely owing to the intensity 
of focus on the genetic architecture of the disease and its epidemiological importance for 
populations across the world.  T2D has the most independent studies of any trait in the 
NHGRI-EBI GWAS catalog (Figure 27A), and it has among the most SNP associations 
reported for any trait (Figure 27B).  Perhaps even more importantly, for our purposes, T2D 
cohorts show substantially more ancestry diversity than typical GWAS traits (Figure 27C).  
A slight majority of T2D GWAS cohorts have European ancestry, but there are a 
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substantial number of cohorts with East Asian, African, and HL ancestry.  A number of 
T2D GWAS have employed a trans-ethnic study design, whereby cohorts with distinct 
ancestries are combined to increase the reliability of discovered SNP associations [194, 
195].   Taken together, the large number of T2D studies with diverse ancestry cohorts and 
the large number of T2D associations provide resolution for our efforts to (i) calculate PRS 






Figure 27. Genome wide association studies (GWAS) on type 2 diabetes (T2D).   
The number of (A) GWAS and the number of (B) SNP-associations per GWAS trait are 
shown, with T2D values in red.  (C)  The fractions of continental ancestry groups 




5.4.3 Ancestry and T2D genetic risk inference: Colombia 
We first explored the relationship between ancestry and T2D genetic risk for the 
Colombian populations of Antioquia and Chocó.  Although these two administrative 
departments (states) share a common border, their populations were historically isolated 
and showed very distinct ancestry profiles.  The population of Antioquia has majority 
European ancestry (75%) followed by Native American (18%) and African (7%) fractions, 
whereas the ancestry of Chocó is primarily African (76%) with smaller European (13%) 
and Native American (11%) components [188].  Genome sequences were characterized for 
individuals from the two populations, and T2D PRS were computed for all individuals as 
described in the Methods.  The distributions of T2D PRS for the two populations were then 
compared in order to assess their relative genetic risk.  Consistent with previous results 
[200], we found that Chocó has significantly higher predicted genetic risk for T2D 
compared to Antioquia (Figure 28A), and the higher genetic risk for T2D in Chocó is 
correlated with African ancestry (Figure 28B).  The elevated T2D risk for Chocó can be 
observed when all 165 T2D-associated SNPs are used for PRS calculation (Figure 28) or 
when a reduced set of 42 linkage disequilibrium (LD) pruned SNPs is used (Additional file 
2: Figure S2 panels A & B).  These findings are consistent with reports from the US 
showing a correlation between T2D genetic risk and African ancestry [132], and African 
Americans are known to have substantially higher T2D prevalence compared to European 
Americans [128, 130, 204, 206].  In Colombia, however, Antioquia shows approximately 
three-times higher observed T2D prevalence compared to Chocó (Figure 28C), in direct 
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contrast to the predicted genetic risk for the two populations and the epidemiological data 
from the US. 
 
Figure 28. T2D genetic risk and observed prevalence in Colombia. 
(A) T2D polygenic risk score distributions are shown for Antioquia (green) and Chocó 
(purple).  (B) T2D polygenic risk scores for individuals from Antioquia and Chocó 
regressed against their percent African ancestry.  (C)  Observed T2D diabetes prevalence 
for Antioquia (green), Chocó (purple), and Colombia overall (gray).  (D) Observed T2D 
relative genetic risk Chocó/Antioquia compared to the null distribution of relative genetic 
risk between the two populations.   
We previously attributed the difference between the relative predicted genetic risk 
of T2D for the two Colombian populations and their observed T2D prevalence to gene-by-
environment interactions, whereby diet and lifestyle in Chocó serve as protective factors 
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against T2D [200].  However, another possible explanation for this discrepancy is that there 
is a systematic bias in T2D PRS calculations across populations of this kind with distinct 
ancestry profiles [23, 29, 185].  We addressed this possibility by comparing the observed 
T2D relative risk for Chocó / Antioquia to a null distribution of relative risk generated by 
permuting 500,000 random sets of GWAS SNPs (risk alleles) of the same size as the T2D 
SNP set.  If there were a systematic bias in the population-specific frequencies of GWAS 
risk alleles for the two populations, then the null distribution would be expected to show 
an overall increase of genetic risk in Chocó.  We do not observe any such bias; the observed 
relative risk of T2D is significantly greater than the null expectation (Figure 28D). 
As previously described, the major source of bias for cross-population PRS 
calculation is attributed to the vast over-representation of European cohort GWAS.  It is 
possible that GWAS SNPs discovered in European study cohorts will not accurately 
capture genetic risk in non-European cohorts.  This problem could be even more 
exacerbated in the case of the admixed Colombian populations studied here, one of which 
looks more European while the other is more African.  The fact that T2D has been the 
subject of numerous GWAS across diverse population cohorts (Figure 27) provides an 
opportunity to interrogate this potential bias.  To do so, we characterized T2D GWAS 
variants according to the ancestry of the study cohorts where they were discovered. We 
then re-calculated population-specific T2D PRS distributions for each ancestry separately.  
We were able to classify T2D SNPs into five different ancestry profiles, three of which 
showed significantly higher risk in Chocó and two of which yielded no significant 
difference (Figure 29).  None of the comparisons showed significantly higher T2D risk in 
Antioquia, and all of the cohorts with ancestry most similar to the Colombian populations 
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(African, Multi-ethnic, and Admixed American) showed higher relative risk in Chocó.  
These results support the finding of higher genetic risk for T2D in Chocó, associated with 
African ancestry. They do not suggest that this finding can be attributed to GWAS SNP 
discovery bias. 
 
Figure 29. T2D genetic risk comparison in Colombia based on different GWAS 
cohort continental ancestries.  
T2D polygenic risk score distributions for Antioquia (green) and Chocó (purple) are shown 
for SNP associations discovered in patient cohorts with distinct continental ancestries. 
5.4.4 Ancestry and T2D risk inference: United States (US) 
We performed a similar comparison of T2D genetic risk for European-American 
(EA) and Mexican-American (MA) populations in the US.  With the same set of T2D SNPs 
used to compare genetic risk in Colombia, the MA population shows marginally higher 
T2D genetic risk than the EA population (Figure 30A).  As was the case for Colombia, the 
same differences in T2D genetic risk between the US populations can be seen when all 165 
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T2D-associated SNPs are used for the PRS calculations (Figure 30A) or when a reduced 
set of 42 linkage disequilibrium (LD) pruned SNPs is used (Figure S2 panels C & D).  For 
these two US populations, T2D genetic risk is negatively correlated with European ancestry 
and positively correlated with Native American ancestry (Figure 30B).  However, unlike 
what we observed in Colombia, the relative genetic risk estimates between the two 
populations are consistent with the observed T2D prevalence; the MA population shows 





Figure 30. T2D genetic risk and observed prevalence for European-American (EA) 
and Mexican-American (MA) cohort populations.   
(A) T2D polygenic risk score distributions are shown for EA (gold) and MA (green). (B) 
T2D polygenic risk scores for EA and MA individuals are regressed against their percent 
European and percent Native American ancestry.  (C) Observed T2D diabetes prevalence 
values for EA (gold), MA (green), and the United States overall (gray).   
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Despite the consistency of the T2D genetic risk estimates and the observed 
prevalence values for these two populations, we wanted to explore further the contribution 
of genetic ancestry differences to potential biases in genetic risk calculation.  To do so, we 
took advantage of a recent trans-ethnic GWAS meta-analysis [194, 195] to curate T2D 
SNPs that were discovered in one or more cohorts with distinct ancestries, including 
European and Mexican ancestry cohorts.  We then computed T2D PRS distributions using 
(i) significant SNPs that showed the same direction of effect between the two ancestry 
cohorts, (ii) SNPs that were significant in the European ancestry cohort only, (iii) SNPs 
that were significant in the Mexican ancestry cohort only, and (iv) SNPs that showed 
different directions of ancestry-specific effects (Figure 31).  The SNPs with effects that are 
shared between populations or effects that are population-specific all yielded higher T2D 
PRS in the MA compared to the EA population.  The magnitude and significance of this 
relationship were most pronounced for the ancestry shared SNPs (Figure 31A).  The SNPs 
with different effects between the two ancestry cohorts were the only ones that showed 
higher T2D PRS in the EA population (Figure 31D).  These results underscore the potential 
utility of combining cohorts with distinct ancestries for GWAS SNP discovery, in terms of 
both increasing the reliability of SNP effect allele discovery and decreasing the likelihood 
of false discoveries.  Indeed, we found that the T2D SNPs that showed shared effects across 
ancestry cohorts had effect size odds-ratio (OR) values almost an order of magnitude higher 
than SNPs with divergent ancestry-specific effects (Shared OR=2.40 versus Divergent 





Figure 31. T2D genetic risk comparison between European-American (EA) and 
Mexican-American (MA) cohort populations based on ancestry-specific SNP effects.   
T2D polygenic risk score distributions for EA (gold) and MA (green) populations are 
compared for (A) all SNPs with consistent ancestry effects, (B) SNPs with European 
ancestry-specific effects, (C) SNPs with Mexican ancestry-specific effects, and (D) SNPs 
with opposing ancestry effects.     
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5.4.5 Correcting for ancestry bias in T2D risk inference 
A number of recent studies have underscored (i) the extreme bias of European 
ancestry cohorts in GWAS [16, 32] and (ii) the corollary potential to misestimate genetic 
risk across populations with diverse ancestries [23, 29, 120, 183, 185].  Kim et al. identified 
two potential sources of bias for cross-population ancestry risk inference [23], which we 
will call here SNP ascertainment bias and SNP discovery bias.  SNP ascertainment bias is 
related to the fact that SNP microarrays are typically used for genotyping in GWAS, and 
these microarrays are designed, for the most part, to capture high minor allele frequency 
(MAF) SNPs in European populations.  This will lead to the ascertainment of SNPs with 
higher MAF in European populations compared to other global populations, particularly 
populations from Africa that are enriched for ancestral alleles [209].  Then, systematic 
differences in the proportions of derived alleles, which most often correspond to the minor 
allele versus ancestral alleles, may lead to directional biases in the estimation of genetic 
risk.  SNP discovery bias is related to the increased power of GWAS to detect SNPs with 
higher MAF.  Irrespective of microarray design, the discovery of SNPs in European cohorts 
will yield relatively higher MAF in European populations compared to other populations, 
which can also lead to misestimation of genetic risk across populations with distinct 
ancestries. 
Here, we propose a potential control for these two sources of PRS bias, based on correction 
for systematic differences in the proportions of ancestral versus derived alleles in 
populations with distinct ancestry profiles.  Ancestral alleles tend to correspond to major 
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alleles, whereas derived alleles most often correspond to minor alleles in discovery cohort 
populations.  While GWAS risk alleles can be more evenly distributed across ancestral 
(44%) versus derived (56%) alleles, differences in the frequencies of these allele classes 
across populations can still introduce bias in genetic risk inference [23].  The idea behind 
the control that we propose here is to eliminate any possible bias owing to population-
specific differences in the frequencies of ancestral versus derived alleles, which are mainly 
attributed to demographic factors (i.e., genetic drift).   
The steps in the control are shown below.  Further detail regarding the execution of each 
step is provided in Additional file 2 (see pages 5-7).  
1. Collect trait SNP set and calculate population-specific PRS values and between-
population PRS differences (∆𝑃𝑃𝑃𝑃𝑃𝑃).  
2. Determine the distribution of derived allele frequencies (DAF) for trait-associated 
SNPs in the GWAS cohort source population. 
3. Randomly sample SNP sets parameterized by this DAF distribution based on the 
DAFs from the distinct populations being compared (thereby eliminating between-
population DAF biases). 
4. Calculate between-population ∆𝑃𝑃𝑃𝑃𝑃𝑃 for all randomly sampled SNP sets and 
determine the null ∆𝑃𝑃𝑃𝑃𝑃𝑃 distribution. 
5. Compare the observed ∆𝑃𝑃𝑃𝑃𝑃𝑃 to the null ∆𝑃𝑃𝑃𝑃𝑃𝑃 distribution and compute a z-score 
as the ancestry-corrected ∆𝑃𝑃𝑃𝑃𝑃𝑃: 𝑝𝑝𝑁𝑁𝑟𝑟𝑟𝑟.∆𝑃𝑃𝑃𝑃𝑃𝑃 =
(𝑁𝑁𝑜𝑜𝑒𝑒∆𝑃𝑃𝑃𝑃𝑃𝑃 − 𝜇𝜇𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛∆𝑃𝑃𝑃𝑃𝑃𝑃 ) 𝜎𝜎𝑛𝑛𝑛𝑛𝑛𝑛𝑛𝑛∆𝑃𝑃𝑃𝑃𝑃𝑃⁄ . 
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An example of this control can be seen for the comparison of T2D genetic risk between the 
EA and MA populations (Figure 32).  The observed value of ∆𝑃𝑃𝑃𝑃𝑃𝑃 for EA-MA is -2.08, 
while the null ∆𝑃𝑃𝑃𝑃𝑃𝑃 distribution is centered around 0 with a mean value of -0.16 and a 
standard deviation of 1.25.  Thus, there is a slight bias in PRS calculation for the two 
populations.  Accordingly, correcting for SNP ascertainment bias does mitigate the 
difference in predicted risk between the two populations, with a corrected ∆𝑃𝑃𝑃𝑃𝑃𝑃 value of 
1.54 that is marginally significant at P=0.054.  Given what we know about the higher 
prevalence of T2D in the MA population, we may consider this correction to be accurate, 
in the sense that it preserves the direction of the genetic risk difference, but conservative 






Figure 32. T2D genetic risk comparison between European-American (EA) and 
Mexican-American (MA) cohort populations based on ancestry-specific SNP effects.   
T2D polygenic risk score distributions for EA (gold) and MA (green) populations are 
compared for (A) all SNPs with consistent ancestry effects, (B) SNPs with European 
ancestry-specific effects, (C) SNPs with Mexican ancestry-specific effects, and (D) SNPs 




HL populations are burdened with a high and increasing prevalence of T2D, both 
in the US and in Latin America (Figure 26) [175, 176].  Recent developments in the 
estimation of genetic risk using PRS provide opportunities to reduce this burden through 
improved screening and prevention efforts [180].  Nevertheless, there are a number of 
challenges that need to be met in order to ensure that genetic risk of T2D, and other 
common heritable diseases, can be accurately predicted using PRS [120, 183].  In 
particular, the bias towards European ancestry cohorts in GWAS [16, 32] has the potential 
to limit the utility of PRS in HL populations.  In addition, the extremely diverse ancestries 
that can be found among HL populations could lead to misestimation of genetic risk for 
distinct HL subgroups.   
There are two broad solutions to these ancestry-related challenges to genetic risk 
inference: (i) more data and (ii) better methods.  Obviously, more GWAS that includes 
cohorts that capture the genetic diversity of HL populations will go a long way towards 
providing the raw material, in the form of risk increasing genetic variants relevant to those 
same populations, which are needed to compute accurate PRS.  However, given the current 
pace of efforts to diversify GWAS, along with the very high cost of these studies, it is 
unrealistic to expect the GWAS coverage of HL populations to approach that of European 
ancestry cohorts any time soon.  In the meantime, new methods that explicitly leverage 
ancestry, e.g., modeling differences in allele frequencies across populations, may help to 
increase confidence in cross-population PRS calculation.   
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Here, we have shown that considering the consistency of GWAS variant effects 
across populations and modeling population-specific allele frequencies can increase 
confidence in cross-population PRS.  T2D is a special case concerning common heritable 
diseases in the sense that it has been extensively studied via numerous GWAS, and it has 
the most diverse set of ancestry cohorts seen for any GWAS trait (Figure 27) [181].  In 
addition, recent studies have combined cohorts from different ancestries to increase 
confidence in the discovery of T2D associated variants [194, 195].  These facts allowed us 
to evaluate the extent to which GWAS variants discovered in cohorts with different 
ancestries yield similar PRS.  The signal of T2D relative risk in Colombia is highly similar 
when GWAS variants discovered in different ancestry cohorts are used for PRS (Figure 
29).  A similar result was seen for T2D risk in the US, but in this case, consistency of T2D 
associations across cohorts seemed to provide more reliable PRS estimates (Figure 31).  
Finally, we proposed a conservative control for cross-population PRS inference based on 
modeling the frequencies of ancestral and derived alleles in the different populations being 
considered (Figure 32). 
A recent study compared the utility of GWAS SNPs ascertained from EA versus 
HL populations for a calculating PRS in HL populations across twelve different traits 
[210].  While there was a wide variety of relative performance of EA SNPs across the traits, 
the majority of EA SNP sets showed comparable risk prediction accuracy compared to the 
best performing SNP sets, which included information from HL GWAS cohorts.  
Nevertheless, the inclusion of non-EA GWAS association results to refine the SNP weights 
improved accuracy across the board.  The results are consistent with our findings 
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suggesting that information from multi-ethnic GWAS cohorts can be used to refine PRS 
inference.   
5.6 Conclusions 
One promising area for future work entails the application of machine learning 
methods to the inference of polygenic risk [211].  Currently, PRS calculations are based on 
GWAS that explicitly assume an additive model of genetic effects on traits of interest.  
Accordingly, standard methods for computing PRS, such as the kind we use here, entail a 
straightforward summation of risk alleles genome-wide.  Of course, it may be more 
biologically realistic to assume that there are non-additive genetic effects among variants 
discovered by GWAS and used for PRS.  If this is indeed the case, then more sophisticated 
machine learning algorithms may ultimately improve the accuracy of PRS calculation.  The 
use of machine learning for polygenic risk inference is still in the very early stages; it 
remains to be seen if this approach will yield demonstrable improvement over current best 
practices. 
The control we developed here for cross-population PRS inference is based on 
differences in ancestral versus derived allele frequencies among populations with distinct 
ancestry profiles.  However, differences in LD across populations with divergent ancestries 
can also confound cross-population PRS inference.  This is particularly true for African 
ancestry populations, which tend to have short and distinct LD blocks compared to non-
African populations.  Accordingly, controlling for such differences provides another 
promising approach for improving cross-population PRS inference.  Indeed, a previous 
study has shown that accommodating differences in LD patterns across populations can 
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substantially improve the accuracy of PRS computed for distinct ancestry cohorts [212].  
In the future, we plan to combine allele frequency and LD based approaches to improving 
the accuracy of cross-population PRS.  
We employed a population-level approach to T2D genetic risk inference and 
evaluation in this study, comparing T2D relative genetic risk between populations to 
population-specific ancestry profiles and epidemiological data on observed T2D 
prevalence.  Taken together with the robust collection of T2D variant associations from 
several diverse GWAS cohorts, this approach allowed us to broadly assess the impacts of 
ancestry on T2D genetic risk inference in HL populations.  Going forward, a more rigorous 
assessment of PRS accuracy will require individual-level phenotype data for both model 
training and test sets.  Data of this kind are beginning to emerge thanks to the activity of a 
number of diabetes research consortia along with more broadly focused biobanks that 
collect patient genotypes and electronic health records.  We anticipate that joint analysis of 
individual-level genotype-phenotype data gleaned from sources of this kind will help to 
further develop and validate ancestry-informed approaches to T2D genetic risk inference. 
5.7 Supplementary Methods 
5.7.1 Genetic ancestry and admixture for Colombian and US populations 
Whole genome genotypes from the HL populations in Colombia and the US were 
compared to genotype data from proxy source populations in Africa, Europe, and the 
Americas (Table 4) using the program ADMIXTURE [203] in order to calculate three-way 
ancestry percentages for each individual genome.  The resulting ancestry percentages were 
then regressed against predicted T2D PRS for these same individuals, as shown in Figure 
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Figure 33. Ancestry and admixture patterns for the Colombian and US populations 
studied here.  
(A) Ancestry percentages – African (blue), European (yellow), and Native American (red) 
– are shown for individuals sampled from proxy ancestral source populations in Africa, 
Europe, and the Americas along with the admixed Colombian (Antioquia and Chocó) and 
US populations (European- and Mexican-American). Each stacked bar represents the 
relative ancestry percentages for one individual from a given population. The population 
sources for this analysis are shown in Table 4. (B) Comparison between ADMIXTURE (x-
axis) and RFMix (y-axis) continental ancestry percent estimates for the admixed 
populations analyzed here. Individuals from each admixed population are color-coded, as 
shown.   
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5.7.2 Effects of linkage disequilibrium (LD) on T2D genetic risk inference 
Divergent patterns of LD across populations with distinct ancestry can confound cross-
population PRS inference.  We first controlled for the effects of LD by performing LD 
pruning on the initial set of 165 T2D-associated SNPs used to compute PRS in the 
Colombian and US populations.  LD pruning was performed for all four populations 
together by removing variants that are linked at r2 > 0.1, retaining the linked SNP with the 
highest minor allele frequency.  Details of this analysis can be found in the Materials and 
Methods section.  Our approach to LD pruning was intended to be very conservative 
(stringent) in terms of both the low r2 threshold and the combined use of the four 
populations.  Consistent with this intention, LD pruning reduced the total number of T2D 
associated SNPs for PRS analysis from 165 to 42.  Nevertheless, the signal of relative T2D 





Figure 34. Effects of linkage disequilibrium (LD) pruning on T2D genetic risk.   
Polygenic risk scores were calculated and presented, as shown in Figure 28 and Figure 
30, using both the full unpruned set of T2D associated SNPs (n=165) and the reduced LD 
pruned set (n=42).  Results are shown for the Colombian (panels A and B) and US 
populations (panels C and D).  
We further attempted to control for LD differences in cross-population PRS by using the 
LDpred program to compute PRS for the EA and MA populations using the DIAGRAM 
multi-ethnic GWAS T2D SNP-association data.  LDpred performs LD clumping, to correct 
for LD structure, along with re-weighting on SNP effect sizes, by choosing the most 
informative SNP within any given LD window [202].  We ran LDpred across of series of 
P-value thresholds (Figure 35 panels B-E) and found the results to be almost entirely 







Figure 35.  Effects of linkage disequilibrium (LD) clumping and P-value 
thresholding on T2D polygenic risk scores. 
Distributions of population PRS using all marginally-significant variant effects from 
GWAS summary data (A) and from LD clumping and P-value thresholding using an LD 
cutoff of r2 > 0.1 and P-value cutoffs of 1x10-1 (B), 1x10-2 (C), 1x10-3 (D), and 1x10-4 (E). 
There are other programs available for controlling for LD when computing PRS – lassosum 
and PRSice-2 – but these programs use individual-level phenotype data to optimize the 
selection of SNPs to be included in PRS tests [213, 214].  Lassosum can be run in the 
pseudo validation mode without phenotypes, but doing so here on the DIAGRAM data 
simply yields overlapping PRS distributions between populations.  Running PRSice-2 
without phenotype data yields an error message and does not produce any output. 
5.7.3 Correcting for ancestry bias in T2D risk inference 
Our control for ancestry bias in polygenic risk inference is presented in the main text; 
additional details of this process are given below. 
1. Collect trait SNP set and calculate population-specific PRS values and between-
population PRS differences (∆𝑃𝑃𝑃𝑃𝑃𝑃). 
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1.1. SNP sets for traits of interest can be curated from the NHGRI-EBI GWAS Catalog 
at https://www.ebi.ac.uk/gwas/ or from GWAS consortium resource webpages, 
such as the DIAGRAM page used to curate T2D SNPs here  http://diagram-
consortium.org/downloads.html.  SNP sets can also be curated from the literature 
using the NCBI PubMed database https://www.ncbi.nlm.nih.gov/pubmed/. In the 
case of literature searches for trait SNP sets, we recommend using the most up-to-
date and comprehensive meta-analyses that can be found for any trait of interest. 
1.2. PRS can be computed from whole genome genotype data by evaluating the 
numbers of risk alleles present in any individual genome (genotype) being 
analyzed. Unweighted PRS or weighted PRS can be computed.  Note that 
unweighted PRS should be used when trait SNPs are curated from multiple studies, 
owing to the fact that effect sizes from different studies cannot be accurately 
combined. 
1.3. Between-population PRS differences (∆PRS) are computed as the difference 
between mean population-specific PRS values. For example, for the EA and MA 
populations, ∆PRS is computed as 
2. Determine the distribution of derived allele frequencies (DAF) for trait-associated 
SNPs in the GWAS cohort source population. 
2.1. PRS are computed with biallelic SNPs taken from the 1000 Genomes Project phase 
3 release VCF file. This file designates each allele as ancestral or derived in the 
‘AA’ field of the ‘INFO’ column. 
2.2. The derived allele frequencies for (DAF) for trait-associated SNPs in the GWAS 
catalog are then calculated. 
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3. Randomly sample SNP sets parameterized by this DAF distribution based on the DAFs 
from the distinct populations being compared (thereby eliminating between-population 
DAF biases). 
3.1. The derived allele frequency (DAF) in the GWAS catalog is represented as D and 
the binomial probability of sampling an ancestral or derived allele is used to 
randomly select SNPs. 
4. Calculate between-population ∆𝑃𝑃𝑃𝑃𝑃𝑃 for all randomly sampled SNP sets and determine 
the null ∆𝑃𝑃𝑃𝑃𝑃𝑃 distribution. 
4.1. For each simulation, population-specific PRS values for the randomly simulated 
SNP sets are computed as shown in #1.2 above, and the mean population-specific 
PRS values are then used to compute the ∆𝑃𝑃𝑃𝑃𝑃𝑃 value as shown in #1.3 above. 
5. Compare the observed ∆𝑃𝑃𝑃𝑃𝑃𝑃 to the null ∆𝑃𝑃𝑃𝑃𝑃𝑃 distribution and compute a z-score as 
the ancestry- corrected ∆𝑃𝑃𝑃𝑃𝑃𝑃. 
5.1. The procedure in #4 above yields a null distribution of ∆𝑃𝑃𝑃𝑃𝑃𝑃 values. 
5.2. The null ∆𝑃𝑃𝑃𝑃𝑃𝑃 value distribution from the simulated data is compared against the 
observed between population ∆𝑃𝑃𝑃𝑃𝑃𝑃 value to derive the ancestry corrected ∆𝑃𝑃𝑃𝑃𝑃𝑃: 






CHAPTER 6. CONCLUSIONS AND FUTURE PROSPECTS 
The causes of common complex diseases remain an active area of study that bridges 
several scientific disciplines, and which requires researchers to disentangle the complex 
network of societal, environmental, and genetic factors that underlie these diseases.  
Through massive GWA studies, studying millions of individuals, genetics research has 
begun to understand some of the genetic architecture of disease.  However, this effort has 
historically and still today been focused on individuals of European descent, contributing 
to increasing minority health disparities.  Interrogating the genomes of diverse populations 
in the Americas – such as Afro-descendent populations in the US and Latin American – is 
a necessary step in decreasing health disparities across the board. 
This dissertation work includes the development of methods that enable scientists 
to apply existing knowledge already derived in one population to new and diverse 
populations.  Part of this development effort is focused on PGS, a crucial part of genomics-
enabled precision medicine.  In this thesis, I explored the distributions of PGS computed 
in diverse global populations as well as the effects of ancestry on PGS computation and 
accuracy using a population genetics approach in the US and Colombia.  In traditional 
PGS, individuals are scored on the basis of SNP associations ascertained in an ancestry-
matched cohort, that is, European-ancestry individuals use PGS derived from European 
cohort GWAS.  These PGS are typically constructed using one of two methods; (1) the 
Top-SNP approach, in which only SNP associations that reach genome-wide significance 
(p < 5 × 10−8) are considered, and (2) the Clump and Threshold approach, where 
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investigators iteratively select the combination of LD-clumping r2 and p-value threshold 
that produces the best score (typically measured as highest AUC).  
As discussed throughout, I use a combination of these two techniques, along with 
several novel controls, to develop and compute PGS for complex common diseases in the 
US and Colombia.  Differences in population PGS distributions are generally an accurate 
indicator of relative disparities between populations in a country, at least for Colombia.  In 
cases where predictions do not match actual disparities, we note that there are significant 
socioeconomic and environmental effects that mediate the genetic component of risk.  In 
the case of type 2 diabetes, low SES, and its association with a low-fat/high vegetable diet 
and increased activity levels were found to be protective against disease.  Similarly, while 
Chocóanos were predicted to have a much lower risk for all P. falciparum caused malaria, 
the high density of parasite and mosquitoes in Chocó compared to Antioquia leads to higher 
rates in Chocó.   
 Ultimately, increased study of population genetics for diverse ancestry groups is 
needed to close the gap in health disparities.  The major limitations of the work presented 
in this thesis are the lack of individual-level phenotype data and the small sample size.  
Unfortunately, the collection of larger datasets, which include individual-level phenotypes, 
is not easily accomplished from across the globe.  Governments and funding agencies must 
invest in local efforts to study diversity. 
 Efforts are underway globally to expand GWA studies to include more diverse 
individuals.  Recruiting, enrolling, and phenotyping study participants scales poorly at the 
individual investigator level.  Thus, large scale and multi-ethnic GWAS are costly and 
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difficult to conduct for individual investigators and require multi-institute collaborations.  
Nevertheless, progress on this front has been slow but steady, resulting in multi-ethnic 
GWAS of hundreds of thousands of diverse individuals.  Analysis efforts on these cohorts 
are hampered by lack of deep phenotyping – that is, phenotyping across the entire spectrum 
of quantitative measures and environmental exposures – which limits the new association 
and meta-analysis studies that can be conducted.   
Researchers prefer, instead, to work with biobank-sized cohorts such as the UK 
Biobank, and remove diverse individuals to create more homogeneous cohorts.  Thus, 
while the scientific community, particularly funding agencies, are beginning to support 
more diverse population-based studies, it is also essential for local and national 
governments to cooperatively fund and support the creation of regional biobanks.  These 
biobanks can leverage the existing health care infrastructure to enroll and phenotype 
participants, the most difficult, costly, and time-consuming step in genetics studies.  
Sequencing and genotyping, by comparison, costs as little as tens of dollars per participant, 
and large sequencing centers are capable of genotyping thousands of individuals per day.  
While the creation of large biobanks is an expensive and daunting task, the UK Biobank 
has shown that they facilitate research at scales never before seen.   
 Finally, further study of individuals from Chocó is necessary to understand the 
genetic architecture of disease fully.  A proposed ChocoGEN2 would encompass a larger 
prospective cohort along with deep phenotyping to provide.  This would enable association 
studies and other analyses that rely on individual-level phenotype data.  This thesis has 
shown that rudimentary population precision health recommendations can be made with 
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the existing data.  Expanding the depth of data available to researchers would enable even 
more public health benefits and decrease health disparities.   
  






























rs16891982 C G 0.361702 0.93617 0.638298 0.06383 C G 0.31 0.362 3.92E-10 
rs11894081 G T 0.202128 0.797872 0.797872 0.202128 T A 1.22 0.355 8.42E-10 
rs1137 T C 0.260646 0.792553 0.739354 0.207447 C G 0.12 0.284 8.90E-07 
rs4474514 G A 0.164894 0.691489 0.835106 0.308511 A T 3.07 0.283 9.72E-07 
rs2472649 A G 0.244681 0.765957 0.755319 0.234043 G C 1.095 0.272 2.50E-06 
rs995030 A G 0.159574 0.670213 0.840426 0.329787 G C 2.69 0.269 3.22E-06 
rs1426654 A G 0.718085 0.207447 0.281915 0.792553 A T 0.484 0.262 5.75E-06 
rs12940030 T C 0.680851 0.175532 0.319149 0.824468 T A 0.08 0.261 6.23E-06 
rs1667394 C T 0.425532 0.882979 0.574468 0.117021 A T 4.94 0.231 6.30E-05 




rs28777 C A 0.345745 0.856383 0.654255 0.143617 C G 0.46 0.272 3.00E-06 
rs1298637 C T 0.718085 0.191489 0.281915 0.808511 A T 5.972 0.280 1.52E-06 
rs9623117 T C 0.851064 0.324468 0.148936 0.675532 C G 1.18 0.286 9.03E-07 
rs1834640 A G 0.781915 0.239362 0.218085 0.760638 G C 12.5 0.294 4.43E-07 
rs509360 A G 0.239362 0.797872 0.760638 0.202128 A T 0.0031 0.312 8.35E-08 
rs10007810 G A 0.765957 0.202128 0.234043 0.797872 A T 1.2 0.318 4.69E-08 
rs11814448 A C 0.904255 0.345745 0.095745 0.654255 C G 1.26 0.333 1.06E-08 
rs12074934 T G 0.941489 0.356383 0.058511 0.643617 C G 15.23 0.376 1.04E-10 
rs2814778 T C 0.925532 0.18617 0.074468 0.81383 C G 1.35 0.554 1.74E-21 
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Table 5 continued 
Effect 






rs16891982 Skin sensitivity to sun SLC24A5 C/G protective against malignant melanoma 
rs11894081 Crohn's disease  Unspecified rate increase 
rs1137 Myopia pathological SEMA4F  Axon growth disorders 
rs4474514 Testicular cancer KITLG 3x rate increase per A 
rs2472649 Inflammatory bowel disease Intronic Unknown function 
rs995030 Testicular germ cell tumor KITLG 2.5x rate increase per G 
rs1426654 Body mass index SLC24A5 Lighter skin color per A allele 
rs12940030 Corneal structure 
HS3ST3B1-
PMP22 Corneal thickness 
rs1667394 Blond vs. brown hair color  A allele 4.4x more likely to be blond  




rs28777 Black( vs. blond) hair color SLC24A5 Darker hair for each C allele 
rs1298637 Nicotine use GLIS1 Increased nicotine use 
rs9623117 Prostate cancer TNRC6B 
Increased prostate cancer risk in African 
Americans 
rs1834640 Skin pigmentation - dark SLC24A5 Darker skin pigmentation for each G 
rs509360 Trans fatty acid levels FEN1 Increased ALA and LA levels from PUFA pathway 
rs10007810 Longevity 90 years and older LIMCH1 Small increase in longevity 
rs11814448 Breast cancer 
ADIPOR1P1, 
DNAJC1 Unknown function 
rs12074934 Diisocyanate-induced asthma OR10J3 Unknown function 
rs2814778 Resistance to Plasmodium vivax DARC (ACKR1) Duffy blood group is protective against malaria 
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Table 6. Concordance between predicted and observed trait differences between 
Antioquia and Chocó. 





Allergic sensitization Antioquia + 
Blond (vs. brown) hair color Antioquia + 
BMI change over time Antioquia - 
Body mass index Antioquia - 
Corneal structure Antioquia + 
Crohn's disease Antioquia + 
Height Antioquia + 
Inflammatory bowel disease Antioquia + 
Myopia (pathological) Antioquia + 
Skin sensitivity to sun Antioquia + 
Stroke, ischemic Antioquia + 
Testicular cancer Antioquia + 
Testicular germ cell tumar Antioquia + 
WHR-adjusted BMI Antioquia - 
Alzheimer's disease, late-onset Chocó U 
Black (vs. blond) hair color Chocó + 
Breast cancer Chocó + 
Diisocyanate-induced asthma Chocó + 
Eye color (Brown vs. 
Blue/Green) Chocó + 
Longevity, 90 years and older Chocó U 
Mortality in heart failure Chocó + 
Nicotine use Chocó - 
Prostate cancer Chocó + 
Resistance to Plasmodium vivax Chocó + 
Skin saturation Chocó + 
Skin pigmentation - dark Chocó + 




Table 7. GWAS Catalog trait PRS differences between Chocó and Antioquia  





&beta;2-Glycoprotein I &beta;2-GPI plasma levels -7.074468 5.34E-03 Chocó European 
Abdominal aortic aneurysm -9.425211 3.39E-11 Chocó NR, European 
Activated partial thromboplastin time 12.471505 2.94E-11 Antioquia East Asian 
Advanced glycation end-product levels -7.180851 1.77E-02 Chocó NR 
Adverse response to chemotherapy in breast cancer alopecia 
cyclophosphamide+doxorubicin+-over--5FU 10.460993 3.44E-07 Antioquia East Asian 
Adverse response to chemotherapy in breast cancer alopecia docetaxel -15.2039 2.61E-09 Chocó East Asian 
Adverse response to chemotherapy in breast cancer alopecia paclitaxel -10.85993 2.65E-10 Chocó East Asian 
Adverse response to chemotherapy neutropenia-over-leucopenia all 
anthracycline-based drugs -10.66489 4.71E-05 Chocó East Asian 
Adverse response to chemotherapy neutropenia-over-leucopenia all 
platinum-based drugs -11.0195 1.32E-11 Chocó East Asian 
Adverse response to chemotherapy neutropenia-over-leucopenia 
gemcitabine 5.9574468 3.81E-02 Antioquia East Asian 
Age at smoking initiation in chronic obstructive pulmonary disease 11.931889 1.30E-11 Antioquia European 
Aggressive periodontitis -11.94149 3.04E-05 Chocó European, Other 
Aging time to event 8.2117528 4.96E-04 Antioquia European 




Table 7 continued 





AIDS -10.94225 8.42E-07 Chocó European 





Airway responsiveness in chronic obstructive pulmonary disease -8.079217 3.70E-10 Chocó European 
Alanine aminotransferase ALT levels after remission induction therapy in 





Hispanic or Latin 
American, Other 
Alcohol consumption 8.8219693 5.54E-08 Antioquia European 
Alcohol consumption drinks per week 16.755319 3.83E-03 Antioquia 
East Asian, 
European, 





Alcohol consumption heavy vs. light-over-non-drinkers -31.91489 3.62E-06 Chocó European 




Table 7 continued 










Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related 
liver cirrhosis 10.992908 4.46E-03 Antioquia European 





Alcohol use disorder total score 9.8210832 3.00E-09 Antioquia European 
Alcoholism alcohol use disorder factor score 15.780142 4.00E-13 Antioquia European 
Allergic disease asthma, hay fever or eczema 2.9188052 6.85E-10 Antioquia European 




Alzheimer's disease biomarkers -8.018521 2.80E-04 Chocó European 
Amyotrophic lateral sclerosis -5.123895 1.92E-08 Chocó European 
Angiotensin-converting enzyme activity 11.968085 3.14E-03 Antioquia East Asian 




Table 7 continued 





Anterior chamber depth 22.87234 7.23E-03 Antioquia 
East Asian, South 
Asian, South East 
Asian 
Anterior cruciate ligament rupture 7.535461 6.08E-04 Antioquia 






Hispanic or Latin 
American 
Anti-saccade response -3.786784 1.79E-03 Chocó European 
Antitragus size 20.212766 3.22E-03 Antioquia 
Hispanic or Latin 
American 
Anxiety and major depressive disorder -27.12766 1.21E-08 Chocó European 





Area under the curve of insulin levels 10.638298 1.86E-03 Antioquia European 




Table 7 continued 





Asparaginase hypersensitivity in acute lymphoblastic leukemia -8.999493 4.20E-04 Chocó 
European, 







Asthma bronchodilator response -18.35106 7.37E-09 Chocó 
European, 
Hispanic or Latin 
American 
Asthma childhood onset -6.391627 1.59E-04 Chocó 
East Asian, 
European, 







Asthma moderate or severe 8.4637312 2.79E-15 Antioquia European 
Atopic dermatitis -3.337761 7.52E-03 Chocó East Asian 
Atopic march -9.840426 1.15E-05 Chocó European 
Attention deficit hyperactivity disorder -3.119673 1.63E-02 Chocó European 




Table 7 continued 





Autism spectrum disorder -15.86879 3.98E-09 Chocó 
European, Other, 
NR 
Autism spectrum disorder or schizophrenia 5.6996313 1.36E-14 Antioquia 
European, Other, 
NR 
Autoimmune thyroid diseases Graves disease or Hashimoto's thyroiditis 8.7765957 1.30E-04 Antioquia NR, European 
Basal cell carcinoma 8.8956712 1.69E-15 Antioquia European 
Basal metabolic rate 23.93617 1.64E-03 Antioquia East Asian 
B-cell malignancies chronic lymphocytic leukemia, Hodgkin lymphoma or 
multiple myeloma pleiotropy -12.43517 1.91E-15 Chocó European 
Behcet's disease -12.14539 8.95E-11 Chocó East Asian 
Biliary atresia -13.67908 4.77E-08 Chocó European 
Bilirubin levels -4.516016 1.48E-02 Chocó East Asian 
Biochemical measures -5.472276 1.81E-05 Chocó European 
Bipolar I disorder -18.35106 2.53E-10 Chocó East Asian 
Black vs. blond hair color -19.7695 1.49E-26 Chocó European 
Black vs. red hair color -20 3.20E-25 Chocó European 
Blond vs. brown hair color 9.3085106 1.32E-02 Antioquia European 
Blond vs. brown-over-black hair color -2.681003 3.68E-05 Chocó European 




Table 7 continued 





Blood glucose levels 11.170213 7.55E-03 Antioquia European 






Blood pressure measurement low sodium intervention -11.43617 6.21E-03 Chocó East Asian 




Hispanic or Latin 
American, 
European 





Table 7 continued 





BMI in smokers 
-
14.45774 8.00E-13 Chocó 





Hispanic or Latin 
American 
BMI smoking interaction 
-
39.89362 3.88E-24 Chocó 





Hispanic or Latin 
American 
Body fat mass 
-
27.12766 2.29E-05 Chocó European 
Body mass index  smoking years interaction 
-









Table 7 continued 





Body mass index age interaction -21.80851 2.29E-04 Chocó NR, European 
Body mass index in asthmatics -9.388298 1.62E-03 Chocó 
NR, European, 
Hispanic or Latin 
American, Other 
Body mass index in non-asthmatics -9.397163 1.87E-07 Chocó 
NR, European, 
Hispanic or Latin 
American, Other 






Body mass index SNP x SNP interaction 7.7001013 6.71E-03 Antioquia East Asian 
Body mass index x sex x age interaction 4df test -7.644262 1.45E-04 Chocó European 




Bone mineral density femoral neck in inflammatory bowel disease -12.6773 3.72E-09 Chocó East Asian 





Table 7 continued 









North African or 
Persian), Other 
Bone ultrasound measurement broadband ultrasound attenuation -6.530286 2.96E-05 Chocó European 
Borderline personality disorder -4.232103 2.57E-02 Chocó European 
Brain structure -21.01064 2.14E-06 Chocó European 
Breast cancer 2.7219777 5.45E-23 Antioquia 
East Asian, 
European 
Breast Cancer in BRCA1 mutation carriers -5.912749 1.52E-04 Chocó European 





Hispanic or Latin 
American 
Brown vs. black hair color -7.196609 3.71E-06 Chocó European 
Brugada syndrome 22.695035 5.51E-15 Antioquia 
East Asian, 
European 




Table 7 continued 





Caffeine metabolism plasma 1,3-dimethylxanthine theophylline level 7.712766 2.15E-04 Antioquia European 
Caffeine metabolism plasma 1,7-dimethylxanthine paraxanthine to 1,3,7-
trimethylxanthine caffeine ratio 7.1032141 4.76E-12 Antioquia European 
Calcium levels 4.5152896 7.26E-05 Antioquia East Asian 
Cannabis use 8.5387116 1.05E-06 Antioquia European 
Cannabis use initiation -4.872758 1.03E-03 Chocó European 
Cardiac repolarization 12.012411 1.72E-06 Antioquia European 





Cardiovascular disease risk factors 8.6992263 1.06E-06 Antioquia European 
Carotid intima media thickness -7.765957 1.74E-02 Chocó East Asian 
Cataracts in type 2 diabetes -18.61702 1.18E-04 Chocó East Asian 
Caudate activity during reward 5.5849459 1.90E-09 Antioquia NR 
Caudate nucleus volume 14.095745 5.41E-04 Antioquia European 
Celiac disease 2.3406319 6.02E-03 Antioquia 
South Asian, 
European 





Table 7 continued 









Cerebral amyloid angiopathy -10.94858 1.21E-03 Chocó NR 
Cerebrospinal AB1-42 levels in Alzheimer's disease dementia -13.56383 1.31E-03 Chocó European 
Cerebrospinal AB1-42 levels in normal cognition -5.162261 6.89E-04 Chocó European 
Cerebrospinal fluid α-synuclein levels -10.07979 1.55E-07 Chocó European 
Cerebrospinal T-tau levels -4.251046 2.93E-06 Chocó NR 
Cerivastatin-induced rhabdomyolysis -22.87234 4.72E-04 Chocó NR, European 
Change in intraocular pressure in response to steroid treatment 





Childhood onset systemic lupus erythematosus 17.021277 3.60E-02 Antioquia East Asian 
Cholesterol and Triglycerides -25 3.42E-03 Chocó European 





Chronic hepatitis B infection 7.7611219 1.23E-09 Antioquia East Asian 




Table 7 continued 





Chronic kidney disease and serum creatinine levels 14.539007 1.40E-06 Antioquia European 
Chronic lymphocytic leukemia -3.034269 1.90E-02 Chocó 
European, NR, 
European 
Chronic myeloid leukemia -21.80851 3.08E-05 Chocó 
East Asian, 
European 
Chronotype -7.163005 1.27E-10 Chocó European 




circulating leptin levels -18.08511 1.69E-03 Chocó European 
Circulating myeloperoxidase levels serum -19.77837 3.99E-13 Chocó European 
Circulating phylloquinone levels 10.01773 2.23E-02 Antioquia European 
Circulating vasoactive peptide levels -13.03191 3.44E-02 Chocó European 
Classic bladder exstrophy -5.8274 5.69E-07 Chocó European 









Table 7 continued 





Cleft palate -25.26596 2.49E-13 Chocó 







Clozapine-induced agranulocytosis 5.5163396 2.50E-14 Antioquia European 
Coffee consumption -8.766253 1.74E-07 Chocó East Asian 
Cognitive decline rate in late mild cognitive impairment 2.6944457 1.08E-02 Antioquia NR, European 
Cognitive performance 1.6577381 2.95E-03 Antioquia European 
Cognitive performance MTAG 1.6805255 3.73E-14 Antioquia European 








Complement C3 and C4 levels -6.170213 2.04E-03 Chocó East Asian 








Table 7 continued 





Congenital left-sided heart lesions -16.2234 9.57E-11 Chocó European 
Corneal astigmatism -4.965165 2.43E-07 Chocó European 
Coronary artery disease in diabetes -17.02128 8.35E-07 Chocó European 
Coronary artery disease in type 1 diabetes 4.8260531 1.93E-04 Antioquia NR, European 
Coronary restenosis -22.34043 2.97E-03 Chocó European 
Cortical thickness 17.553191 3.14E-03 Antioquia European 






Hispanic or Latin 
American 
Craniofacial microsomia 10.91218 9.03E-10 Antioquia East Asian 
C-reactive protein levels -5.489546 1.31E-06 Chocó East Asian 
C-reactive protein levels or HDL-cholesterol levels pleiotropy 5.8795593 4.34E-05 Antioquia NR 
Creatinine levels 4.1578014 3.09E-03 Antioquia East Asian 
Crohn's disease and celiac disease -25.79787 1.89E-09 Chocó European 
Crohn's disease and psoriasis -17.02128 1.10E-04 Chocó European 




Table 7 continued 










Cutaneous malignant melanoma -9.362911 2.64E-06 Chocó NR, European 
Cutaneous squamous cell carcinoma 19.379433 5.79E-18 Antioquia European 
Cystic fibrosis severity 16.489362 1.04E-05 Antioquia NR, European 
Cystic fibrosis-related diabetes -29.78723 1.10E-05 Chocó NR 
Dehydroepiandrosterone sulphate levels 6.7354779 1.07E-03 Antioquia NR, European 
Delta-5 desaturase activity response to n3-polyunsaturated fat supplement -10.60284 1.44E-13 Chocó NR 
Delta-6 desaturase activity -9.521277 2.58E-04 Chocó East Asian 
Dementia and core Alzheimer's disease neuropathologic changes -5.489957 1.62E-03 Chocó NR 
Dentate gyrus granule cell layer volume -9.83156 5.43E-05 Chocó European 
Dentate gyrus molecular layer volume corrected for total hippocampal 
volume -27.65957 1.20E-05 Chocó European 
Depression 2.722528 8.72E-07 Antioquia European 
Developmental dysplasia of the hip 13.696809 1.17E-03 Antioquia European 




Table 7 continued 










Hispanic or Latin 
American, Native 
American 
Diastolic blood pressure x alcohol consumption light vs heavy interaction 








Hispanic or Latin 
American 
Digit length ratio 10.967579 6.23E-08 Antioquia European 
Digit length ratio right hand 6.5634498 1.17E-02 Antioquia NR, European 
Diisocyanate-induced asthma -3.408175 1.07E-31 Chocó European 
Disease progression in age-related macular degeneration -3.863861 1.20E-06 Chocó European 
Disease-free survival in breast cancer -13.38652 1.03E-03 Chocó East Asian 
Disrupted circadian rhythm low relative amplitude of rest-activity cycles 15.780142 1.90E-07 Antioquia European 




Table 7 continued 





DNA methylation parent-of-origin 8.6879433 5.28E-03 Antioquia European 
Ear morphology 13.994428 4.60E-14 Antioquia 
Hispanic or Latin 
American 
Economic and political preferences -8.87633 1.78E-11 Chocó European 
Economic and political preferences environmentalism 5.7537309 9.77E-04 Antioquia European 
Educational attainment MTAG 1.8611321 2.09E-25 Antioquia European 
Educational attainment years of education 2.1101014 3.09E-34 Antioquia European 
Electrocardiographic conduction measures 12.047239 9.76E-09 Antioquia European 
Elevated fasting plasma glucose -4.361702 2.05E-03 Chocó East Asian 
Empathy quotient 8.3510638 1.63E-02 Antioquia European 





Emphysema-related traits 7.9787234 1.15E-03 Antioquia European 
Endometrial cancer endometrioid histology 5.8271293 4.05E-08 Antioquia European 




Eosinophil counts 3.1882989 1.19E-12 Antioquia East Asian 




Table 7 continued 





Eosinophil percentage of white cells 2.3195984 3.48E-07 Antioquia European 
Epilepsy generalized -8.546099 2.05E-07 Chocó European 
Epirubicin-induced leukopenia 16.489362 4.97E-07 Antioquia East Asian 
Epithelial ovarian cancer 4.9057505 6.66E-09 Antioquia European 
Erythrocyte sedimentation rate -35.6383 6.15E-09 Chocó European 
Esophageal adenocarcinoma x smoking interaction -9.840426 1.05E-02 Chocó European 
Esophageal cancer 6.2886272 4.99E-04 Antioquia East Asian 
Esophageal cancer squamous cell 10.514184 1.97E-05 Antioquia East Asian 
Estradiol levels -9.299645 1.86E-05 Chocó European 
Estrone-over-androstenedione ratio in resected early stage-receptor positive 







Eudaimonic well-being 5.5834847 6.34E-04 Antioquia European 









Table 7 continued 





Eye color -11.36229 3.95E-13 Chocó European 
Facial morphology factor 12, vertical position of sublabial sulcus relative 
to central midface 8.0350811 2.66E-03 Antioquia European 
Facial morphology factor 17, height of vermillion upper lip 5.4252633 3.57E-03 Antioquia European 
Facial morphology factor 18 -5.044264 8.29E-03 Chocó European 
Facial morphology factor 23 6.8234971 3.14E-03 Antioquia European 
Facial morphology factor 3, length of philtrum -9.267139 1.89E-11 Chocó European 
Facial morphology factor 5, width of mouth relative to central midface -7.123227 7.54E-03 Chocó European 




Fasting blood glucose BMI interaction -3.982747 2.20E-03 Chocó European 













Table 7 continued 













Hispanic or Latin 
American 
Feeling lonely -10.21277 4.39E-07 Chocó European 
Feeling nervous 3.4290164 8.61E-07 Antioquia European 
Feeling worry 3.9579882 2.78E-07 Antioquia European 
Fibrinogen levels smoking status, alcohol consumption or body mass index 
interaction -18.88298 5.19E-05 Chocó European 
Folding of antihelix 28.191489 6.42E-13 Antioquia 
Hispanic or Latin 
American 
Formal thought disorder in schizophrenia #VALUE! 1.52E-02 #VALUE! European 
Fractional excretion of metabolites in chronic kidney disease 12.5 1.77E-04 Antioquia European 
Fractional exhaled nitric oxide childhood -9.046353 9.24E-06 Chocó 
European, 





Table 7 continued 





Fractures 5.0040814 8.46E-03 Antioquia European 
Freckling -8.156028 2.13E-03 Chocó European 
Frontotemporal dementia 7.8492371 1.43E-04 Antioquia European 





Hispanic or Latin 
American 
Gamma glutamyl transferase levels 7.9787234 4.27E-03 Antioquia East Asian 
Gene methylation in lung tissue -30.31915 5.58E-14 Chocó European 
General cognitive ability 1.1833135 4.77E-04 Antioquia European 
Gestational age at birth in labor-initiated deliveries child effect 4.061128 3.59E-03 Antioquia European 
Gestational age at birth in premature rupture of membrane-initiated 
deliveries child effect -19.23759 1.33E-18 Chocó European 







Table 7 continued 





Glaucoma primary open-angle -6.276442 5.06E-13 Chocó 









Hispanic or Latin 
American 
Glomerular filtration rate creatinine 4.4173314 3.68E-17 Antioquia European 

















Table 7 continued 





Granulocyte percentage of myeloid white cells 2.9208545 1.10E-12 Antioquia European 
Graves' disease 5.6138389 6.05E-07 Antioquia European 
Gut microbiota bacterial taxa 6.5950614 2.72E-09 Antioquia European 
Hair color 5.8992957 1.02E-04 Antioquia 
Hispanic or Latin 
American 











HDL Cholesterol - Triglycerides HDLC-TG -14.71631 2.58E-11 Chocó European 






Table 7 continued 

































Table 7 continued 


















Hispanic or Latin 
American 





Hispanic or Latin 
American 
Hedonic well-being 11.968085 4.58E-05 Antioquia European 
Heel bone mineral density -2.20024 1.27E-30 Chocó European 
Hematocrit 3.2300364 4.08E-12 Antioquia East Asian 




Table 7 continued 





Hemoglobin -7.609338 4.12E-07 Chocó East Asian 









Hemoglobin levels -7.87234 6.81E-03 Chocó NR 
Hen's egg allergy 14.095745 5.73E-04 Antioquia European 
Hepatocellular carcinoma in hepatitis B infection -12.76596 1.90E-02 Chocó 
East Asian, South 
East Asian 
Hepatocyte growth factor levels -7.052841 5.29E-08 Chocó European 
Hepcidin-over-transferrin saturation ratio 14.911348 2.96E-10 Antioquia NR, European 
Heschl's gyrus morphology 3.290158 1.60E-02 Antioquia NR, European 
High altitude adaptation 6.3012918 9.12E-03 Antioquia East Asian 
Highest math class taken -2.514678 5.78E-14 Chocó European 




Table 7 continued 














Hippocampal subfield CA3 volume -8.156028 4.27E-02 Chocó European 
Hippocampal subfield CA4 volume -9.83156 5.43E-05 Chocó European 
Hippocampal tail volume corrected for total hippocampal volume -10.99291 7.98E-06 Chocó European 
Hippocampal volume in Alzheimer's disease dementia 8.643617 7.92E-06 Antioquia European 
Hirschsprung disease 11.347518 5.08E-17 Antioquia European 
HIV-associated dementia 6.7375887 3.62E-02 Antioquia European 
Hoarding 10.815603 2.34E-03 Antioquia European 
Homoarginine levels 25.531915 5.26E-04 Antioquia European 




Table 7 continued 





Hypertension -2.679299 3.40E-02 Chocó 
South Asian, 
European, 











Idiopathic inflammatory myopathy 15.691489 8.77E-03 Antioquia European 
Idiopathic membranous nephropathy -2.852744 2.49E-03 Chocó European 





Hispanic or Latin 
American 
IgE levels in asthmatics D.f. specific -23.40426 1.72E-02 Chocó East Asian 




Table 7 continued 





IgG fucosylation phenotypes multivariate analysis -7.819149 2.70E-02 Chocó European 
IgG glycosylation patterns 10.34824 7.64E-04 Antioquia European 
IgG N-glycosylation phenotypes multivariate analysis -8.35233 4.77E-04 Chocó European 
IgG sialylation phenotypes multivariate analysis -10.22036 6.99E-05 Chocó European 
























Table 7 continued 












Hispanic or Latin 
American 










Inflammatory biomarkers -7.408815 3.10E-02 Chocó European 
Inflammatory biomarkers in Kawasaki disease -26.06383 1.27E-06 Chocó East Asian 
Inguinal hernia -17.28723 4.70E-06 Chocó European 





Table 7 continued 





Insulin secretion rate -32.44681 2.00E-06 Chocó 
European, 
Hispanic or Latin 
American, Native 
American 
Insulin-like growth factors 10.54078 1.14E-02 Antioquia European 
Intelligence MTAG 0.9187886 3.27E-02 Antioquia NR, European 
Interleukin-13 levels 4.4854968 1.30E-02 Antioquia European 
Interleukin-17 levels -4.316933 7.32E-04 Chocó European 
Interleukin-1-beta levels -6.83574 3.67E-04 Chocó European 
Interleukin-4 levels -8.449532 1.76E-07 Chocó European 
Interleukin-5 levels -8.739657 9.27E-08 Chocó European 





Interstitial lung disease -4.979662 2.87E-03 Chocó European 
Intraocular pressure -1.992853 1.11E-07 Chocó European 
Iron levels -22.34043 1.32E-02 Chocó NR, European 
Iron status biomarkers ferritin levels -11.35702 2.66E-12 Chocó 





Table 7 continued 





Irritable mood 3.1622038 7.80E-04 Antioquia European 
Ischemic stroke small artery occlusion 44.148936 1.99E-15 Antioquia 







Hispanic or Latin 
American 
Ischemic stroke small-vessel -10.6383 1.70E-02 Chocó 







Hispanic or Latin 
American 
Isovolumetric relaxation time 14.804965 1.47E-07 Antioquia European 
Kidney disease end stage renal disease vs non-end stage renal disease in 




Table 7 continued 





L-arginine levels -12.5 1.48E-02 Chocó 
South Asian, 
European, NR 
Late-onset myasthenia gravis 8.0870061 1.73E-03 Antioquia European 
LDL cholesterol levels -3.307453 2.00E-04 Chocó NR, European 
Leisure-time exercise behaviour -10.50532 2.41E-03 Chocó East Asian 
Leprosy 3.4959782 8.06E-03 Antioquia East Asian 
Lipoprotein a levels -3.125087 6.30E-03 Chocó European 













admixed ancestry,  




Table 7 continued 





Lipoprotein-associated phospholipase A2 activity and mass -7.162315 7.74E-10 Chocó European 
Lipoprotein-associated phospholipase A2 activity change in response to 
statin therapy 8.0851064 9.76E-04 Antioquia European 
Liver injury in anti-tuberculosis drug treatment 22.606383 4.10E-08 Antioquia 
Sub-Saharan 
African 
Lobe size 10.505319 7.52E-04 Antioquia 
Hispanic or Latin 
American 
Loneliness -7.625457 6.62E-05 Chocó European 
Loneliness MTAG -8.471582 2.25E-06 Chocó European 
Longevity 90 years and older -15.02026 1.53E-13 Chocó European 
Low tan response -15.11195 1.01E-43 Chocó NR, European 




Lower body strength 12.327761 3.41E-08 Antioquia NR, European 
Lung adenocarcinoma 4.2362955 3.92E-08 Antioquia European 
Lung cancer in ever smokers 3.6223337 1.35E-09 Antioquia European 




Table 7 continued 





Lung function FEV1 5.3203936 2.68E-07 Antioquia 
East Asian, 





Lung function FEV1-over-FVC 3.627147 3.66E-07 Antioquia 
East Asian, 





Lung function forced vital capacity -11.34752 8.99E-03 Chocó 
East Asian, 










Table 7 continued 





Lung function FVC 4.0658476 6.13E-04 Antioquia 
East Asian, 





Lymphoma -11.34752 7.22E-04 Chocó NR, European 
Mammographic density -8.191489 1.73E-02 Chocó European 
Mammographic density dense area -5.817215 3.65E-03 Chocó 
NR, European, 
Other 
Maximum cranial width -6.540853 1.29E-06 Chocó European 
Mean arterial pressure 2.2651123 1.25E-02 Antioquia East Asian 
Mean arterial pressure x alcohol consumption light vs heavy interaction 








Hispanic or Latin 
American 
Mean corpuscular hemoglobin 2.2065264 9.18E-11 Antioquia East Asian 
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Mean corpuscular volume 3.0844077 1.67E-17 Antioquia East Asian 
Mean platelet volume 1.6620452 2.85E-07 Antioquia European 
Melanoma 6.7520954 9.07E-05 Antioquia European 
Membranous nephropathy -15.15957 2.29E-05 Chocó European 
Memory dysfunction in frontotemporal lobe dementia -13.12943 4.62E-08 Chocó European 
Menarche and menopause age at onset -16.17021 6.04E-11 Chocó European 
Menopause age at onset -4.186097 6.33E-08 Chocó 
East Asian, 
European 
Menstruation quality of life impact acne -8.118034 2.66E-03 Chocó East Asian 
Menstruation quality of life impact headache -10.90426 1.93E-02 Chocó East Asian 
Metabolite levels -5.167105 3.93E-08 Chocó European 




Metabolite levels HVA-5-HIAA Factor score -15.98727 1.01E-21 Chocó European 
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MGMT methylation in smokers -20.47872 4.52E-07 Chocó 
European, 
Hispanic or Latin 
American 
Migraine - clinic-based -7.31383 1.67E-07 Chocó European 
Migraine with aura -13.78143 4.09E-15 Chocó European 
Monocyte chemoattractant protein-1 levels -3.035025 8.33E-03 Chocó European 
Monocyte chemoattractant protein-3 levels 5.3698075 1.60E-02 Antioquia European 
Monocyte count 1.6290198 1.02E-04 Antioquia East Asian 
Monocyte percentage of white cells 3.2923709 5.83E-16 Antioquia European 
Mortality in heart failure -12.14096 1.27E-11 Chocó European 
Mortality in sepsis -8.251224 7.84E-07 Chocó NR, European 
Multiple myeloma -4.326545 1.13E-04 Chocó European 
Multiple sclerosis -1.154707 3.28E-02 Chocó European 
Multiple system atrophy -5.649696 2.03E-03 Chocó European 
Myeloproliferative neoplasms -16.48936 5.41E-07 Chocó European 
Myocardial infarction early onset 7.5132979 3.28E-04 Antioquia European 





Table 7 continued 












Hispanic or Latin 
American 
Neovascular age-related macular degeneration 12.721631 5.14E-07 Antioquia South East Asian 
Neuroblastoma 1p deletion -26.06383 7.63E-05 Chocó European 
Neurociticism 1.5732397 3.85E-02 Antioquia European 





Hispanic or Latin 
American, NR 
Neurofibrillary tangles -6.095775 2.07E-03 Chocó NR 
Neuroticism 1.382575 1.36E-06 Antioquia European 
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Neutrophil count in HIV-infection -73.93617 9.44E-45 Chocó 
European, 




Neutrophil level response to clozapine in treatment-resistant schizophrenia -73.93617 9.44E-45 Chocó 
Sub-Saharan 
African 
Neutrophil percentage of granulocytes 3.5444048 4.59E-12 Antioquia European 
Neutrophil percentage of white cells 2.4744523 2.46E-05 Antioquia European 
Nicotine use -8.244681 1.14E-05 Chocó European 
Non-albumin protein levels -27.83688 5.47E-15 Chocó East Asian 
Nonalcoholic fatty liver disease 9.5803783 5.62E-04 Antioquia East Asian 
Non-alcoholic fatty liver disease histology other 6.1057659 5.09E-10 Antioquia European 
Non-melanoma skin cancer -3.10881 1.36E-03 Chocó NR, European 
Non-small cell lung cancer survival 12.234043 5.27E-04 Antioquia East Asian 
Number of children ever born 14.361702 2.59E-03 Antioquia European 
Obesity early onset extreme -10.06891 1.76E-15 Chocó European 
Obesity-related traits -2.911325 1.73E-39 Chocó 
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Hispanic or Latin 
American 





Hispanic or Latin 
American, Asian 
unspecified 





Hispanic or Latin 
American, Asian 
unspecified 
Oppositional defiant disorder dimensions in attention-deficit hyperactivity 
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Optic disc area -30.67059 7.24E-32 Chocó 
South East Asian, 
South Asian, East 
Asian, European 
Optic nerve measurement rim area 9.0248227 3.10E-04 Antioquia European 
Ossification of the posterior longitudinal ligament of the spine -5.868794 1.74E-02 Chocó East Asian 
Osteoarthritis of the hip with total joint replacement -13.93617 2.02E-06 Chocó European 
Osteoarthritis of the knee hospital diagnosed 7.2251773 7.01E-03 Antioquia European 
Osteoporosis-related phenotypes 8.9184397 2.10E-04 Antioquia European 
Osteoprotegerin levels -12.05674 1.96E-02 Chocó 
East Asian, 
European 
Overall survival in osteosarcoma -11.28314 5.28E-11 Chocó 
European, 
Hispanic or Latin 
American 
Overweight status -14.09574 7.69E-05 Chocó South Asian 
Pain 21.808511 2.99E-03 Antioquia European 
Pain medicine use during menstruation -7.593718 1.30E-02 Chocó East Asian 
Palmitic acid 16:0 levels 8.7505373 4.68E-08 Antioquia European 
Pancreatitis 15.602837 2.73E-05 Antioquia European 
Paraoxonase activity -25 1.10E-06 Chocó European 
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Parental longevity combined parental attained age, Martingale residuals -5.485727 2.39E-06 Chocó European 
Parental longevity father's age at death 7.3138298 3.98E-02 Antioquia European 
Parkinsonism in frontotemporal lobe dementia 12.85461 8.18E-04 Antioquia European 
Parkinson's disease 2.8948549 1.84E-04 Antioquia European 
Parkinson's disease age of onset -19.90248 1.78E-11 Chocó NR, European 
Pediatric autoimmune diseases 7.3415744 7.04E-14 Antioquia European 
Pediatric bone mineral content femoral neck 7.385385 1.29E-02 Antioquia European 
Pediatric bone mineral content hip -5.217114 1.28E-02 Chocó European 
Pediatric bone mineral density femoral neck 5.9553656 1.13E-03 Antioquia European 
Pediatric bone mineral density hip 9.2907801 2.11E-08 Antioquia European 
Perceived skin darkness -22.07447 1.55E-07 Chocó European 




Percent mammographic density -10.74468 7.02E-04 Chocó 
NR, European, 
Other 
Periodontitis DPAL 6.6986353 2.00E-04 Antioquia European 
Periodontitis PAL4Q3 11.409786 4.30E-09 Antioquia European 
Pharmacokinetics of antidepressant drugs in severe mental disorder 




Table 7 continued 





Philtrum width -23.67021 6.92E-10 Chocó NR, European 
Photic sneeze reflex -8.599291 2.33E-03 Chocó European 
Physical activity moderate intensity activity duration 16.223404 2.98E-03 Antioquia European 
Pit-and-Fissure caries 5.4477437 1.67E-02 Antioquia European 
Placental abruption -8.076241 1.56E-04 Chocó NR 
Plasma amyloid beta peptide concentrations ABx-40 -10.63197 5.54E-07 Chocó European 





Plasma neurofilament light levels -22.87234 1.34E-02 Chocó European 
Plasma omega-3 polyunsaturated fatty acid level eicosapentaenoic acid 4.4232216 3.07E-03 Antioquia European 
Plasma omega-3 polyunsaturated fatty acid levels docosahexaenoic acid 5.5972839 5.38E-04 Antioquia East Asian 
Plasma trimethyllysine levels 9.751773 1.33E-04 Antioquia European 
Platelet count 2.0467445 3.35E-11 Antioquia East Asian 
Platelet distribution width 2.7499875 3.06E-11 Antioquia European 
Plateletcrit 3.914265 2.37E-20 Antioquia European 
Platelet-derived growth factor BB levels -6.338909 4.21E-07 Chocó European 




Table 7 continued 










Post bronchodilator FEV1-over-FVC ratio in smoking 10.638298 3.82E-11 Antioquia European 
Post-traumatic stress disorder 12.748227 3.85E-05 Antioquia European 
PR segment 12.319529 4.82E-09 Antioquia European 
Preschool internalizing problems 6.0345476 1.13E-05 Antioquia NR, European 






Hispanic or Latin 
American 
Primary tooth development number of teeth 6.8345849 2.12E-11 Antioquia European 
Progression free survival in metastatic colorectal cancer CAPOX-B vs 
CAPOX-B plus cetuximab -19.32624 2.18E-10 Chocó European 
Proliferative diabetic retinopathy in type 2 diabetes -27.12766 1.94E-04 Chocó European 
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Prostate-specific antigen levels -3.893027 2.99E-03 Chocó 
East Asian, 
European, 





Proteinuria and chronic kidney disease 11.968085 1.08E-03 Antioquia European, Other 
Psoriasis 3.0482491 3.74E-04 Antioquia European 
Psoriatic arthritis 4.8063904 4.22E-02 Antioquia European 
Pulmonary emphysema 15.248227 6.72E-07 Antioquia 
East Asian, 
European, 





Pulmonary function in asthmatics -9.734887 2.80E-08 Chocó European 





Table 7 continued 













Hispanic or Latin 
American 






QT interval drug interaction -10.74673 1.07E-10 Chocó European 
RANTES levels 3.4406905 1.13E-02 Antioquia European 
Ratio of the peak velocity of the mitral E-Wave divided by the peak 
velocity of the mitral A-wave. -46.2766 3.75E-15 Chocó European 
Recalcitrant atopic dermatitis -8.271277 1.50E-02 Chocó East Asian 
Recurrent major depressive disorder 4.6564163 3.01E-02 Antioquia European 
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Red cell distribution width 3.3158002 1.00E-13 Antioquia European 
Regular attendance at a religious group -9.043422 1.23E-11 Chocó European 
Remission after SSRI treatment in MDD or neuroticism -10.47366 1.18E-05 Chocó NR 
Renal function-related traits BUN 9.0251947 8.81E-08 Antioquia 
East Asian, South 
Asian, South East 
Asian 
Renal function-related traits eGRFcrea 7.8457447 1.60E-03 Antioquia 
East Asian, South 
Asian, South East 
Asian 
Renal function-related traits urea -19.41489 7.86E-04 Chocó 
East Asian, South 
Asian, South East 
Asian 
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Hispanic or Latin 
American, NR 
Resistin levels -27.34929 7.45E-20 Chocó East Asian 





Response to anti-TNF therapy in rheumatoid arthritis -6.458333 5.36E-03 Chocó East Asian 
Response to gemcitabine in pancreatic cancer -9.911348 7.50E-09 Chocó East Asian 
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Response to metformin in type 2 diabetes HbA1c reduction 
-









Response to methotrexate in rheumatoid arthritis 
-
14.09574 5.76E-05 Chocó South Asian 
Response to methylphenidate treatment in attention-deficit-over-
hyperactivity disorder blood pressure 
-




Hispanic or Latin 
American, Other 
Response to montelukast in asthma change in FEV1 
-






Response to olanzapine in schizophrenia 
-
15.15957 1.36E-02 Chocó East Asian 
Response to perphenazine in schizophrenia 
-
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Response to SSRI in MDD or openness -13.1383 2.82E-10 Chocó NR 
Response to statin therapy -3.337924 1.08E-03 Chocó European 
Response to tamoxifen in breast cancer 30.851064 2.58E-07 Antioquia East Asian 
Response to Vitamin E supplementation 9.3085106 1.32E-02 Antioquia European 
Resting-state electroencephalogram vigilance -3.537472 1.17E-04 Chocó European 
Reticulocyte count 1.9674487 2.89E-05 Antioquia European 
Reticulocyte fraction of red cells 1.8814177 5.45E-05 Antioquia European 
Retinal arteriolar caliber -14.62766 1.23E-03 Chocó European 
Retinol levels -17.81915 7.01E-04 Chocó NR, European 
Rhegmatogenous retinal detachment -10.19504 9.86E-12 Chocó European 
Rosacea symptom severity 4.0255965 5.96E-10 Antioquia European 
Schizophrenia -2.220293 1.18E-15 Chocó NR, European 
Self-rated health -9.413416 5.06E-06 Chocó European 
Self-reported allergy 5.8550646 2.99E-07 Antioquia European 
Self-reported math ability -3.958835 8.89E-41 Chocó European 
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Hispanic or Latin 
American 
Serum albumin level -14.89362 1.51E-03 Chocó 
East Asian, 
European 
Serum C3d:C3 ratio systemic complement activation 14.62766 1.51E-07 Antioquia European 
Serum ceruloplasmin levels -25.53191 1.05E-05 Chocó European 
Serum dimethylarginine levels asymmetric-over-symetric ratio -7.730496 2.26E-02 Chocó European 
Serum tamsulosin hydrochloride concentration 8.9539007 2.32E-04 Antioquia East Asian 
Serum urate levels in chronic kidney disease 15.966312 9.54E-13 Antioquia European 
Serum vitamin D-binding protein levels 5.6737589 4.22E-02 Antioquia European 
Severity of facial solar lentigines 8.2446809 4.09E-02 Antioquia European 
Severity of nausea and vomiting of pregnancy 7.7039007 1.84E-02 Antioquia European 
Sex hormone-binding globulin levels -6.380189 4.33E-04 Chocó European 
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Sjögren's syndrome 4.842304 1.59E-03 Antioquia European 
Skin colour saturation -34.17553 7.70E-33 Chocó European 
Skin pigmentation -8.156178 1.35E-20 Chocó 
Sub-Saharan 
African 
Skin sensitivity to sun -57.44681 2.08E-24 Chocó European 
Sleep duration -6.906329 5.76E-12 Chocó European 
Sleep quality -11.09929 2.12E-06 Chocó European 
Smoking cessation in chronic obstructive pulmonary disease -9.014691 1.43E-04 Chocó European 





Hispanic or Latin 
American 
Smooth-surface caries 4.4678668 3.87E-09 Antioquia European 
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Population Study population(s) 
Glomerular filtration rate change in heart transplantation 0.24 1.0E+00 Antioquia 
NR, European, Native 
American 
Glomerular filtration rate creatinine 4.42 3.7E-17 Antioquia European 
Glomerular filtration rate cystatin C -2.13 1.0E+00 Chocó European 
Glomerular filtration rate in chronic kidney disease 2.46 1.0E+00 Antioquia European, Other 
Glomerular filtration rate in non diabetics creatinine 5.44 9.7E-07 Antioquia 
Asian unspecified, African 
unspecified, European 
GLP-1 levels in response to oral glucose tolerance test 120 
minutes 1.06 1.0E+00 Antioquia European 
Glucocorticoid-induced osteonecrosis -3.89 1.0E+00 Chocó 
East Asian, African 
American or Afro-
Caribbean, European, NR, 
Hispanic or Latin 
American 
Glycated hemoglobin levels 1.48 1.0E+00 Antioquia East Asian 
Glycemic traits 0.00 NA Antioquia East Asian 
Glycemic traits pregnancy 23.85 6.7E-18 Antioquia 
African American or Afro-
Caribbean, European, 
Hispanic or Latin 
American, South East 
Asian 
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Spherical equivalent 5.8388537 1.46E-03 Antioquia 
South Asian, East 









Squamous cell lung carcinoma 3.0243053 9.23E-07 Antioquia European 
Stearic acid 18:0 levels 10.437774 1.19E-08 Antioquia European 
Stroke 3.6815139 1.56E-02 Antioquia 







Hispanic or Latin 
American 
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Subclinical trait of interstitial lung disease basilar peel-core ratio of high 






Hispanic or Latin 
American 
Subclinical trait of interstitial lung disease basilar percentage of high 






Hispanic or Latin 
American 
Subcortical brain region volumes 13.297872 1.21E-09 Antioquia 
East Asian, 
European, 
Hispanic or Latin 
American 
Sub-foveal choroidal thickness -39.89362 1.20E-10 Chocó East Asian 
Subiculum volume 12.721631 9.33E-06 Antioquia European 
Subjective response to lithium treatment in bipolar disorder 11.746454 2.20E-03 Antioquia European 
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Suicide ideation score in major depressive disorder -13.65248 5.81E-06 Chocó European 
Suicide in bipolar disorder -15.0266 4.52E-05 Chocó European 
Sum basophil neutrophil counts 2.6969014 1.13E-07 Antioquia European 
Supraventricular ectopy -21.03723 6.31E-22 Chocó 
African 
unspecified, 
Hispanic or Latin 
American, 
European 
Survival in colorectal cancer distant metastatic -15.15957 9.53E-04 Chocó European 
Systemic lupus erythematosus -3.844557 8.56E-25 Chocó European 
Systolic blood pressure cigarette smoking interaction -8.619554 2.61E-06 Chocó 
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Systolic blood pressure x alcohol consumption light vs heavy interaction 








Hispanic or Latin 
American 
Testicular cancer 26.41844 7.01E-13 Antioquia European 





Thrombin-activatable fibrinolysis inhibitor activation peptide -10.8156 9.17E-05 Chocó European 
Thyroid cancer Papillary, radiation-related 17.553191 2.70E-02 Antioquia NR, European 
Thyroid function 12.411348 2.25E-02 Antioquia European 
Thyroid hormone levels 22.340426 4.60E-05 Antioquia European 
Thyroid peroxidase antibody levels 15.957447 1.36E-09 Antioquia European 
Thyroid peroxidase antibody positivity 8.4736998 5.50E-04 Antioquia East Asian 
Thyroid peroxidase autoantibody levels in type 1 diabetes 26.595745 4.88E-05 Antioquia NR, European 
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Tooth agenesis mandibular second premolars -35.10638 6.88E-12 Chocó European, NR 
Total body bone mineral density 2.4686377 8.46E-05 Antioquia European 















Hispanic or Latin 
American, NR 
Tourette's syndrome or obsessive-compulsive disorder -8.228128 2.07E-07 Chocó European 
Triglycerides-Blood Pressure TG-BP 7.2695035 1.80E-05 Antioquia European 
Tuberculosis 4.548807 3.51E-05 Antioquia East Asian 
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Tumor necrosis factor alpha levels -5.871327 4.21E-03 Chocó European 
Two-hour glucose challenge 10.585106 3.86E-04 Antioquia 
European, 
European, Other 
Type 1 diabetes -3.887702 2.26E-05 Chocó European 
Type 2 diabetes -1.796435 2.40E-05 Chocó European 
Type 2 diabetes and other traits -7.624113 1.06E-02 Chocó European 
Type 2 diabetes nephropathy -23.7766 4.42E-23 Chocó East Asian 
Upper eyelid morphology 7.8723404 4.72E-03 Antioquia East Asian 
Upper eyelid sagging severity -4.205164 1.37E-02 Chocó European 
Urate levels BMI interaction 4.258304 9.15E-03 Antioquia European 
Urea levels 18.218085 6.44E-12 Antioquia European 
Urinary albumin-to-creatinine ratio 8.4542231 7.28E-08 Antioquia 
Hispanic or Latin 
American 
Urinary electrolytes magnesium-over-calcium ratio -18.70567 9.22E-08 Chocó European 
Urinary metabolite ratios in chronic kidney disease -14.22872 1.62E-02 Chocó European 
Urinary tract infection frequency -17.55319 5.93E-09 Chocó European 
Vascular endothelial growth factor levels 5.4204783 1.05E-07 Antioquia European 
Verbal memory performance residualized delayed recall change 5.5851064 2.13E-04 Antioquia European 
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Vertical cup-disc ratio -7.88584 1.37E-06 Chocó 
South East Asian, 
South Asian, East 
Asian, European 
Very long-chain saturated fatty acid levels fatty acid 20:0 5.3350904 9.35E-03 Antioquia European 







Hispanic or Latin 
American 
Visceral fat -3.272413 1.35E-02 Chocó European 
Vitamin B12 levels -7.624113 5.76E-09 Chocó South Asian 
Vitamin D levels dietary vitamin D intake interaction -16.0461 1.79E-07 Chocó European, NR 
Vitamin E levels 12.234043 2.36E-03 Antioquia European, Other 
Vogt-Koyanagi-Harada syndrome 15.425532 1.10E-02 Antioquia East Asian 
vWF and FVIII levels -6.576402 2.64E-06 Chocó European 
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Waist circumference adjusted for BMI in non-smokers 4.743928 2.99E-06 Antioquia 





Hispanic or Latin 
American 
Waist circumference adjusted for BMI joint analysis main effects and 
smoking interaction 4.1804563 2.97E-04 Antioquia 





Hispanic or Latin 
American 
Waist-hip ratio 5.6317353 1.53E-05 Antioquia European 
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Waist-to-hip ratio adjusted for BMI in non-smokers 5.5371297 2.10E-05 Antioquia 





Hispanic or Latin 
American 
Waist-to-hip ratio adjusted for BMI x sex interaction 8.7242438 9.38E-14 Antioquia European 
Waist-to-hip ratio adjusted for BMI x sex x age interaction 4df test 5.0693275 3.11E-15 Antioquia European 
White blood cell count 3.4422366 1.16E-15 Antioquia East Asian 
White blood cell count monocyte 16.115755 5.55E-19 Antioquia 
Hispanic or Latin 
American 
White blood cell count neutrophil 10.01773 7.56E-07 Antioquia 
Hispanic or Latin 
American 
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White matter hyperintensity burden 
-
8.235605 5.96E-03 Chocó 










18.19149 5.01E-22 Chocó European 
Worry too long after an embarrassing experience 
-
5.844995 2.02E-08 Chocó European 
Yeast infection 
-






Table 8.  PRS derived from ancestry-specific studies 
rsid EA effect_size Trait PMID Accession 
rs11210537 A 5.824 Myopia-Multiethnic 29808027 GCST006291 
rs11589487 A 6.665 Myopia-Multiethnic 29808027 GCST006291 
rs1237670 A 5.815 Myopia-Multiethnic 29808027 GCST006291 
rs11802995 A 6.203 Myopia-Multiethnic 29808027 GCST006291 
rs1556867 T 8.806 Myopia-Multiethnic 29808027 GCST006291 
rs2225986 A 7.963 Myopia-Multiethnic 29808027 GCST006291 
rs1858001 C 7.276 Myopia-Multiethnic 29808027 GCST006291 
rs2745953 A 5.759 Myopia-Multiethnic 29808027 GCST006291 
rs11118367 T 7.288 Myopia-Multiethnic 29808027 GCST006291 
rs6753137 T 6.39E+00 Myopia-Multiethnic 29808027 GCST006291 
rs28658452 A 5.49 Myopia-Multiethnic 29808027 GCST006291 
rs17032696 A 5.766 Myopia-Multiethnic 29808027 GCST006291 
rs41393947 A 6.42E+00 Myopia-Multiethnic 29808027 GCST006291 
rs10187371 T 6.561 Myopia-Multiethnic 29808027 GCST006291 
rs56075542 T 8.994 Myopia-Multiethnic 29808027 GCST006291 
rs297593 T 7.816 Myopia-Multiethnic 29808027 GCST006291 
rs17428076 C 8.183 Myopia-Multiethnic 29808027 GCST006291 
rs2573081 C 8.212 Myopia-Multiethnic 29808027 GCST006291 
rs1550094 A 12.738 Myopia-Multiethnic 29808027 GCST006291 
rs12998513 A 6.855 Myopia-Multiethnic 29808027 GCST006291 
rs931302 T 5.75E+00 Myopia-Multiethnic 29808027 GCST006291 
rs9681162 T 6.699 Myopia-Multiethnic 29808027 GCST006291 
rs1454776 T 6.65 Myopia-Multiethnic 29808027 GCST006291 
rs4260345 T 5.662 Myopia-Multiethnic 29808027 GCST006291 
rs4687586 C 6.547 Myopia-Multiethnic 29808027 GCST006291 
rs2303635 C 6.088 Myopia-Multiethnic 29808027 GCST006291 
rs7624084 T 8.811 Myopia-Multiethnic 29808027 GCST006291 
rs4894529 A 5.646 Myopia-Multiethnic 29808027 GCST006291 
rs7662551 A 8.53 Myopia-Multiethnic 29808027 GCST006291 
rs7747 T 7.031 Myopia-Multiethnic 29808027 GCST006291 
rs1994840 A 5.566 Myopia-Multiethnic 29808027 GCST006291 
rs7692381 A 9.398 Myopia-Multiethnic 29808027 GCST006291 
rs2166181 A 6.642 Myopia-Multiethnic 29808027 GCST006291 
rs11952819 T 5.795 Myopia-Multiethnic 29808027 GCST006291 
rs7737179 A 5.527 Myopia-Multiethnic 29808027 GCST006291 
rs7449443 T 5.51 Myopia-Multiethnic 29808027 GCST006291 
rs10458138 A 6.049 Myopia-Multiethnic 29808027 GCST006291 
rs144370238 T 6.046 Myopia-Multiethnic 29808027 GCST006291 
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Table 8 comtinued 
rsid EA effect_size Trait PMID Accession 
rs1207782 T 7.915 Myopia-Multiethnic 29808027 GCST006291 
rs1150687 T 6.784 Myopia-Multiethnic 29808027 GCST006291 
rs9395623 A 7.25 Myopia-Multiethnic 29808027 GCST006291 
rs7744813 A 14.555 Myopia-Multiethnic 29808027 GCST006291 
rs1064583 A 6.52E+00 Myopia-Multiethnic 29808027 GCST006291 
rs12193446 A 19.431 Myopia-Multiethnic 29808027 GCST006291 
rs9388766 T 6.23E+00 Myopia-Multiethnic 29808027 GCST006291 
rs1358684 T 5.512 Myopia-Multiethnic 29808027 GCST006291 
rs12667032 A 7.994 Myopia-Multiethnic 29808027 GCST006291 
rs60884546 A 6.23E+00 Myopia-Multiethnic 29808027 GCST006291 
rs2116093 C 5.527 Myopia-Multiethnic 29808027 GCST006291 
rs10104039 T 5.582 Myopia-Multiethnic 29808027 GCST006291 
rs1532278 T 5.69E+00 Myopia-Multiethnic 29808027 GCST006291 
rs7829127 A 10.911 Myopia-Multiethnic 29808027 GCST006291 
rs284816 A 7.212 Myopia-Multiethnic 29808027 GCST006291 
rs72621438 C 13.137 Myopia-Multiethnic 29808027 GCST006291 
rs72655575 A 6.867 Myopia-Multiethnic 29808027 GCST006291 
rs28891973 A 6.27E+00 Myopia-Multiethnic 29808027 GCST006291 
rs10511652 A 7.355 Myopia-Multiethnic 29808027 GCST006291 
rs11145465 A 9.546 Myopia-Multiethnic 29808027 GCST006291 
rs7042950 A 6.797 Myopia-Multiethnic 29808027 GCST006291 
rs10760673 A 5.986 Myopia-Multiethnic 29808027 GCST006291 
rs10122788 A 5.491 Myopia-Multiethnic 29808027 GCST006291 
rs11101263 T 7.329 Myopia-Multiethnic 29808027 GCST006291 
rs1649068 A 9.439 Myopia-Multiethnic 29808027 GCST006291 
rs9416017 T 5.655 Myopia-Multiethnic 29808027 GCST006291 
rs4237284 A 5.476 Myopia-Multiethnic 29808027 GCST006291 
rs7895108 T 8.866 Myopia-Multiethnic 29808027 GCST006291 
rs745480 C 8.314 Myopia-Multiethnic 29808027 GCST006291 
rs11202736 A 6.919 Myopia-Multiethnic 29808027 GCST006291 
rs17382981 T 6.31E+00 Myopia-Multiethnic 29808027 GCST006291 
rs807037 C 5.466 Myopia-Multiethnic 29808027 GCST006291 
rs72826094 A 7.883 Myopia-Multiethnic 29808027 GCST006291 
rs511217 A 6.793 Myopia-Multiethnic 29808027 GCST006291 
rs7941828 T 5.483 Myopia-Multiethnic 29808027 GCST006291 
rs11602008 A 13.978 Myopia-Multiethnic 29808027 GCST006291 
rs7107014 A 5.459 Myopia-Multiethnic 29808027 GCST006291 
rs478304 T 6.099 Myopia-Multiethnic 29808027 GCST006291 
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rs2155413 A 7.755 Myopia-Multiethnic 29808027 GCST006291 
rs1954761 T 8.397 Myopia-Multiethnic 29808027 GCST006291 
rs7122817 A 7.514 Myopia-Multiethnic 29808027 GCST006291 
rs1790165 A 6.854 Myopia-Multiethnic 29808027 GCST006291 
rs4764038 T 6.196 Myopia-Multiethnic 29808027 GCST006291 
rs7971334 T 5.724 Myopia-Multiethnic 29808027 GCST006291 
rs117735470 A 6.07 Myopia-Multiethnic 29808027 GCST006291 
rs10880855 T 7.778 Myopia-Multiethnic 29808027 GCST006291 
rs3138141 A 13.803 Myopia-Multiethnic 29808027 GCST006291 
rs11178469 T 7.403 Myopia-Multiethnic 29808027 GCST006291 
rs7337610 T 6.144 Myopia-Multiethnic 29808027 GCST006291 
rs1359543 A 6.30E+00 Myopia-Multiethnic 29808027 GCST006291 
rs9547035 T 5.69E+00 Myopia-Multiethnic 29808027 GCST006291 
rs9516194 A 6.25E+00 Myopia-Multiethnic 29808027 GCST006291 
rs9517964 T 8.423 Myopia-Multiethnic 29808027 GCST006291 
rs837323 T 6.32E+00 Myopia-Multiethnic 29808027 GCST006291 
rs12883788 T 6.24E+00 Myopia-Multiethnic 29808027 GCST006291 
rs36024104 A 9.09 Myopia-Multiethnic 29808027 GCST006291 
rs2855530 C 8.575 Myopia-Multiethnic 29808027 GCST006291 
rs2753462 C 6.49E+00 Myopia-Multiethnic 29808027 GCST006291 
rs17125093 A 6.23E+00 Myopia-Multiethnic 29808027 GCST006291 
rs11160044 A 6.531 Myopia-Multiethnic 29808027 GCST006291 
rs35337422 A 6.35E+00 Myopia-Multiethnic 29808027 GCST006291 
rs524952 A 17.075 Myopia-Multiethnic 29808027 GCST006291 
rs34539187 C 5.808 Myopia-Multiethnic 29808027 GCST006291 
rs12898755 A 7.533 Myopia-Multiethnic 29808027 GCST006291 
rs6495367 A 10.202 Myopia-Multiethnic 29808027 GCST006291 
rs1969091 A 6.37E+00 Myopia-Multiethnic 29808027 GCST006291 
rs79266634 C 5.932 Myopia-Multiethnic 29808027 GCST006291 
rs10500355 A 13.732 Myopia-Multiethnic 29808027 GCST006291 
rs56055503 A 6.719 Myopia-Multiethnic 29808027 GCST006291 
rs8075280 A 5.75E+00 Myopia-Multiethnic 29808027 GCST006291 
rs2908972 A 11.125 Myopia-Multiethnic 29808027 GCST006291 
rs62070229 A 8.578 Myopia-Multiethnic 29808027 GCST006291 
rs3213636 A 6.26E+00 Myopia-Multiethnic 29808027 GCST006291 
rs4795364 A 5.532 Myopia-Multiethnic 29808027 GCST006291 
rs11654644 T 6.32E+00 Myopia-Multiethnic 29808027 GCST006291 
rs12451582 A 7.02 Myopia-Multiethnic 29808027 GCST006291 
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rs4793501 T 7.212 Myopia-Multiethnic 29808027 GCST006291 
rs6420484 A 5.943 Myopia-Multiethnic 29808027 GCST006291 
rs10853531 A 6.882 Myopia-Multiethnic 29808027 GCST006291 
rs12965607 T 7.073 Myopia-Multiethnic 29808027 GCST006291 
rs4808962 A 6.056 Myopia-Multiethnic 29808027 GCST006291 
rs4805962 T 5.773 Myopia-Multiethnic 29808027 GCST006291 
rs235770 T 5.926 Myopia-Multiethnic 29808027 GCST006291 
rs1555075 T 6.215 Myopia-Multiethnic 29808027 GCST006291 
rs2229742 C 6.121 Myopia-Multiethnic 29808027 GCST006291 
rs11088317 T 6.895 Myopia-Multiethnic 29808027 GCST006291 
rs9680365 A 5.751 Myopia-Multiethnic 29808027 GCST006291 
rs2150458 A 7.735 Myopia-Multiethnic 29808027 GCST006291 
rs9606967 C 5.866 Myopia-Multiethnic 29808027 GCST006291 
rs1983554 A 5.51 Myopia-Multiethnic 29808027 GCST006291 
rs10910076 A 0.648 Myopia-European 29808027 GCST006290 
rs479445 A 0.0481 Myopia-European 29808027 GCST006290 
rs57382675 A 0.0641 Myopia-European 29808027 GCST006290 
rs10919908 A 0.0507 Myopia-European 29808027 GCST006290 
rs2162488 T 0.1078 Myopia-European 29808027 GCST006290 
rs61049169 A 0.0629 Myopia-European 29808027 GCST006290 
rs297587 A 0.0497 Myopia-European 29808027 GCST006290 
rs72890842 T 0.0673 Myopia-European 29808027 GCST006290 
rs17400325 T 0.1383 Myopia-European 29808027 GCST006290 
rs1550094 A 0.0861 Myopia-European 29808027 GCST006290 
rs12998513 A 0.4513 Myopia-European 29808027 GCST006290 
rs77016368 A 0.5618 Myopia-European 29808027 GCST006290 
rs62236760 A 0.0473 Myopia-European 29808027 GCST006290 
rs826222 T 0.0395 Myopia-European 29808027 GCST006290 
rs2303635 C 0.8739 Myopia-European 29808027 GCST006290 
rs7624084 T 0.0573 Myopia-European 29808027 GCST006290 
rs7662551 A 0.056 Myopia-European 29808027 GCST006290 
rs77676437 T 0.0616 Myopia-European 29808027 GCST006290 
rs79504986 A 0.167 Myopia-European 29808027 GCST006290 
rs5022942 A 0.0743 Myopia-European 29808027 GCST006290 
rs10011267 T 0.0481 Myopia-European 29808027 GCST006290 
rs411535 A 0.0429 Myopia-European 29808027 GCST006290 
rs13217285 T 0.0647 Myopia-European 29808027 GCST006290 
rs35909544 A 0.0625 Myopia-European 29808027 GCST006290 
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rs36042294 C 0.0603 Myopia-European 29808027 GCST006290 
rs7754960 C 0.0559 Myopia-European 29808027 GCST006290 
rs7744813 A 0.0928 Myopia-European 29808027 GCST006290 
rs1064583 A 0.0467 Myopia-European 29808027 GCST006290 
rs12193446 A 0.2514 Myopia-European 29808027 GCST006290 
rs28613963 T 0.1783 Myopia-European 29808027 GCST006290 
rs12667032 A 0.9345 Myopia-European 29808027 GCST006290 
rs7829127 A 0.0915 Myopia-European 29808027 GCST006290 
rs72621438 C 0.0851 Myopia-European 29808027 GCST006290 
rs2272774 T 1.801 Myopia-European 29808027 GCST006290 
rs7028032 T 0.045 Myopia-European 29808027 GCST006290 
rs11145461 T 0.0668 Myopia-European 29808027 GCST006290 
rs334354 A 0.0515 Myopia-European 29808027 GCST006290 
rs11101263 T 0.047 Myopia-European 29808027 GCST006290 
rs4141671 T 0.0515 Myopia-European 29808027 GCST006290 
rs10824518 A 0.0597 Myopia-European 29808027 GCST006290 
rs10887265 C 0.0568 Myopia-European 29808027 GCST006290 
rs11202704 T 0.0454 Myopia-European 29808027 GCST006290 
rs56299331 T 0.0608 Myopia-European 29808027 GCST006290 
rs534311 T 0.0452 Myopia-European 29808027 GCST006290 
rs11602008 A 0.1349 Myopia-European 29808027 GCST006290 
rs2155413 A 0.0576 Myopia-European 29808027 GCST006290 
rs715315 T 0.0486 Myopia-European 29808027 GCST006290 
rs1790165 A 0.0504 Myopia-European 29808027 GCST006290 
rs4768672 T 0.0478 Myopia-European 29808027 GCST006290 
rs3138141 A 0.1201 Myopia-European 29808027 GCST006290 
rs9508026 T 0.0451 Myopia-European 29808027 GCST006290 
rs7333969 T 0.0481 Myopia-European 29808027 GCST006290 
rs9513696 A 0.0558 Myopia-European 29808027 GCST006290 
rs837335 C 0.04 Myopia-European 29808027 GCST006290 
rs6602906 A 0.0843 Myopia-European 29808027 GCST006290 
rs79501380 A 0.2733 Myopia-European 29808027 GCST006290 
rs12883788 T 0.0491 Myopia-European 29808027 GCST006290 
rs61991628 A 0.0608 Myopia-European 29808027 GCST006290 
rs36024104 A 0.0761 Myopia-European 29808027 GCST006290 
rs2738265 C 0.0525 Myopia-European 29808027 GCST006290 
rs57391541 T 0.0809 Myopia-European 29808027 GCST006290 
rs524952 A 0.099 Myopia-European 29808027 GCST006290 
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rs12898755 A 0.0533 Myopia-European 29808027 GCST006290 
rs17648524 C 0.0986 Myopia-European 29808027 GCST006290 
rs77409432 A 0.2585 Myopia-European 29808027 GCST006290 
rs9972635 T 0.0842 Myopia-European 29808027 GCST006290 
rs873693 A 0.0841 Myopia-European 29808027 GCST006290 
rs80124906 A 0.6211 Myopia-European 29808027 GCST006290 
rs4785742 T 0.0512 Myopia-European 29808027 GCST006290 
rs2908972 A 0.0637 Myopia-European 29808027 GCST006290 
rs62067167 T 0.0632 Myopia-European 29808027 GCST006290 
rs3213636 A 0.1054 Myopia-European 29808027 GCST006290 
rs714832 A 0.0402 Myopia-European 29808027 GCST006290 
rs28488643 T 1.3391 Myopia-European 29808027 GCST006290 
rs62075723 A 0.0568 Myopia-European 29808027 GCST006290 
rs12965607 T 0.0678 Myopia-European 29808027 GCST006290 
rs629631 T 0.1346 Myopia-European 29808027 GCST006290 
rs3745548 T 0.4723 Myopia-European 29808027 GCST006290 
rs7253703 A 0.512 Myopia-European 29808027 GCST006290 
rs4805962 T 0.0884 Myopia-European 29808027 GCST006290 
rs232660 A 0.147 Myopia-European 29808027 GCST006290 
rs17274750 A 0.07 Myopia-European 29808027 GCST006290 
rs2823141 A 0.046 Myopia-European 29808027 GCST006290 
rs7275394 A 0.2892 Myopia-European 29808027 GCST006290 
rs8132840 A 0.0502 Myopia-European 29808027 GCST006290 
rs7286621 A 1.7808 Myopia-European 29808027 GCST006290 
rs11913426 A 0.2963 Myopia-European 29808027 GCST006290 
rs2500281 A 0.0579 Stroke-TransethnicMeta 29531354 GCST005843 
rs55704954 T 0.087 Stroke-TransethnicMeta 29531354 GCST005843 
rs593113 A 0.0467 Stroke-TransethnicMeta 29531354 GCST005843 
rs6577389 A -0.0457 Stroke-TransethnicMeta 29531354 GCST005843 
rs12046010 A -0.0524 Stroke-TransethnicMeta 29531354 GCST005843 
rs3790607 A -0.0761 Stroke-TransethnicMeta 29531354 GCST005843 
rs2758603 T 0.0586 Stroke-TransethnicMeta 29531354 GCST005843 
rs11240504 A 0.0515 Stroke-TransethnicMeta 29531354 GCST005843 
rs4614977 C 0.0978 Stroke-TransethnicMeta 29531354 GCST005843 
rs1516174 A -0.0528 Stroke-TransethnicMeta 29531354 GCST005843 
rs13035520 T -0.1086 Stroke-TransethnicMeta 29531354 GCST005843 
rs72889922 A 0.2591 Stroke-TransethnicMeta 29531354 GCST005843 
rs12470845 A -0.0477 Stroke-TransethnicMeta 29531354 GCST005843 
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rs11695863 T -0.0485 Stroke-TransethnicMeta 29531354 GCST005843 
rs6599168 T 0.059 Stroke-TransethnicMeta 29531354 GCST005843 
rs17189291 T 0.0895 Stroke-TransethnicMeta 29531354 GCST005843 
rs74878305 T -0.2311 Stroke-TransethnicMeta 29531354 GCST005843 
rs77737462 T -0.0574 Stroke-TransethnicMeta 29531354 GCST005843 
rs2723334 T 0.0925 Stroke-TransethnicMeta 29531354 GCST005843 
rs28502066 A -0.0576 Stroke-TransethnicMeta 29531354 GCST005843 
rs6050 T -0.0591 Stroke-TransethnicMeta 29531354 GCST005843 
rs116326120 A 0.2143 Stroke-TransethnicMeta 29531354 GCST005843 
rs7710854 A -0.0677 Stroke-TransethnicMeta 29531354 GCST005843 
rs11957829 A 0.0691 Stroke-TransethnicMeta 29531354 GCST005843 
rs17115954 A -0.0461 Stroke-TransethnicMeta 29531354 GCST005843 
rs202808 C 0.0676 Stroke-TransethnicMeta 29531354 GCST005843 
rs7750826 A -0.0663 Stroke-TransethnicMeta 29531354 GCST005843 
rs77190919 A 0.084 Stroke-TransethnicMeta 29531354 GCST005843 
rs9504375 A -0.1151 Stroke-TransethnicMeta 29531354 GCST005843 
rs958762 C 0.047 Stroke-TransethnicMeta 29531354 GCST005843 
rs7744623 T 0.0617 Stroke-TransethnicMeta 29531354 GCST005843 
rs2223588 T 0.0475 Stroke-TransethnicMeta 29531354 GCST005843 
rs3176336 A 0.0445 Stroke-TransethnicMeta 29531354 GCST005843 
rs2894439 A -0.218 Stroke-TransethnicMeta 29531354 GCST005843 
rs6908662 T 0.0441 Stroke-TransethnicMeta 29531354 GCST005843 
rs17705303 A -0.0755 Stroke-TransethnicMeta 29531354 GCST005843 
rs10248020 T -0.0423 Stroke-TransethnicMeta 29531354 GCST005843 
rs2158496 T 0.0747 Stroke-TransethnicMeta 29531354 GCST005843 
rs2526619 A -0.0815 Stroke-TransethnicMeta 29531354 GCST005843 
rs2107595 A 0.0882 Stroke-TransethnicMeta 29531354 GCST005843 
rs1029510 A 0.0452 Stroke-TransethnicMeta 29531354 GCST005843 
rs2390117 A 0.1094 Stroke-TransethnicMeta 29531354 GCST005843 
rs57957164 A 0.0548 Stroke-TransethnicMeta 29531354 GCST005843 
rs35197511 T -0.1168 Stroke-TransethnicMeta 29531354 GCST005843 
rs42377 A -0.0526 Stroke-TransethnicMeta 29531354 GCST005843 
rs11971846 A -0.0741 Stroke-TransethnicMeta 29531354 GCST005843 
rs12675410 T -0.0482 Stroke-TransethnicMeta 29531354 GCST005843 
rs12681792 A 0.0512 Stroke-TransethnicMeta 29531354 GCST005843 
rs1471859 A -0.0471 Stroke-TransethnicMeta 29531354 GCST005843 
rs2931351 T -0.0408 Stroke-TransethnicMeta 29531354 GCST005843 
rs7822041 A -0.0418 Stroke-TransethnicMeta 29531354 GCST005843 
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rs2383205 A -0.0415 Stroke-TransethnicMeta 29531354 GCST005843 
rs1333048 A -0.0539 Stroke-TransethnicMeta 29531354 GCST005843 
rs10812752 A 0.0426 Stroke-TransethnicMeta 29531354 GCST005843 
rs657659 A -0.0436 Stroke-TransethnicMeta 29531354 GCST005843 
rs28560429 A 0.1006 Stroke-TransethnicMeta 29531354 GCST005843 
rs7077598 A 0.1202 Stroke-TransethnicMeta 29531354 GCST005843 
rs56941894 T 0.1123 Stroke-TransethnicMeta 29531354 GCST005843 
rs7394038 T 0.0426 Stroke-TransethnicMeta 29531354 GCST005843 
rs6584579 A 0.0448 Stroke-TransethnicMeta 29531354 GCST005843 
rs61007562 T 0.0907 Stroke-TransethnicMeta 29531354 GCST005843 
rs77544954 A 0.0816 Stroke-TransethnicMeta 29531354 GCST005843 
rs55815645 A -0.101 Stroke-TransethnicMeta 29531354 GCST005843 
rs12577661 T -0.0478 Stroke-TransethnicMeta 29531354 GCST005843 
rs55693083 A -0.0518 Stroke-TransethnicMeta 29531354 GCST005843 
rs117876107 A 0.1408 Stroke-TransethnicMeta 29531354 GCST005843 
rs11603150 T 0.0452 Stroke-TransethnicMeta 29531354 GCST005843 
rs9651613 A 0.0533 Stroke-TransethnicMeta 29531354 GCST005843 
rs72930274 T 0.0649 Stroke-TransethnicMeta 29531354 GCST005843 
rs76349035 A -0.1235 Stroke-TransethnicMeta 29531354 GCST005843 
rs470928 A -0.0836 Stroke-TransethnicMeta 29531354 GCST005843 
rs36053597 T 0.0609 Stroke-TransethnicMeta 29531354 GCST005843 
rs77248876 A 0.1179 Stroke-TransethnicMeta 29531354 GCST005843 
rs11064171 T -0.1337 Stroke-TransethnicMeta 29531354 GCST005843 
rs1981440 T 0.048 Stroke-TransethnicMeta 29531354 GCST005843 
rs58989256 A -0.0493 Stroke-TransethnicMeta 29531354 GCST005843 
rs73338169 C 0.1215 Stroke-TransethnicMeta 29531354 GCST005843 
rs10777230 A 0.0452 Stroke-TransethnicMeta 29531354 GCST005843 
rs10774623 A 0.061 Stroke-TransethnicMeta 29531354 GCST005843 
rs7137828 T -0.0731 Stroke-TransethnicMeta 29531354 GCST005843 
rs12427276 A -0.0625 Stroke-TransethnicMeta 29531354 GCST005843 
rs10744777 T 0.0641 Stroke-TransethnicMeta 29531354 GCST005843 
rs3752631 A 0.0587 Stroke-TransethnicMeta 29531354 GCST005843 
rs11066283 A -0.0774 Stroke-TransethnicMeta 29531354 GCST005843 
rs11066322 A -0.0526 Stroke-TransethnicMeta 29531354 GCST005843 
rs79280766 A 0.1518 Stroke-TransethnicMeta 29531354 GCST005843 
rs10459401 T -0.0884 Stroke-TransethnicMeta 29531354 GCST005843 
rs4942561 T 0.0655 Stroke-TransethnicMeta 29531354 GCST005843 
rs4942570 A -0.0624 Stroke-TransethnicMeta 29531354 GCST005843 
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rs7333406 T 0.0545 Stroke-TransethnicMeta 29531354 GCST005843 
rs7318338 A 0.0554 Stroke-TransethnicMeta 29531354 GCST005843 
rs9564881 A -0.0658 Stroke-TransethnicMeta 29531354 GCST005843 
rs148225043 C 0.2739 Stroke-TransethnicMeta 29531354 GCST005843 
rs7176568 T 0.0479 Stroke-TransethnicMeta 29531354 GCST005843 
rs6496123 A -0.0476 Stroke-TransethnicMeta 29531354 GCST005843 
rs7200604 T 0.0514 Stroke-TransethnicMeta 29531354 GCST005843 
rs747762 T -0.0739 Stroke-TransethnicMeta 29531354 GCST005843 
rs78884723 T -0.1288 Stroke-TransethnicMeta 29531354 GCST005843 
rs62089968 A 0.12 Stroke-TransethnicMeta 29531354 GCST005843 
rs117953218 T -0.0605 Stroke-TransethnicMeta 29531354 GCST005843 
rs917016 T -0.0516 Stroke-TransethnicMeta 29531354 GCST005843 
rs878484 T -0.048 Stroke-TransethnicMeta 29531354 GCST005843 
rs72903534 A 0.1326 Stroke-TransethnicMeta 29531354 GCST005843 
rs7235691 T 0.0771 Stroke-TransethnicMeta 29531354 GCST005843 
rs2043304 T -0.0522 Stroke-TransethnicMeta 29531354 GCST005843 
rs60314748 T 0.0493 Stroke-TransethnicMeta 29531354 GCST005843 
rs9749384 T -0.0433 Stroke-TransethnicMeta 29531354 GCST005843 
rs10402802 T 0.1011 Stroke-TransethnicMeta 29531354 GCST005843 
rs6074239 T -0.0771 Stroke-TransethnicMeta 29531354 GCST005843 
rs9653750 A 0.0611 Stroke-TransethnicMeta 29531354 GCST005843 
rs8184945 A 0.0438 Stroke-TransethnicMeta 29531354 GCST005843 
rs12170360 A 0.0477 Stroke-TransethnicMeta 29531354 GCST005843 
rs139169 A 0.0563 Stroke-TransethnicMeta 29531354 GCST005843 
rs2500281 A 0.0532 Stroke-EuropeanMeta 29531354 GCST006908 
rs2065524 A -0.0778 Stroke-EuropeanMeta 29531354 GCST006908 
rs55704954 T 0.0862 Stroke-EuropeanMeta 29531354 GCST006908 
rs1537407 T -0.0554 Stroke-EuropeanMeta 29531354 GCST006908 
rs228725 T 0.0365 Stroke-EuropeanMeta 29531354 GCST006908 
rs11121153 A 0.0405 Stroke-EuropeanMeta 29531354 GCST006908 
rs284234 C -0.0485 Stroke-EuropeanMeta 29531354 GCST006908 
rs17035646 A 0.0536 Stroke-EuropeanMeta 29531354 GCST006908 
rs77793475 C 0.1579 Stroke-EuropeanMeta 29531354 GCST006908 
rs761291 A 0.0364 Stroke-EuropeanMeta 29531354 GCST006908 
rs12057512 A 0.051 Stroke-EuropeanMeta 29531354 GCST006908 
rs75178217 A -0.0746 Stroke-EuropeanMeta 29531354 GCST006908 
rs6695915 A 0.0687 Stroke-EuropeanMeta 29531354 GCST006908 
rs112476957 T -0.061 Stroke-EuropeanMeta 29531354 GCST006908 
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rs10922534 T 0.0534 Stroke-EuropeanMeta 29531354 GCST006908 
rs12752866 T -0.0383 Stroke-EuropeanMeta 29531354 GCST006908 
rs7513849 A 0.0382 Stroke-EuropeanMeta 29531354 GCST006908 
rs6537837 T 0.0432 Stroke-EuropeanMeta 29531354 GCST006908 
rs1777606 A 0.0408 Stroke-EuropeanMeta 29531354 GCST006908 
rs10776752 T 0.0648 Stroke-EuropeanMeta 29531354 GCST006908 
rs7553733 T -0.0393 Stroke-EuropeanMeta 29531354 GCST006908 
rs909269 T -0.0475 Stroke-EuropeanMeta 29531354 GCST006908 
rs1052053 A 0.0576 Stroke-EuropeanMeta 29531354 GCST006908 
rs4950874 T -0.0355 Stroke-EuropeanMeta 29531354 GCST006908 
rs11240746 A -0.0422 Stroke-EuropeanMeta 29531354 GCST006908 
rs7532642 T 0.0397 Stroke-EuropeanMeta 29531354 GCST006908 
rs17015183 A -0.0473 Stroke-EuropeanMeta 29531354 GCST006908 
rs17015250 T -0.0348 Stroke-EuropeanMeta 29531354 GCST006908 
rs12476527 T -0.0472 Stroke-EuropeanMeta 29531354 GCST006908 
rs4665894 T 0.1678 Stroke-EuropeanMeta 29531354 GCST006908 
rs79835740 A 0.0851 Stroke-EuropeanMeta 29531354 GCST006908 
rs9309154 T -0.0447 Stroke-EuropeanMeta 29531354 GCST006908 
rs12105026 A -0.0433 Stroke-EuropeanMeta 29531354 GCST006908 
rs11647 C -0.0465 Stroke-EuropeanMeta 29531354 GCST006908 
rs79488306 A 0.0648 Stroke-EuropeanMeta 29531354 GCST006908 
rs6728833 T 0.0411 Stroke-EuropeanMeta 29531354 GCST006908 
rs55863310 A -0.0901 Stroke-EuropeanMeta 29531354 GCST006908 
rs13035520 T -0.1001 Stroke-EuropeanMeta 29531354 GCST006908 
rs143229390 T 0.1077 Stroke-EuropeanMeta 29531354 GCST006908 
rs72864740 A 0.0532 Stroke-EuropeanMeta 29531354 GCST006908 
rs301816 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs11121240 T 1 Asthma-European-Ferreira 30929738 GCST007799 
rs67551275 T 1 Asthma-European-Ferreira 30929738 GCST007799 
rs4845604 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs115045402 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs12123821 T 1 Asthma-European-Ferreira 30929738 GCST007799 
rs61816761 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs2070901 T 1 Asthma-European-Ferreira 30929738 GCST007799 
rs2056625 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs1617333 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs1102705 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs10158467 G 1 Asthma-European-Ferreira 30929738 GCST007799 
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rs17668708 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs12023876 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs3856439 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs74180212 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs78545931 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs60227565 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs12470864 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs72823641 T 1 Asthma-European-Ferreira 30929738 GCST007799 
rs1861245 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs2381712 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs6755248 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs10187276 T 1 Asthma-European-Ferreira 30929738 GCST007799 
rs34290285 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs35570272 T 1 Asthma-European-Ferreira 30929738 GCST007799 
rs4491851 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs1806656 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs7625643 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs62296577 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs7626218 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs9860547 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs55661102 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs11715524 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs1684466 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs190438685 T 1 Asthma-European-Ferreira 30929738 GCST007799 
rs45613035 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs17454584 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs62322662 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs16903574 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs11742240 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs7734635 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs1837253 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs1898671 T 1 Asthma-European-Ferreira 30929738 GCST007799 
rs6594499 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs6866614 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs3749833 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs2299012 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs113010607 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs449454 G 1 Asthma-European-Ferreira 30929738 GCST007799 
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rs139088362 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs116189786 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs28798705 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs3116989 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs28522747 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs62408233 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs58521088 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs9372120 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs55743914 T 1 Asthma-European-Ferreira 30929738 GCST007799 
rs6927172 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs12531500 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs6954667 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs57585717 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs4722758 G 1 Asthma-European-Ferreira 30929738 GCST007799 
rs2221641 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs13277355 A 1 Asthma-European-Ferreira 30929738 GCST007799 
rs62557312 C 1 Asthma-European-Ferreira 30929738 GCST007799 
rs7848215 T 1 Asthma-European-Ferreira 30929738 GCST007799 
rs274943 T 1 Asthma-European-Ferreira 30929738 GCST007799 
rs12568266 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs14271 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs114190122 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs12143327 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs74346392 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs7551641 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs12074934 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs7534485 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs116493700 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs73912949 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs1435547 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs13405366 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs1877101 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs12622534 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs7588010 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs4143116 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs4954192 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs72974161 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs76247873 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
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rs16841200 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs7576072 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs76833157 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs76506302 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs61741390 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs6436285 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs13391419 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs116212486 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs10174165 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs6442708 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs79143957 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs27387 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs75515191 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs3796392 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs9871967 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs190141647 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs1479279 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs6858365 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs114326390 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs7693389 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs342958 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs16995986 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs111361850 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs74964132 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs77156671 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs115683773 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs2309284 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs908084 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs28375794 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs16867528 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs76684306 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs16867713 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs73132886 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs74935252 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs3852186 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs7733624 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs7720886 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs76314368 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
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rs77885874 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs7735563 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs9367895 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs2479808 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs79014439 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs16894878 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs2646928 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs116278466 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs351328 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs61613191 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs116146467 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs17167307 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs56868568 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs73302615 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs79835348 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs76917448 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs10435178 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs10237103 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs10268774 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs11971779 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs73737676 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs114252942 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs6586977 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs59294057 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs16876083 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs117628011 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs55798256 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs2514805 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs7000447 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs4736655 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs117405208 G 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs117260909 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs60244812 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs118106262 C 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs76780579 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs114646018 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs7020553 A 1 Asthma-European-Yucesoy 25918132 GCST002875 
rs17461620 T 1 Asthma-European-Yucesoy 25918132 GCST002875 
224 
 
Table 8 continued 
rsid EA effect_size Trait PMID Accession 
rs10157802 G 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs2352521 T 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs4129267 C 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs1348135 C 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs6694672 G 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs1122396 G 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs10924970 C 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs4268898 C 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs1420101 T 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs12634582 C 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs9870718 C 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs12521260 T 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs10455025 C 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs20541 A 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs7705042 A 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs1233578 G 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs2855812 T 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs9272346 A 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs2325291 G 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs10951405 T 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs10233459 G 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs12543811 G 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs12542922 A 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs2073617 A 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs992969 A 1 Asthma-MultiEthnic-Demenais 29273806 GCST005212 
rs7542900 C 1 T2D-African 22238593 GCST001369 
rs7560163 C 1 T2D-African 22238593 GCST001369 
rs2722769 C 1 T2D-African 22238593 GCST001369 
rs7107217 C 1 T2D-African 22238593 GCST001369 
rs2237897 C 1 T2D-African 22238593 GCST001369 
rs824248 T 1 T2D-African 22238593 GCST001369 
rs7903146 T 1 T2D-African 22238593 GCST001369 
rs335810 A 1 T2D-African 22238593 GCST001369 
rs3842770 A 1 T2D-African 22238593 GCST001369 
rs2283228 A 1 T2D-African 22238593 GCST001369 
rs335810 A 1 T2D-African 22238593 GCST001369 
rs2283228 A 1 T2D-African 22238593 GCST001369 
rs12613372 G 1 T2D-African 22238593 GCST001369 
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rs2244020 G 1 T2D-African 22238593 GCST001369 
rs17359493 G 1 T2D-African 22238593 GCST001369 
rs11043007 G 1 T2D-African 22238593 GCST001369 
rs2244020 G 1 T2D-African 22238593 GCST001369 
rs17359493 G 1 T2D-African 22238593 GCST001369 
rs679992 T 1 T2D-African 22238593 GCST001369 
rs10231619 T 1 T2D-African 22238593 GCST001369 
rs7003257 T 1 T2D-African 22238593 GCST001369 
rs7903146 T 1 T2D-African 22238593 GCST001369 
rs343092 T 1 T2D-African 22238593 GCST001369 
rs7903146 T 1 T2D-African 22238593 GCST001369 
rs343092 T 1 T2D-African 22238593 GCST001369 
rs231356 T 1 T2D-African 22238593 GCST001369 
rs7769051 A 1 T2D-African 22238593 GCST001369 
rs6930576 A 1 T2D-African 22238593 GCST001369 
rs773506 G 1 T2D-African 22238593 GCST001369 
rs2358944 G 1 T2D-African 22238593 GCST001369 
rs2106294 T 1 T2D-African 22238593 GCST001369 
rs10461617 A 1 T2D-EuropeanAsian 23209189 GCST001759 
rs11165354 A 1 T2D-EuropeanAsian 23209189 GCST001759 
rs8050136 A 1 T2D-EuropeanAsian 23209189 GCST001759 
rs6723108 T 1 T2D-EuropeanAsian 23209189 GCST001759 
rs7903146 T 1 T2D-EuropeanAsian 22101970 GCST001326 
rs2383208 T 1 T2D-EuropeanAsian 23209189 GCST001759 
rs6134031 T 1 T2D-EuropeanAsian 26584805 GCST004782 
rs17106184 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs243021 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7612463 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4689388 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs702634 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4457053 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs329122 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2796441 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs11787792 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7957197 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs1359790 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2028299 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs8042680 A 1 T2D-EuropeanAsian 28869590 GCST004894 
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rs8050136 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4430796 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs12970134 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs11671664 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4812829 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs17106184 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs243021 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4689388 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs702634 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4457053 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs329122 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4607517 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2796441 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7957197 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs10507349 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs576674 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs1359790 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7985179 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs8042680 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs9940149 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs8050136 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs12970134 A 1 T2D-EuropeanAsian 28869590 GCST004894 
rs340874 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2867125 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs780094 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7578597 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs3923113 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2943640 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs1470579 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs6808574 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7754840 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs864745 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs12681990 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs516946 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs896854 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs10811661 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2421016 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs1552224 C 1 T2D-EuropeanAsian 28869590 GCST004894 
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rs1531343 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4275659 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs11873305 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs12454712 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs340874 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs780094 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7578597 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs11123406 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs3923113 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7607980 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2943640 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs1470579 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7754840 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs864745 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs516946 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs944801 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs10811661 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs1552224 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs1531343 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4275659 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2925979 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs11873305 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs1470579 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs10811661 C 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2296172 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs1801282 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs11708067 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs6815464 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2706785 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs459193 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs9505118 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs3130501 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4897182 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7041847 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs12571751 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs231362 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs10830963 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs11063069 G 1 T2D-EuropeanAsian 28869590 GCST004894 
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rs10507349 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs576674 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7172432 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7178572 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs9940149 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7202877 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs3786897 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4420638 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7674212 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2296172 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7578326 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs1801282 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs11708067 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2706785 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs459193 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs9505118 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs3130501 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4897182 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs12571751 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs231362 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs163184 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs10830963 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs11063069 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7178572 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7202877 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4420638 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7178572 G 1 T2D-EuropeanAsian 28869590 GCST004894 
rs11123406 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs6813195 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2050188 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs1535500 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs622217 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs17168486 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2191349 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs9648716 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs13266634 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs13292136 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs11257655 T 1 T2D-EuropeanAsian 28869590 GCST004894 
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Table 8 continued 
rsid EA effect_size Trait PMID Accession 
rs1111875 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7903146 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7111341 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2237892 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs5215 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs10842994 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7961581 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7985179 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2925979 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs3794991 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs10923931 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs4607103 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs6813195 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2050188 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs17168486 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2191349 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs9648716 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs13266634 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs13292136 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs11257655 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs1111875 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7903146 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2421016 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2237892 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs5215 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs2129869 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs10842994 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs3794991 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs13266634 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs7903146 T 1 T2D-EuropeanAsian 28869590 GCST004894 
rs849134 A 1 T2D-Multiethnic 27189021 GCST003619 
rs7766070 A 1 T2D-Multiethnic 27189021 GCST003619 
rs9687833 A 1 T2D-Multiethnic 27189021 GCST003619 
rs11927381 C 1 T2D-Multiethnic 27189021 GCST003619 
rs13266634 C 1 T2D-Multiethnic 27189021 GCST003619 
rs6857 C 1 T2D-Multiethnic 27189021 GCST003619 
rs9273401 G 1 T2D-Multiethnic 27189021 GCST003619 
rs10811661 T 1 T2D-Multiethnic 27189021 GCST003619 
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rsid EA effect_size Trait PMID Accession 
rs3768321 T 1 T2D-Multiethnic 27189021 GCST003619 
rs34872471 C 1 T2D-Multiethnic 27189021 GCST003619 
rs12453394 A 1 T2D-Multiethnic 29358691 GCST005898 
rs7589501 A 1 T2D-Multiethnic 29358691 GCST005898 
rs1002061 A 1 T2D-Multiethnic 29358691 GCST005898 
rs11708067 A 1 T2D-Multiethnic 29358691 GCST005898 
rs4234733 A 1 T2D-Multiethnic 29358691 GCST005898 
rs703983 A 1 T2D-Multiethnic 29358691 GCST005898 
rs10404333 A 1 T2D-Multiethnic 29358691 GCST005898 
rs505922 C 1 T2D-Multiethnic 29358691 GCST005898 
rs66502159 C 1 T2D-Multiethnic 29358691 GCST005898 
rs340874 C 1 T2D-Multiethnic 29358691 GCST005898 
rs757110 C 1 T2D-Multiethnic 29358691 GCST005898 
rs3794205 G 1 T2D-Multiethnic 29358691 GCST005898 
rs11616380 G 1 T2D-Multiethnic 29358691 GCST005898 
rs2396083 G 1 T2D-Multiethnic 29358691 GCST005898 
rs12912009 G 1 T2D-Multiethnic 29358691 GCST005898 
rs2358954 G 1 T2D-Multiethnic 29358691 GCST005898 
rs10011174 G 1 T2D-Multiethnic 29358691 GCST005898 
rs2820443 T 1 T2D-Multiethnic 29358691 GCST005898 
rs10771367 T 1 T2D-Multiethnic 29358691 GCST005898 
rs7113297 T 1 T2D-Multiethnic 29358691 GCST005898 
rs146662075 T 1 T2D-Multiethnic 29358691 GCST005898 
rs115884658 A 1 T2D-Multiethnic 29358691 GCST005898 
rs6986080 G 1 T2D-Multiethnic 29358691 GCST005898 
rs9502570 A 1 T2D-Multiethnic 24509480 GCST002352 
rs702634 A 1 T2D-Multiethnic 24509480 GCST002352 
rs6937795 A 1 T2D-Multiethnic 24509480 GCST002352 
rs10788575 A 1 T2D-Multiethnic 24509480 GCST002352 
rs3923113 A 1 T2D-Multiethnic 24509480 GCST002352 
rs17791513 A 1 T2D-Multiethnic 24509480 GCST002352 
rs1552224 A 1 T2D-Multiethnic 24509480 GCST002352 
rs4812829 A 1 T2D-Multiethnic 24509480 GCST002352 
rs7041847 A 1 T2D-Multiethnic 24509480 GCST002352 
rs12571751 A 1 T2D-Multiethnic 24509480 GCST002352 
rs12970134 A 1 T2D-Multiethnic 24509480 GCST002352 
rs6813195 C 1 T2D-Multiethnic 24509480 GCST002352 
rs6808574 C 1 T2D-Multiethnic 24509480 GCST002352 
231 
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rsid EA effect_size Trait PMID Accession 
rs1727313 C 1 T2D-Multiethnic 24509480 GCST002352 
rs10510110 C 1 T2D-Multiethnic 24509480 GCST002352 
rs1561927 C 1 T2D-Multiethnic 24509480 GCST002352 
rs10190052 C 1 T2D-Multiethnic 24509480 GCST002352 
rs319598 C 1 T2D-Multiethnic 24509480 GCST002352 
rs2820446 C 1 T2D-Multiethnic 24509480 GCST002352 
rs2812533 C 1 T2D-Multiethnic 24509480 GCST002352 
rs1111875 C 1 T2D-Multiethnic 24509480 GCST002352 
rs5215 C 1 T2D-Multiethnic 24509480 GCST002352 
rs16861329 C 1 T2D-Multiethnic 24509480 GCST002352 
rs2028299 C 1 T2D-Multiethnic 24509480 GCST002352 
rs9936385 C 1 T2D-Multiethnic 24509480 GCST002352 
rs1801282 C 1 T2D-Multiethnic 24509480 GCST002352 
rs516946 C 1 T2D-Multiethnic 24509480 GCST002352 
rs10842994 C 1 T2D-Multiethnic 24509480 GCST002352 
rs7163757 C 1 T2D-Multiethnic 24509480 GCST002352 
rs2943640 C 1 T2D-Multiethnic 24509480 GCST002352 
rs7612463 C 1 T2D-Multiethnic 24509480 GCST002352 
rs17106184 G 1 T2D-Multiethnic 24509480 GCST002352 
rs3132524 G 1 T2D-Multiethnic 24509480 GCST002352 
rs10507349 G 1 T2D-Multiethnic 24509480 GCST002352 
rs7795991 G 1 T2D-Multiethnic 24509480 GCST002352 
rs4273712 G 1 T2D-Multiethnic 24509480 GCST002352 
rs7756992 G 1 T2D-Multiethnic 24509480 GCST002352 
rs163184 G 1 T2D-Multiethnic 24509480 GCST002352 
rs849135 G 1 T2D-Multiethnic 24509480 GCST002352 
rs10830963 G 1 T2D-Multiethnic 24509480 GCST002352 
rs2075423 G 1 T2D-Multiethnic 24509480 GCST002352 
rs8108269 G 1 T2D-Multiethnic 24509480 GCST002352 
rs1359790 G 1 T2D-Multiethnic 24509480 GCST002352 
rs4430796 G 1 T2D-Multiethnic 24509480 GCST002352 
rs12899811 G 1 T2D-Multiethnic 24509480 GCST002352 
rs12427353 G 1 T2D-Multiethnic 24509480 GCST002352 
rs3802177 G 1 T2D-Multiethnic 24509480 GCST002352 
rs4458523 G 1 T2D-Multiethnic 24509480 GCST002352 
rs2796441 G 1 T2D-Multiethnic 24509480 GCST002352 
rs7178572 G 1 T2D-Multiethnic 24509480 GCST002352 
rs9472138 T 1 T2D-Multiethnic 24509480 GCST002352 
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rs2284219 T 1 T2D-Multiethnic 24509480 GCST002352 
rs7903146 T 1 T2D-Multiethnic 24509480 GCST002352 
rs11257655 T 1 T2D-Multiethnic 24509480 GCST002352 
rs17168486 T 1 T2D-Multiethnic 24509480 GCST002352 
rs1535500 T 1 T2D-Multiethnic 24509480 GCST002352 
rs2261181 T 1 T2D-Multiethnic 24509480 GCST002352 
rs4402960 T 1 T2D-Multiethnic 24509480 GCST002352 
rs10811661 T 1 T2D-Multiethnic 24509480 GCST002352 
rs7845219 T 1 T2D-Multiethnic 24509480 GCST002352 
rs243088 T 1 T2D-Multiethnic 24509480 GCST002352 





Table 9.  R2 values for traits with robust ancestry correlations. 
Trait EUR_r2 AFR_r2 NAT_r2 
Black vs. blond hair color -0.537 0.547 -0.229 
Black vs. red hair color -0.509 0.508 -0.197 
BMI smoking interaction -0.493 0.521 -0.244 
Breast cancer 0.435 -0.464 0.224 
Cleft palate -0.356 0.415 -0.254 
Common carotid intima-media thickness in HIV infection 0.340 -0.420 0.296 
Cutaneous squamous cell carcinoma 0.470 -0.414 0.098 
Diisocyanate-induced asthma -0.614 0.630 -0.268 
Fear of minor pain -0.634 0.722 -0.417 
Gestational age at birth in premature rupture of membrane-initiated deliveries child effect -0.389 0.415 -0.200 
Glycemic traits pregnancy 0.373 -0.419 0.234 
Heel bone mineral density -0.494 0.567 -0.333 
Hip circumference 0.445 -0.420 0.134 
Ischemic stroke small artery occlusion 0.391 -0.407 0.182 
Low tan response -0.684 0.712 -0.318 
Low white blood cell count -0.739 0.822 -0.445 
Metabolite levels HVA-5-HIAA Factor score -0.389 0.437 -0.245 
Methotrexate phramacokinetics acute lymphoblastic leukemia 0.457 -0.478 0.218 
Migraine with aura -0.378 0.404 -0.196 
Neutrophil count in HIV-infection -0.739 0.822 -0.445 
Neutrophil level response to clozapine in treatment-resistant schizophrenia -0.739 0.822 -0.445 




Table 9 continued 
Trait EUR_r2 AFR_r2 NAT_r2 
Optic disc area -0.548 0.614 -0.339 
Plateletcrit 0.343 -0.428 0.310 
Resistin levels -0.394 0.448 -0.258 
Response to methylphenidate treatment in attention-deficit-over-hyperactivity disorder blood pressure -0.430 0.486 -0.275 
Schizophrenia -0.369 0.431 -0.266 
Self-reported math ability -0.653 0.720 -0.380 
Skin colour saturation -0.619 0.589 -0.193 
Skin pigmentation -0.526 0.541 -0.233 
Skin sensitivity to sun -0.567 0.530 -0.163 
Supraventricular ectopy -0.497 0.543 -0.281 
Systemic lupus erythematosus -0.511 0.521 -0.219 
Tumor biomarkers -0.400 0.433 -0.219 
Type 2 diabetes nephropathy -0.455 0.499 -0.261 
White blood cell count monocyte 0.392 -0.469 0.305 
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